Skip to main content
Research

Publications: Prof John Gribben

Moschopoulou E, Brewin D, Ridge D, Donovan S, Taylor SJC, Bourke L, Eva G, Khan I et al. ( 2022 ) . Evaluating an interactive acceptance and commitment therapy (ACT) workshop delivered to trained therapists working with cancer patients in the United Kingdom: a mixed methods approach . BMC Cancer vol. 22 , ( 1 )
Baptista MJ, Tapia G, Muñoz-Marmol AM, Muncunill J, Garcia O, Montoto S, Gribben JG, Calaminici M et al. ( 2022 ) . Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications . Histopathology vol. 81 , ( 6 ) 826 - 840 .
Michaeli M, Carlotti E, Hazanov H, Gribben JG, Mehr R ( 2022 ) . Mutational patterns along different evolution paths of follicular lymphoma . Frontiers in Oncology vol. 12 ,
Robbe P, Ridout KE, Vavoulis DV, Dréau H, Kinnersley B, Denny N, Chubb D, Appleby N et al. ( 2022 ) . Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features . Nature Genetics vol. 54 , ( 11 ) 1675 - 1689 .
Ghione P, Palomba ML, Ghesquieres H, Bobillo S, Patel AR, Nahas M, Kanters S, Deighton K et al. ( 2022 ) . Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study . Haematologica
Los-De Vries GT, Stevens WBC, Van Dijk E, Langois-Jacques C, Clear AJ, Stathi P, Roemer MGM, Mendeville M et al. ( 2022 ) . Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV . Blood Advances vol. 6 , ( 18 ) 5482 - 5493 .
Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L et al. ( 2022 ) . The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee . Blood vol. 140 , ( 11 ) 1229 - 1253 .
Seymour F, Cavenagh JD, Mathews J, Gribben JG ( 2022 ) . NK cells CD56<sup>bright</sup> and CD56<sup>dim</sup> subset cytokine loss and exhaustion is associated with impaired survival in myeloma . Blood Advances vol. 6 , ( 17 ) 5152 - 5159 .
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Novak J et al. ( 2022 ) . First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial . Haematologica vol. 107 , ( 9 ) 2108 - 2120 .
van Havre N, Orsini E, Almeida A, Gribben J, Bolanos N, Doeswijk R, Gaidano G, Mouhssine S et al. ( 2022 ) . How a Medical Association Can Make a Difference in a Crisis Situation . Hemasphere vol. 6 , ( 9 )
Ghione P, Palomba ML, Patel AR, Bobillo S, Deighton K, Jacobson CA, Nahas M, Hatswell AJ et al. ( 2022 ) . Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma . Blood vol. 140 , ( 8 ) 851 - 860 .
Bewicke-Copley F, Korfi K, Araf S, Hodkinson B, Kumar E, Cummin T, Ashton-Key M, Barrans SL et al. ( 2022 ) . Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type Diffuse Large B Cell Lymphoma . Blood Adv
Taylor JG, Truelove E, Clear A, Calaminici M, Gribben JG ( 2022 ) . PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T cell exhaustion . Haematologica
Grey W, Rio-Machin A, Casado P, Grönroos E, Ali S, Miettinen JJ, Bewicke-Copley F, Parsons A et al. ( 2022 ) . CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia . Science Translational Medicine vol. 14 , ( 650 )
Dreyling M, André M, Gökbuget N, Tilly H, Jerkeman M, Gribben J, Ferreri A, Morel P et al. ( 2022 ) . The EHA Research Roadmap: Malignant Lymphoid Diseases . HemaSphere vol. 6 , ( 6 )
Kluckova K, Clear AJ, D'Avola A, Rassenti LZ, Kipps TJ, Gribben JG, Riches JC ( 2022 ) . B-cell Receptor Signaling Induced Metabolic Alterations in Chronic Lymphocytic Leukemia Can Be Partially Bypassed by TP53 Abnormalities . HemaSphere vol. 6 , ( 6 )
Saunderson E, Encabo H, Rouault-Pierre K, Piganeau M, Bonnet D, Gribben J, Ficz G ( 2022 ) . P1411: DUAL EPIGENETIC AND GENETIC EDITING OF PRIMARY HUMAN HAEMATOPOIETIC STEM AND PROGENITOR CELLS . HemaSphere vol. 6 , ( Suppl ) 1295 - 1296 .
Grey W, Rio-Machin A, Casado-Izquierdo P, Gronroos E, Ali S, Miettinen J, Bewicke-Copley F, Parsons A et al. ( 2022 ) . P405: INHIBITION OF CKS1-DEPENDENT PROTEOSTASIS REVEALS VULNERABILITIES IN LEUKAEMIC STEM CELLS WITH CONCOMITANT PROTECTION OF HEALTHY HAEMATOPOIETIC STEM CELLS . HemaSphere vol. 6 , 305 - 306 .
Hillmen P, Pitchford A, Bloor A, Pettitt A, Patten P, Forconi F, Schuh A, Fox C et al. ( 2022 ) . S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL . HemaSphere vol. 6 , 46 - 47 .
Townsend W, Hiddemann W, Buske C, Cartron G, Cunningham D, Dyer MJ, Gribben J, Phillips E et al. ( 2022 ) . S206: OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM BENEFIT OVER RITUXIMAB PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: FINAL ANALYSIS OF THE GALLIUM STUDY . HemaSphere vol. 6 , 107 - 108 .
D’Avola A, Legrave N, Tajan M, Chakravarty P, Shearer RL, King HW, Kluckova K, Cheung EC et al. ( 2022 ) . PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma . Journal of Clinical Investigation vol. 132 , ( 9 )
Thanarajasingam G, Minasian LM, Bhatnagar V, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N et al. ( 2022 ) . Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies . The Lancet Haematology vol. 9 , ( 5 ) e374 - e384 .
Pedicona F, Casado P, Hijazi M, Gribben JG, Rouault-Pierre K, Cutillas PR ( 2022 ) . Targeting the lysine-specific demethylase 1 rewires kinase networks and primes leukemia cells for kinase inhibitor treatment . Science Signaling vol. 15 , ( 730 )
Buske C, Dreyling M, Alvarez-Larrán A, Apperley J, Arcaini L, Besson C, Bullinger L, Corradini P et al. ( 2022 ) . Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus . ESMO Open vol. 7 , ( 2 )
Swan D, Hayden PJ, Eikema DJ, Koster L, Sauer S, Blaise D, Nicholson E, Rabin N et al. ( 2022 ) . Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019 . British Journal of Haematology vol. 197 , ( 1 ) 82 - 96 .
Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F et al. ( 2022 ) . Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA) . Annals of Oncology vol. 33 , ( 3 ) 259 - 275 .
Gagelmann N, Gribben J, Kröger N ( 2022 ) . Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL . The EBMT/EHA CAR-T Cell Handbook ,
Kröger N, Gribben J, Sánchez-Ortega I ( 2022 ) . Educational Needs for Physicians . The EBMT/EHA CAR-T Cell Handbook ,
Grey W, Rio-Machin A, Casado-Izquierdo P, Gronroos E, Ali S, Miettinen J, Copley FB, Parsons A et al. ( 2022 ) . 3094 – INHIBITION OF CKS1-DEPENDENT PROTEOSTASIS REVEALS VULNERABILITIES IN LEUKAEMIC STEM CELLS WITH CONCOMITANT PROTECTION OF HEALTHY HAEMATOPOIESIS . Experimental Hematology vol. 111 , s91 - s92 .
de Leval L, Alizadeh AA, Bergsagel PL, Campo E, Davies A, Dogan A, Fitzgibbon J, Horwitz SM et al. ( 2022 ) . Genomic profiling for clinical decision making in lymphoid neoplasms . Blood
McCay J, Gribben JG ( 2022 ) . The role of BTK inhibitors on the tumor microenvironment in CLL . Leukemia and Lymphoma vol. 63 , ( 9 ) 2023 - 2032 .
Nobre LV, Basanta CC, Pedicona SF, Dokal AD, Arruda A, Smith R, Greenhalgh C, Patella F et al. ( 2021 ) . Abstract LBA013: Phosphoproteomics reveals active drug targets on pathways of resistance and predicts response to midostaurin plus chemotherapy in FLT3 mutant-positive acute myeloid leukemia . Molecular Cancer Therapeutics . vol. 20 , lba013 - lba013 .
Gribben J ( 2021 ) . Umbralisib and ublituximab: An upcoming regimen for chronic lymphocytic leukemia . Clinical Advances in Hematology and Oncology vol. 19 , ( 12 ) 768 - 769 .
Palomba ML, Ghione P, Patel AR, Deighton K, Jacobson C, Nahas M, Jung AS, Hatswell AJ et al. ( 2021 ) . A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL) . Blood vol. 138 , ( Supplement 1 ) 3543 - 3543 .
Jacobs R, Jurczak W, Flinn IW, Grosicki S, Giannopoulos K, Wróbel T, Zafar SF, Cultrera JL et al. ( 2021 ) . Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study . Blood vol. 138 , ( Supplement 1 ) 3726 - 3726 .
D'Avola A, Legrave N, Tajan M, Chakravarty P, Shearer R, King H, Cheung E, Clear AJ et al. ( 2021 ) . Phosphoglycerate Dehydrogenase Is Required for Germinal Center Formation and Is a Therapeutic Target in MYC- driven Lymphoma . Blood vol. 138 , ( Supplement 1 ) 717 - 717 .
Austin MJ, Halim L, Miraki-Moud F, Taussig D, Bomalaski J, Maher J, Gribben J, Szlosarek P et al. ( 2021 ) . Priming Death Receptor Mediated Apoptosis with Arginine Starvation Sensitises Arginine Auxotrophic B-ALL to CAR-T . Blood vol. 138 , ( Supplement 1 ) 2787 - 2787 .
Veiga Nobre LMV, Pedicona SF, Dokal A, Arruda A, Smith R, Greenhalgh C, Patella F, Casado-Izquierdo P et al. ( 2021 ) . Proteomics and Phospho-Proteomics Reveal Predictive Signatures of Response and Mechanisms of Resistance to Midostaurin Plus Chemotherapy in FLT3 Mutant Positive Acute Myeloid Leukemia . Blood vol. 138 , ( Supplement 1 ) 3462 - 3462 .
Mian S, Philippe C, Maniati E, Bergot T, Piganeau M, Di Bella D, Morales V, Finch A et al. ( 2021 ) . Vitamin B5 and Succinyl-CoA Improve Ineffective Erythropoiesis in SF3B1 Mutated Myelodysplasia . Blood vol. 138 , ( Supplement 1 ) 324 - 324 .
Wood G, Pinto A, Evans S, Daly A, Adams S, Costelloe S, Gribben J, Ellerton C et al. ( 2021 ) . Special low protein foods prescribed in england for pku patients: An analysis of prescribing patterns and cost . Nutrients vol. 13 , ( 11 )
Edwards K, Zaitseva K, Sayed U, Volpi EV, Nathwani A, Gribben JG, Lydyard P, Krysov S et al. ( 2021 ) . Expression patterns of CD180 in the lymph nodes of patients with chronic lymphocytic leukaemia . British Journal of Haematology vol. 195 , ( 2 ) e131 - e134 .
Moschopoulou E, Deane J, Duncan M, Ismail SA, Moriarty S, Sarker SJ, White P, Korszun A et al. ( 2021 ) . Measuring quality of life in people living with and beyond cancer in the UK . Supportive Care in Cancer vol. 29 , ( 10 ) 6031 - 6038 .
Heydt Q, Xintaropoulou C, Clear A, Austin M, Pislariu I, Miraki-Moud F, Cutillas P, Korfi K et al. ( 2021 ) . Adipocytes disrupt the translational programme of acute lymphoblastic leukaemia to favour tumour survival and persistence . Nature Communications
Bloehdorn J, Braun A, Taylor-Weiner A, Jebaraj BMC, Robrecht S, Krzykalla J, Pan H, Giza A et al. ( 2021 ) . Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia . Nature Communications vol. 12 , ( 1 ) Article 5395 ,
Gribben JG ( 2021 ) . To start and stop or just keep going? . Blood vol. 138 , ( 10 ) 819 - 820 .
Heward J, Konali L, D'Avola A, Close K, Yeomans A, Philpott M, Dunford J, Rahim T et al. ( 2021 ) . KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas . Blood vol. 138 , ( 5 ) 370 - 381 .
Gomes AL, Gribben J, Siow B, Passaro D, Bonnet D ( 2021 ) . Dynamic contrast-enhanced magnetic resonance imaging quantification of leukemia-induced changes in bone marrow vascular function . Haematologica vol. 106 , ( 8 ) 2281 - 2286 .
Greil R, Tedeschi A, Moreno C, Anz B, Larratt L, Simkovic M, Gill D, Gribben JG et al. ( 2021 ) . Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study . Annals of Hematology vol. 100 , ( 7 ) 1733 - 1742 .
Mansur MB, Furness CL, Nakjang S, Enshaei A, Alpar D, Colman SM, Minto L, Irving J et al. ( 2021 ) . The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia . Cancer Medicine vol. 10 , ( 14 ) 4864 - 4873 .
Ghione P, Ghesquieres H, Bobillo S, Patel AR, Kanters S, Deighton K, Dong H, Yang Y et al. ( 2021 ) . OUTCOMES IN LATER‐LINES OF THERAPY FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: RESULTS FROM THE INTERNATIONAL SCHOLAR‐5 STUDY . Hematological Oncology vol. 39 , ( S2 )
Chabannon C, Terwel S, Hoogenboom JD, Basak G, Corbacioglu S, de la Camara R, Dolstra H, Glass B et al. ( 2021 ) . Building of The G0-CAR-T Initiative to Promote Use of Data Collected from Patients Treated With CAR-T Cells AT EU OR EBMT Affiliated Programs . BONE MARROW TRANSPLANTATION . vol. 56 , 43 - 44 .
Gribben J, Macintyre E, Sonneveld P ( 2021 ) . The EHA2021 Annual Congress Award Winners: Celebrating Excellence in Hematology . HemaSphere vol. 5 , ( 6 )
Dillon J, Hayden PJ, Eikema D-J, Koster L, Blaise D, Nicholson E, Potter V, Rabin N et al. ( 2021 ) . Trends in Autologous Stem Cell Mobilisation Practices in Myeloma Patients in Ebmt Centers Between 2008 And 2017 . BONE MARROW TRANSPLANTATION . vol. 56 , 327 - 328 .
Dokal AD, Arruda A, Smith R, Greenhalgh C, Patella F, Casado-Izquierdo PM, Wrench B, Theaker J et al. ( 2021 ) . Predictive phosphoproteomic signatures for midostaurin plus chemotherapy response in FLT3 mutant positive acute myeloid leukaemia . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 7019 - 7019 .
Passaro D, Garcia-Albornoz M, Diana G, Chakravarty P, Ariza-McNaughton L, Batsivari A, Borràs-Eroles C, Abarrategi A et al. ( 2021 ) . Integrated OMICs unveil the bone-marrow microenvironment in human leukemia . Cell Reports vol. 35 , ( 6 )
Jurgensen-Rauch A, Gibbs S, Farrell M, Aries J, Grantham M, Eccersley L, Gribben J, Hallam S et al. ( 2021 ) . Reduced intensity allogeneic hematopoietic stem cell transplantation is a safe and effective treatment option in high-risk myeloma patients – a single centre experience . British Journal of Haematology vol. 193 , ( 2 ) 420 - 423 .
Collins GP, Clevenger TN, Burke KA, Yang B, MacDonald A, Cunningham D, Fox CP, Goy A et al. ( 2021 ) . A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies . Leukemia and Lymphoma vol. 62 , ( 11 ) 2625 - 2636 .
Delvecchio FR, Fincham REA, Spear S, Clear A, Roy-Luzarraga M, Balkwill FR, Gribben JG, Bombardieri M et al. ( 2021 ) . Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in Mice . Cellular and Molecular Gastroenterology and Hepatology vol. 12 , ( 5 ) 1543 - 1565 .
Jurczak W, Rule S, Townsend W, Tucker D, Sarholz B, Scheele J, Dyroff M, Gribben JG et al. ( 2021 ) . Phase I, first-in-human trial of Bruton’s tyrosine kinase inhibitor M7583 in patients with B-cell malignancies . Leukemia and Lymphoma . vol. 62 , 2392 - 2399 .
Edelmann J, Dokal AD, Vilventhraraja E, Holzmann K, Britton D, Klymenko T, Döhner H, Cragg M et al. ( 2021 ) . Rituximab and obinutuzumab differentially hijack the B-cell receptor and NOTCH1 signaling pathways . iScience102089 - 102089 .
Halligan R, White FJ, Schwahn B, Stepien KM, Kamarus Jaman N, McSweeney M, Kitchen S, Gribben J et al. ( 2021 ) . The natural history of glycogen storage disease type Ib in England: A multisite survey . JIMD Reports vol. 59 , ( 1 ) 52 - 59 .
Hayden PJ, Eikema D-J, Koster L, Goldschmidt H, Blaise D, Potter M, Touzeau C, Huynh A et al. ( 2020 ) . 25 Years of Autologous Transplantation for Myeloma in Ebmt Centres - Changing Practice Patterns . BONE MARROW TRANSPLANTATION . vol. 55 , 130 - 132 .
Seymour JF, Gribben JG, Davids MS, Mato A, Sharman JP, Cyr A, Bartkus C, Pena G et al. ( 2020 ) . Assessment of Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax in the Clinical Trial and Post-Marketing Settings . Blood vol. 136 , ( Supplement 1 ) 37 - 38 .
Hillmen P, Boucher RH, Webster N, Dalal S, Brock K, Yates F, Sankhalpara C, Macdonald D et al. ( 2020 ) . Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial . Blood vol. 136 , ( Supplement 1 ) 17 - 18 .
Bloehdorn J, Braun A, Jebaraj BMC, Taylor-Weiner A, Robrecht S, Krzykalla J, Holzmann K, Johnston H et al. ( 2020 ) . Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia . Blood . Conference: American Society of Hematology Annual Meeting vol. 136 , 12 - 13 .
Gribben JG, Jurczak W, Jacobs RW, Grosicki S, Giannopoulos K, Wrobel T, Zafar SF, Cultrera JL et al. ( 2020 ) . Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study . Blood vol. 136 , ( Supplement 1 ) 37 - 39 .
Pinto A, Ashmore C, Batzios S, Daly A, Dawson C, Dixon M, Evans S, Green D et al. ( 2020 ) . Dietary management, clinical status and outcome of patients with citrin deficiency in the uk . Nutrients vol. 12 , ( 11 ) 1 - 21 .
Merlini G, Gribben J, Macintyre E, Piggin M, Doeswijk R ( 2020 ) . Access to Affordable Orphan Medicines in Europe: An EHA Position Paper . Hemasphere vol. 4 , ( 5 )
Roy-Luzarraga M, Abdel-Fatah T, Reynolds LE, Clear A, Taylor JG, Gribben JG, Chan S, Jones L et al. ( 2020 ) . Association of Low Tumor Endothelial Cell pY397-Focal Adhesion Kinase Expression With Survival in Patients With Neoadjuvant-Treated Locally Advanced Breast Cancer . JAMA network open vol. 3 , ( 10 )
Jäger U, Kapitein P, Gribben J ( 2020 ) . Personalized Treatment for Hematologic Diseases in Europe: An EHA Position Paper . Hemasphere vol. 4 , ( 5 )
La Rosee P, Graeven U, Leonard JP, Gribben J, Zhang H, Nowakowski G, Izutsu K, Fowler NH et al. ( 2020 ) . Subgroup analyses of patients aged >= 70 years in AUGMENT: Phase III randomized study of Lenalidomide plus rituximab (R-2) vs rituximab plus placebo (R-placebo) in patients with Relapsed/Refractory (R/R) indolent Non-Hodgkin Lymphoma (iNHL) . ONCOLOGY RESEARCH AND TREATMENT . vol. 43 , 68 - 68 .
Ball J, Clear A, Aries J, Charrot S, Besley C, Mee M, Stagg A, Lindsay J et al. ( 2020 ) . Retinoic acid-responsive CD8 effector T-cells are selectively increased in IL-23-rich tissue in gastrointestinal GvHD . Blood
Anthias C, Apperley J, Bloor A, Byrne J, Collin M, Crawley C, Craddock C, Finnegan D et al. ( 2020 ) . Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization Initiative . Bone Marrow Transplantation vol. 55 , ( 9 ) 1840 - 1843 .
Evans S, Adam S, Adams S, Allen H, Ashmore C, Bailey S, Banks J, Churchill H et al. ( 2020 ) . Uniformity of food protein interpretation amongst dietitians for patients with phenylketonuria (Pku): 2020 uk national consensus statements . Nutrients vol. 12 , ( 8 ) 1 - 12 .
Wong PP, Muñoz-Félix JM, Hijazi M, Kim H, Robinson SD, De Luxán-Delgado B, Rodríguez-Hernández I, Maiques O et al. ( 2020 ) . Cancer Burden Is Controlled by Mural Cell-β3-Integrin Regulated Crosstalk with Tumor Cells . Cell vol. 181 , ( 6 ) 1346 - 1363.e21 .
Waclawiczek A, Hamilton A, Rouault-Pierre K, Abarrategi A, Albornoz MG, Miraki-Moud F, Bah N, Gribben J et al. ( 2020 ) . Mesenchymal niche remodeling impairs hematopoiesis via stanniocalcin 1 in acute myeloid leukemia . Journal of Clinical Investigation vol. 130 , ( 6 ) 3038 - 3050 .
Townsend W, Buske C, Cartron G, Cunningham D, Dyer MJS, Gribben JG, Zhang Z, Rufibach K et al. ( 2020 ) . Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: Updated results from the phase III Gallium Study . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,
Aries JA, Davies JK, Auer RL, Hallam SL, Montoto S, Smith M, Sevillano B, Foggo V et al. ( 2020 ) . Clinical Outcome of Coronavirus Disease 2019 in Haemato-oncology Patients . British Journal of Haematology
Méndez-Ferrer S, Bonnet D, Steensma DP, Hasserjian RP, Ghobrial IM, Gribben JG, Andreeff M, Krause DS ( 2020 ) . Bone marrow niches in haematological malignancies . Nature Reviews Cancer vol. 20 , ( 5 ) 285 - 298 .
Gribben JG ( 2020 ) . Do we need to analyse everything at diagnosis in chronic lymphocytic leukaemia? . British Journal of Haematology vol. 189 , ( 4 ) 603 - 604 .
Edelmann J, Holzmann K, Tausch E, Saunderson EA, Jebaraj BMC, Steinbrecher D, Dolnik A, Blätte TJ et al. ( 2020 ) . Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription . Haematologica vol. 105 , ( 5 ) 1379 - 1390 .
Ghazaly EA, Miraki-Moud F, Smith P, Gnanaranjan C, Koniali L, Oke A, Saied MH, Petty R et al. ( 2020 ) . Repression of sphingosine kinase (SK)-interacting protein (SKIP) in acute myeloid leukemia diminishes SK activity and its re-expression restores SK function . Journal of Biological Chemistry vol. 295 , ( 16 ) 5496 - 5508 .
Lazarian G, Friedrich C, Quinquenel A, Tran J, Ouriemmi S, Dondi E, Martin A, Mihoub I et al. ( 2020 ) . Stabilization of β-catenin upon B-cell receptor signaling promotes NF-kB target genes transcription in mantle cell lymphoma . Oncogene vol. 39 , ( 14 ) 2934 - 2947 .
Dexter T, Aries J, Sevillano B, Gribben J, Oakervee H, Cavenagh J, Smith M, Wrench B ( 2020 ) . Antibody immunotherapy treatment for adults with B-acute lymphoblastic leukaemia-a real-world analysis . BRITISH JOURNAL OF HAEMATOLOGY . vol. 189 , 186 - 186 .
Gribben JG, de Vries E, Cherny NI, Sonneveld P ( 2020 ) . Measuring Clinical Benefit of Treatments for Hematologic Malignancies: Critical First Steps Accomplished-What is Next? . Hemasphere vol. 4 , ( 2 )
Gribben J, Macintyre E, Sonneveld P, Doorduijn J, Gisselbrecht C, Jäger U, Le Gouill S, Rule S et al. ( 2020 ) . Reducing Bureaucracy in Clinical Research: A Call for Action . Hemasphere vol. 4 , ( 2 )
Di Mambro A, Arroyo-Berdugo Y, Calle Y, Wrench B, Gribben J, Esposito MT ( 2020 ) . Targeting SET-PP2A complex as a new avenue of treatment for Mixed Lineage Leukemia (MLL) treatment . BRITISH JOURNAL OF HAEMATOLOGY . vol. 189 , 51 - 52 .
Prynn N, Jackson G, Gribben J, Follows G, McDougall L ( 2020 ) . The Haematology Summit 2014-2019: evolution of a national medical education programme . BRITISH JOURNAL OF HAEMATOLOGY . vol. 189 , 62 - 63 .
Munir T, Rawstron A, Brock K, Munoz-Vicente S, Yates F, Bishop R, MacDonald D, Fegan C et al. ( 2020 ) . Ibrutinib plus venetoclax in Relapsed/Refractory CLL: The CLARITY Study . LEUKEMIA & LYMPHOMA . vol. 61 , 227 - 228 .
Krysov S, Odabashian M, Carlotti E, Araf S, Okosun J, Spada F, Gribben J, Forconi F et al. ( 2020 ) . IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution . Blood vol. 135 , ( 11 ) 834 - 844 .
Wu Y, Chang YM, Polton G, Stell AJ, Szladovits B, Macfarlane M, Peters LM, Priestnall SL et al. ( 2020 ) . Gene Expression Profiling of B Cell Lymphoma in Dogs Reveals Dichotomous Metabolic Signatures Distinguished by Oxidative Phosphorylation . Frontiers in Oncology vol. 10 ,
Gribben JG ( 2020 ) . Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia . British Journal of Haematology vol. 188 , ( 6 ) 844 - 851 .
Pott C, Sehn LH, Belada D, Gribben J, Hoster E, Kahl B, Kehden B, Nicolas-Virelizier E et al. ( 2020 ) . MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial . Leukemia vol. 34 , ( 2 ) 522 - 532 .
Tedeschi A, Greil R, Demirkan F, Robak T, Moreno C, Barr PM, Anz B, Simpson D et al. ( 2020 ) . A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma . Haematologica vol. 105 , ( 4 ) E164 - E168 .
Pinto A, Evans S, Daly A, Almeida MF, Assoun M, Belanger-Quintana A, Bernabei SM, Bollhalder S et al. ( 2020 ) . Dietary practices in methylmalonic acidaemia: A European survey . Journal of Pediatric Endocrinology and Metabolism
Macintyre E, Gribben J, Döhner K ( 2020 ) . EU-wide access to high-quality, affordable precision diagnostics: An EHA position paper . HemaSphere vol. 4 , ( 3 )
Hagenbeek A, Gribben J, Jäger U, Kapitein P, Merlini G, Piggin M, Uyl-De Groot CA, Doeswijk R ( 2020 ) . Fair pricing of innovative medicines: An EHA position paper . HemaSphere vol. 4 , ( 5 )
Pieri CA, Roberts N, Gribben J, Manisty C ( 2020 ) . Graft-versus-host disease: A case report of a rare but reversible cause of constrictive pericarditis . European Heart Journal - Case Reports vol. 4 , ( 2 ) 1 - 5 .
Gribben JG ( 2020 ) . Marrow contamination: Immunological treatment . Autologous Stem Cell Transplantation: Biological and Clinical Results in Malignancies ,
Cools J, Engert A, Gribben J, Macintyre E ( 2020 ) . Open access is the plan S way forward in hematology research . HemaSphere vol. 4 , ( 1 )
Petersdorf EW, Carrington M, O'hUigin C, Bengtsson M, De Santis D, Dubois V, Gooley T, Horowitz M et al. ( 2020 ) . Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study . The Lancet Haematology vol. 7 , ( 1 ) e50 - e60 .
Wodehouse T, Demopoulos M, Petty R, Miraki-Moud F, Belhaj A, Husband M, Fulton L, Randive N et al. ( 2019 ) . A randomized pilot study to investigate the effect of opioids on immunomarkers using gene expression profiling during surgery . Pain vol. 160 , ( 12 ) 2691 - 2698 .
Gribben J, Merlini G, Hagenbeek A ( 2019 ) . Here to Stay: Biosimilars in Hematology . HemaSphere vol. 3 , ( 6 )
Goulart MR, Hlavaty SI, Chang YM, Polton G, Stell A, Perry J, Wu Y, Sharma E et al. ( 2019 ) . Phenotypic and transcriptomic characterization of canine myeloid-derived suppressor cells . Scientific Reports vol. 9 , ( 1 )
Wu Y, Chang YM, Stell AJ, Priestnall SL, Sharma E, Goulart MR, Gribben J, Xia D et al. ( 2019 ) . Phenotypic characterisation of regulatory T cells in dogs reveals signature transcripts conserved in humans and mice . Scientific Reports vol. 9 , ( 1 )
Taylor JG, Clear AJ, Truelove E, Calaminici M, Gribben JG ( 2019 ) . Beyond Exhaustion: The PDL1-PD1 Axis Shapes the Classical Hodgkin Lymphoma Microenvironment . Blood . vol. 134 , 658 - 658 .
Sanderson R, Romero-Toledo A, Gribben JG ( 2019 ) . CAR T Cells Derived from Healthy Mice Lead to Cytokine Release Syndrome (CRS) in the TCL1 Chronic Lymphocytic Leukemia Model; Mice with CLL Treated with Acalabrutinib or Ibrutinib Have Improved CAR T Cell Function without Increasing the Cytokines of CRS . Blood . vol. 134 , 249 - 249 .
Saunderson EA, Rouault-Pierre K, Gribben JG, Ficz G ( 2019 ) . CRISPR/Cas9-Targeted De Novo DNA Methylation Is Maintained and Impacts the Colony Forming Potential of Human Hematopoietic CD34+ Cells . Blood vol. 134 , ( Supplement_1 ) 2517 - 2517 .
Schönland SO, Iacobelli S, Koster L, Blaise D, Potter M, Cornelissen JJ, Chevallier P, Mayer J et al. ( 2019 ) . Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT . Blood . vol. 134 , 324 - 324 .
Aries J, Charrot S, Ball J, Mee M, Theocharidis S, Van Gassen S, Iqbal S, Gribben JG et al. ( 2019 ) . Integrated Immune Signature Analyses Identifies Evolution of Distinct Immunoregulatory Cell Populations Which Control Alloreactivity after Allogeneic HSCT . Blood . vol. 134 , 595 - 595 .
Bewicke-Copley F, Korfi K, Araf S, Kumar EA, Cummin TEC, Ashton-Key M, Barrans S, Van Hoppe S et al. ( 2019 ) . Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel . Blood vol. 134 , ( Supplement_1 ) 2769 - 2769 .
Edelmann J, Dokal A, Holzmann K, Britton DJ, Vilventhraraja E, Smith RJ, Cragg MS, Braun A et al. ( 2019 ) . Rituximab and Obinutuzumab Induce Direct B-Cell Death Via B-Cell Receptor (BCR) Signaling, but Rituximab Elicits Stronger BCR-Derived Pro-Survival Signals Diminishing Apoptosis . Blood vol. 134 , ( Supplement_1 ) 1579 - 1579 .
Trněný M, Leonard JP, Zhang H, Nowakowski G, Izutsu K, Fowler NH, Thieblemont C, Zinzani PL et al. ( 2019 ) . Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) . Blood vol. 134 , ( Supplement_1 ) 347 - 347 .
Sehn LH, Trněný M, Bouabdallah K, Dueck G, Gribben JG, Lugtenburg PJ, Salles GA, Knapp A et al. ( 2019 ) . Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study . Blood vol. 134 , ( Supplement_1 ) 2822 - 2822 .
Truelove E, Seymour F, Taylor JG, Calaminici M, Clear AJ, Gribben JG ( 2019 ) . The Immune Micro-Environment in Diffuse Large B Cell Lymphoma Is Characterised By an Immunosuppressive Shift in T Cell Subsets . Blood vol. 134 , ( Supplement_1 ) 5240 - 5240 .
Romero-Toledo A, Sanderson R, Gribben JG ( 2019 ) . Treatment with Acalibrutinib, Ibrutinib and CD19 CAR T Cells Restore the Number of Granulocytic Myeloid Derived Supressor Cells in CLL-Bearing Mice . Blood vol. 134 , ( Supplement_1 ) 3032 - 3032 .
Hayden PJ, Eikema D-J, Koster L, Goldschmidt H, Blaise D, Potter M, Touzeau C, Huynh A et al. ( 2019 ) . Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017 . Blood vol. 134 , ( Supplement_1 ) 4575 - 4575 .
Pinto A, Gribben J, Trneny M, Izutsu K, Fowler NH, Hong X, Zhang H, Offner F et al. ( 2019 ) . LENALIDOMIDE/RITUXIMAB (R2) VERSUS RITUXIMAB/PLACEBO EFFICACY BY POD24 STATUS AND TIME TO NEXT TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NHL (AUGMENT) . HAEMATOLOGICA . vol. 104 , 7 - 8 .
Savoie ML, Davies JK, Cavenagh J, Oakervee H, Sive J, Smith M, Anderson D, Gribben J et al. ( 2019 ) . Low treatment related mortality and relapse leading to excellent outcomes after allogeneic transplantation for acute lymphoblastic leukaemia using a non-myeloablative conditioning without T CELL depletion . BONE MARROW TRANSPLANTATION . vol. 54 , 144 - 145 .
Aries J, Ball J, Charrot S, Mee M, Van Gassen S, Iqbal S, Gribben J, Davies J ( 2019 ) . Novel mass cytometry analysis identifies reciprocal changes in NKREG and CD4EM as the dominant early immune reconstitution signature associated with subsequent acute GVHD after RIC-AHST . BONE MARROW TRANSPLANTATION . vol. 54 , 117 - 118 .
Gruber M, Bozic I, Leshchiner I, Livitz D, Stevenson K, Rassenti L, Rosebrock D, Taylor-Weiner A et al. ( 2019 ) . Growth dynamics in naturally progressing chronic lymphocytic leukaemia . Nature vol. 570 , ( 7762 ) 474 - 479 .
Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, Hillmen P, Rogers KA et al. ( 2019 ) . Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia . Blood vol. 133 , ( 26 ) 2765 - 2775 .
Leonard J, Trneny M, Izutsu K, Fowler N, Hong X, Zhang H, Offner F, Scheliga A et al. ( 2019 ) . AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS . Hematological Oncology vol. 37 , 114 - 115 .
Gribben J, Trneny M, Izutsu K, Fowler NH, Hong X, Zhang H, Offner F, Scheliga A et al. ( 2019 ) . AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO . Hematological Oncology vol. 37 , 227 - 229 .
Leonard JP, Trněny M, Izutsu K, Fowler NH, Hong X, Zhang H, Offner F, Scheliga A et al. ( 2019 ) . HEALTH‐RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2) VERSUS R PLUS PLACEBO . Hematological Oncology vol. 37 , 232 - 234 .
Greil R, Tedeschi A, Moreno C, Anz B, Larratt L, Simkovic M, Gill D, Gribben JG et al. ( 2019 ) . IBRUTINIB DECREASES OBINUTUZUMAB‐INDUCED SECRETION OF CYTOKINES ASSOCIATED WITH INFUSION‐RELATED REACTIONS IN PATIENTS WITH CLL: ANALYSIS FROM THE ILLUMINATE STUDY . Hematological Oncology vol. 37 , 210 - 212 .
Korfi K, Araf S, Bewicke‐Copley F, Kumar E, Cummin T, Ashton‐Key M, Barrans S, Van Hoppe S et al. ( 2019 ) . LONGITUDINAL ANALYSES OF DIAGNOSTIC‐RELAPSE BIOPSIES OF DIFFUSE LARGE B CELL LYMPHOMA SUGGEST THAT RELAPSE IS MEDIATED BY DISTINCT MECHANISMS IN ABC AND GCB LYMPHOMA . Hematological Oncology vol. 37 , 142 - 143 .
Thieblemont C, Leonard J, Trneny M, Izutsu K, Fowler N, Hong X, Zhang H, Offner F et al. ( 2019 ) . POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO (AUGMENT) . Hematological Oncology vol. 37 , 226 - 227 .
Araf S, Wang J, Korfi K, Pangault C, Kotsiou E, Rio-Machin A, Rahim T, Heward J et al. ( 2019 ) . Correction: Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma (Leukemia, (2018), 32, 5, (1261-1265), 10.1038/s41375-018-0043-y) . Leukemia vol. 33 , ( 6 )
Di Mambro A, Arroyo-Berdugo Y, Calle-Patino Y, Wrench B, Gribben J, Esposito MT ( 2019 ) . PF241 TARGETING SET-PP2A INTERACTION AS A NOVEL THERAPEUTIC APPROACH FOR MIXED LINEAGE LEUKEMIA (MLL) . HemaSphere vol. 3 , ( S1 ) 72 - 73 .
Jurgensen-Rauch A, Gibbs S, Farrell M, Cavenagh J, Eccersley L, Gribben J, Hallam S, Oakervee H et al. ( 2019 ) . PF642 REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS A SAFE AND EFFECTIVE TREATMENT OPTION IN HIGH RISK MYELOMA PATIENTS – A SINGLE CENTRE EXPERIENCE . HemaSphere vol. 3 , ( S1 )
Arroyo-Berdugo Y, Di Mambro A, Calle-Patino Y, Wrench B, Gribben J, Esposito MT ( 2019 ) . PS1000 POST-TRANSLATIONAL MODIFICATIONS OF PROTEIN PHOSPHATASE 2A (PP2A) IN MIXED LINEAGE LEUKEMIA (MLL) . HemaSphere vol. 3 , ( S1 )
Romero-Toledo A, Schwarzbich M, Sanderson R, Gribben J ( 2019 ) . PS1135 MONOCYTIC BUT NOT GRANULOCYTIC MDSCS INCREASE WITH IBRUTINIB BUT NOT ACALABRUTINIB TREATMENT IN EM-TCL1 MICE WITH CLL, SUGGESTING A ROLE FOR ITK INHIBITION IN MONOCYTIC MDSCS . HemaSphere vol. 3 , ( S1 )
Gribben J, Trneny M, Izutsu K, Fowler NH, Hong X, Zhang H, Offner F, Scheliga A et al. ( 2019 ) . PS1252 PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO (AUGMENT) . HemaSphere vol. 3 , ( S1 ) 571 - 572 .
Thieblemont C, Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhang H, Offner F et al. ( 2019 ) . PS1262 POST HOC ANALYSIS OF THE AUGMENT PHASE III RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA . HemaSphere vol. 3 , ( S1 ) 577 - 578 .
Heward J, Koniali L, D’Avola A, Close K, Yeomans A, Johnson P, Okosun J, Neve R et al. ( 2019 ) . S844 KDM5 INHIBITION OFFERS A NOVEL THERAPEUTIC STRATEGY FOR THE TREATMENT OF KMT2D MUTANT LYMPHOMAS . HemaSphere vol. 3 , ( S1 ) 376 - 377 .
Sanderson R, Romero-Toledo A, Gribben J ( 2019 ) . S898 CD19+ RELAPSE POST CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IS DETERMINED BY T CELL FITNESS . HemaSphere vol. 3 , ( S1 ) 404 - 405 .
Snowden JA, Hawkey C, Hind D, Swaby L, Mellor K, Emsley R, Mandefield L, Lee E et al. ( 2019 ) . Autologous stem cell transplantation in refractory Crohn's disease - Low intensity therapy evaluation (ASTIClite): Study protocols for a multicentre, randomised controlled trial and observational follow up study . BMC Gastroenterology vol. 19 , ( 1 )
McClanahan F, Gribben J ( 2019 ) . The Eμ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia . Handbook of Immunosenescence ,
Gribben JG, Izutsu K, Fowler NH, Hong X, Zhang H, Offner F, Scheliga AAS, Nowakowski GS et al. ( 2019 ) . Efficacy and time to next treatment following lenalidomide/rituximab (R 2 ) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT) . Journal of Clinical Oncology vol. 37 , ( 15_suppl ) 7514 - 7514 .
Gribben JG, Izutsu K, Fowler NH, Hong X, Zhang H, Offner F, Scheliga AAS, Nowakowski GS et al. ( 2019 ) . Efficacy and time to next treatment following lenalidomide/rituximab (R-2) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT) . JOURNAL OF CLINICAL ONCOLOGY . vol. 37 ,
Zhang T, Guan XW, Gribben JG, Liu FT, Jia L ( 2019 ) . Blockade of HMGB1 signaling pathway by ethyl pyruvate inhibits tumor growth in diffuse large B-cell lymphoma . Cell Death and Disease vol. 10 , ( 5 )
Potter N, Miraki-Moud F, Ermini L, Titley I, Vijayaraghavan G, Papaemmanuil E, Campbell P, Gribben J et al. ( 2019 ) . Single cell analysis of clonal architecture in acute myeloid leukaemia . Leukemia vol. 33 , ( 5 ) 1113 - 1123 .
Sun D, Stopka-Farooqui U, Barry S, Aksoy E, Parsonage G, Vossenkämper A, Capasso M, Wan X et al. ( 2019 ) . Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation . Cell Reports vol. 27 , ( 5 ) 1461 - 1471.e4 .
BARRY S, Sun D, Stopka-Farooqui U, Aksoy E, Parsonage G, Vossenkamper A, Capasso M, Wan X et al. ( 2019 ) . SAT-LB056 Is AIP a Tumor Suppressor or an Oncogene? AIP as a Novel Regulator of the Oncogene BCL6 in Diffuse Large B Cell Lymphoma . Journal of the Endocrine Society vol. 3 , ( Suppl 1 ) sat - lb056 .
Baptista MJ, Tapia G, Morgades M, Muncunill J, Muñoz-Marmol AM, Montoto S, Gribben JG, Calaminici M et al. ( 2019 ) . Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma . Leukemia and Lymphoma vol. 60 , ( 4 ) 1087 - 1091 .
Munir T, Rawstron A, Brock K, Vicente SM, Yates F, Bishop R, Macdonald D, Fegan C et al. ( 2019 ) . Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study . BRITISH JOURNAL OF HAEMATOLOGY . vol. 185 , 25 - 25 .
Gribben J, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F et al. ( 2019 ) . Phase III Randomized AUGMENT Study of Lenalidomide/Rituximab vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma . BRITISH JOURNAL OF HAEMATOLOGY . vol. 185 , 79 - 79 .
Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F et al. ( 2019 ) . AUGMENT: A Phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma . Journal of Clinical Oncology vol. 37 , ( 14 ) 1188 - 1199 .
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Samoilova O et al. ( 2019 ) . Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial . The Lancet Oncology vol. 20 , ( 1 ) 43 - 56 .
Hillmen P, Rawstron AC, Brock K, Muñoz-Vicente S, Yates FJ, Bishop R, Boucher R, MacDonald D et al. ( 2019 ) . Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: The CLARITY study . Journal of Clinical Oncology vol. 37 , ( 30 ) 2722 - 2729 .
Crombie JL, Letai A, Gribben JG ( 2019 ) . Lymphoma genetics . Molecular Hematology ,
Provan D, Gribben JG ( 2019 ) . Molecular hematology: Fourth edition .
Provan D, Gribben JG ( 2019 ) . Preface to the fourth edition .
Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, Natkunam Y, Calaminici M et al. ( 2019 ) . Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: A study by the Lunenburg Lymphoma Biomarker Consortium . Journal of Clinical Oncology vol. 37 , ( 35 ) 3359 - 3368 .
Taylor JG, Clear A, Calaminici M, Gribben JG ( 2019 ) . Programmed cell death protein-1 (PD1) expression in the microenvironment of classical hodgkin lymphoma is similar between favorable and adverse outcome and does not enrich over serial relapses with conventional chemotherapy . Haematologica vol. 104 , ( 1 ) e42 - e44 .
Gribben JG ( 2019 ) . The molecular biology of chronic lymphocytic leukemia . Molecular Hematology ,
Jurczak W, Rule S, Townsend W, Tucker D, Sarholz B, Scheele J, Gribben JG, Zinzani PL ( 2018 ) . A Phase I/II, First in Human Trial of the Bruton's Tyrosine Kinase Inhibitor M7583 in Patients with B-Cell Malignancies . Blood . vol. 132 , 4161 - 4161 .
Leonard JP, Trněný M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F et al. ( 2018 ) . AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma . Blood . vol. 132 , 445 - 445 .
Edelmann J, Britton DJ, Vilventhraraja E, Dokal A, Holzmann K, Cragg MC, Braun A, Cutillas P et al. ( 2018 ) . Anti-CD20 Monoclonal Antibodies Hijack the B-Cell Receptor Signaling Cascade Thereby Activating the NOTCH1 Signaling Pathway . Blood . Conference: American Society of Hematology Annual Congress vol. 132 , 588 - 588 .
Clear AJ, D'Avola A, Agrawal SG, Rassenti LZ, Kipps TJ, Gribben JG, Riches J ( 2018 ) . B-Cell Receptor Signaling Drives Glycolysis in Chronic Lymphocytic Leukemia Cells . Blood . vol. 132 , 3121 - 3121 .
Seymour F, Cavenagh J, Gribben JG ( 2018 ) . Characterising the Immunological Microenvironment in Newly Diagnosed Multiple Myeloma Bone Marrow By Time of Flight Cytometry Reveals Abnormalities in Antigen Presenting and Effector Lymphocyte Populations with Prognostic Significance . Blood . vol. 132 , 58 - 58 .
Truelove E, Seymour F, Matthews J, Gribben JG ( 2018 ) . Deep Phenotypic Analysis Reveals a Monocyte Subpopulation Predictive of Relapse/Refractory Diffuse Large B-Cell Lymphoma . Blood . vol. 132 , 2863 - 2863 .
Sanderson R, Romero-Toledo A, Gribben JG ( 2018 ) . Exhausted CLL T Cells Mediated By PD1 Expression an Important Mechanism for CD19 CAR Efficacy in CLL in the Adoptive Transfer TCL1 Mouse Model . Blood vol. 132 , ( Supplement 1 ) 4537 - 4537 .
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Samoilova O et al. ( 2018 ) . Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE . Blood . vol. 132 , 691 - 691 .
Hillmen P, Rawstron A, Brock K, Munoz Vicente S, Yates F, Bishop R, Macdonald D, Fegan C et al. ( 2018 ) . Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study . Blood . vol. 132 , 182 - 182 .
Seymour F, Young MH, Tometsko M, Cavenagh J, Thompson EG, Whalen E, Danziger SA, Fitch A et al. ( 2018 ) . Immune Microenvironment Analysis of Bone Marrow By Mass Cytometry and RNA Sequencing in Multiple Myeloma Patients Treated with Daratumumab and Durvalumab . Blood . vol. 132 , 3296 - 3296 .
Odabashian M, Carlotti E, Araf S, Okosun J, Forconi F, Stevenson FK, Gribben JG, Calaminici M et al. ( 2018 ) . Immunoglobulin Variable Region Gene Sequences Reveal N-Glycosylation Motifs As an Early and Stable Event in Follicular Lymphoma Pathology . Blood . Conference: Search Results Web results ASH Meeting on Lymphoma Biology vol. 132 , 4101 - 4101 .
Ribrag V, Morschhauser F, McKay P, Salles GA, Batlevi CL, Schmitt A, Tilly H, Cartron G et al. ( 2018 ) . Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) . Blood vol. 132 , ( Supplement 1 ) 4196 - 4196 .
Schwarzbich M-A, Romero-Toledo A, Gribben JG ( 2018 ) . Modulation of T-Cell Function and Immune Phenotype in the Microenvironment of Emu-TCL1 CLL Bearing Mice By Ibrutinib . Blood . vol. 132 , 3138 - 3138 .
Schwarzbich M-A, Romero-Toledo A, Frigault M, Gribben JG ( 2018 ) . Modulation of T-Cell Function in the Microenvironment of Emu-TCL1 CLL Bearing Mice By Btki Appears Independent of ITK . Blood vol. 132 , ( Supplement 1 ) 3139 - 3139 .
Townsend W, Buske C, Cartron G, Cunningham D, Dyer MJ, Gribben JG, Hess G, Ishikawa T et al. ( 2018 ) . Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study . Blood . vol. 132 , 1597 - 1597 .
Tedeschi A, Greil R, Demirkan F, Robak T, Moreno C, Barr P, Anz B, Simpson D et al. ( 2018 ) . Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison . Blood vol. 132 , ( Supplement 1 ) 5565 - 5565 .
Taylor JG, Clear AJ, Matthews J, Calaminici M, Gribben JG ( 2018 ) . The Treg/Th17 Axis Is Skewed in Classical Hodgkin Lymphoma By PDL1+Ve but Not PDL1-Ve Lymphoma Cells and By Lymphoma MHC Class 2 Expression . Blood . vol. 132 , 4124 - 4124 .
Freeman CL, Böttcher S, De la Serna J, Delgado J, Falzetti F, Gobbi M, Lejniece S, Di Bernardo MC et al. ( 2018 ) . Tocilizumab to Prevent Infusion-Related Events in Patients with Chronic Lymphocytic Leukemia and Co-Morbidities Treated with Obinutuzumab and Chlorambucil: Results from the Randomized Phase Ib GALACTA Trial . Blood . vol. 132 , 4419 - 4419 .
McDonald A, Thomas E, Daigle S, Morschhauser F, Salles G, Ribrag V, McKay P, Tilly H et al. ( 2018 ) . Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study . Blood . vol. 132 , 4097 - 4097 .
Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N et al. ( 2018 ) . Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies . The Lancet Haematology vol. 5 , ( 11 ) e563 - e598 .
Trotman J, Barrington SF, Belada D, Meignan M, MacEwan R, Owen C, Ptáčník V, Rosta A et al. ( 2018 ) . Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial . The Lancet Oncology vol. 19 , ( 11 ) 1530 - 1542 .
Robak T, Burger JA, Tedeschi A, Barr PM, Owen C, Bairey O, Hillmen P, Simpson D et al. ( 2018 ) . Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies . American Journal of Hematology vol. 93 , ( 11 ) 1402 - 1410 .
Jurczak W, Rule S, Townsend W, Tucker D, Sarholz B, Scheele J, Gribben J, Zinzani PL ( 2018 ) . 1014PD Phase I/II, first in human trial with M7583, a Bruton’s tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies . Annals of Oncology vol. 29 , viii362 - viii363 .
McClanahan F, Gribben J ( 2018 ) . The Eμ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia . Handbook of Immunosenescence ,
Gribben JG ( 2018 ) . No longer too exhausted to run . Blood vol. 132 , ( 5 ) 464 - 465 .
Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V et al. ( 2018 ) . Overall survival benefit in patients with rituximab-refractory indolent non-hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study . Journal of Clinical Oncology vol. 36 , ( 22 ) 2259 - 2266 .
Casado P, Wilkes EH, Miraki-Moud F, Hadi MM, Rio-Machin A, Rajeeve V, Pike R, Iqbal S et al. ( 2018 ) . Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells . Leukemia vol. 32 , ( 8 ) 1818 - 1822 .
Gribben JG ( 2018 ) . How and when I do allogeneic transplant in CLL . Blood vol. 132 , ( 1 ) 31 - 39 .
Araf S, Wang J, Korfi K, Pangault C, Kotsiou E, Rio-Machin A, Rahim T, Heward J et al. ( 2018 ) . Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma . Leukemia vol. 32 , ( 5 ) 1258 - 1263 .
Pockley AG, Lindsay JO, Foulds GA, Rutella S, Gribben JG, Alexander T, Snowden JA ( 2018 ) . Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Crohn's Disease: Current Status and Future Directions. A Review on Behalf of the EBMT Autoimmune Diseases Working Party and the Autologous Stem Cell Transplantation In Refractory CD-Low Intensity Therapy Evaluation Study Investigators . Front Immunol vol. 9 , 646 - 646 .
Munir T, Rawstron A, Brock K, Vicente SM, Yates F, Bishop R, Fegan C, Macdonald D et al. ( 2018 ) . Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy . BRITISH JOURNAL OF HAEMATOLOGY . vol. 181 , 34 - 35 .
Dürr C, Hanna BS, Schulz A, Lucas F, Zucknick M, Benner A, Clear A, Ohl S et al. ( 2018 ) . Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin . Haematologica vol. 103 , ( 4 ) 688 - 697 .
Griessinger E, Vargaftig J, Horswell S, Taussig DC, Gribben J, Bonnet D ( 2018 ) . Acute myeloid leukemia xenograft success prediction: Saving time . Experimental Hematology vol. 59 , 66 - 71.e4 .
Gribben JG, Bosch F, Cymbalista F, Geisler CH, Ghia P, Hillmen P, Moreno C, Stilgenbauer S ( 2018 ) . Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice . British Journal of Haematology vol. 180 , ( 5 ) 666 - 679 .
Pinto A, Alfadhel M, Akroyd R, Atik Altlnok Y, Bernabei SM, Bernstein L, Bruni G, Caine G et al. ( 2018 ) . International practices in the dietary management of fructose 1-6 biphosphatase deficiency . Orphanet Journal of Rare Diseases vol. 13 , ( 1 )
Gribben JG ( 2018 ) . Clinical Manifestations, Staging, and Treatment of Follicular Lymphoma . Hematology: Basic Principles and Practice ,
Casado P, Wilkes EH, Miraki-Moud F, Hadi MM, Rio-Machin A, Rajeeve V, Pike R, Iqbal S et al. ( 2017 ) . Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells . Leukemia
Warrick N, Miraki-Moud F, Aicher A, McNaughton LA, Casado-Izquierdo P, Nagano A, Carroll R, Bonnet D et al. ( 2017 ) . Adipocyte Induced Antagonism of ALL Growth Highlights a Novel Inhibitory Niche and Potential Therapeutic Opportunity . BLOOD . vol. 130 ,
Araf S, Wang J, Korfi K, Pangault C, Kotsiou E, Rio-Machin A, Rahim T, Heward JA et al. ( 2017 ) . Genomic Profiling Reveals Spatial Intra-Tumor Heterogeneity in Follicular Lymphoma . BLOOD . vol. 130 ,
Ball JA, Clear AJ, Calaminici M, Stagg A, Lindsay J, Gribben JG, Davies J ( 2017 ) . Human Gastro-Intestinal Graft-Versus-Host Disease Is Mediated By Retinoic Acid-Responsive CD8+ Effector T-Cells Under IL-23 Polarising Conditions . Blood . vol. 130 , 77 - 77 .
Zhang J, Reddy A, Davis N, Moffitt A, Love C, Waldrop A, Leppa S, Pasanen A et al. ( 2017 ) . Integrative Analysis of 1001 Diffuse Large B Cell Lymphoma Identifies Novel Oncogenic Roles for Rhoa . BLOOD . vol. 130 ,
Araf S, Korfi K, Nagano A, Cummin TEC, Bentley M, Thorner AR, Ashton-Key M, Calaminici M et al. ( 2017 ) . Longitudinal Analyses of the Genomic, Transcriptomic, and T Cell Repertoire in Diffuse Large B Cell Lymphoma Demonstrates Changes in Signaling and Immune Recognition at Relapse . BLOOD . vol. 130 ,
Dreger P, Koster L, Passweg JR, Collin M, Scheid C, Charbonnier A, Ciceri F, Thieblemont C et al. ( 2017 ) . Safety and Efficacy of Idelalisib Treatment of Chronic Lymphocytic Leukemia (CLL) or Lymphoma Relapsing after Allogeneic Hematopoietic Cell Transplantation (alloHCT): A Survey By the EBMT Chronic Malignancies and Lymphoma Working Parties . BLOOD . vol. 130 ,
Pearce OMT, Delaine-Smith R, Maniati E, Nichols S, Wang J, Böhm S, Rajeeve V, Ullah D et al. ( 2017 ) . Deconstruction of a metastatic tumor microenvironment reveals a common matrix response in human cancers . Cancer Discov
Daly A, Pinto A, Evans S, Almeida MF, Assoun M, Belanger-Quintana A, Bernabei SM, Bollhalder S et al. ( 2017 ) . Dietary practices in propionic acidemia: A European survey . Molecular Genetics and Metabolism Reports vol. 13 , 83 - 89 .
Gascoyne RD, Nadel B, Pasqualucci L, Fitzgibbon J, Payton JE, Melnick A, Weigert O, Tarte K et al. ( 2017 ) . Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015 . Hematological Oncology vol. 35 , ( 4 ) 397 - 407 .
Saunderson EA, Stepper P, Gomm JJ, Hoa L, Morgan A, Allen MD, Jones JL, Gribben JG et al. ( 2017 ) . Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors . Nature Communications vol. 8 , ( 1 )
Munoz-Vicente S, Bishop R, Hillmen P, Munir T, Rawstron A, Brock K, Fox C, Gribben J et al. ( 2017 ) . The initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory CLL shows acceptable safety and promising early indications of efficacy . LEUKEMIA & LYMPHOMA . vol. 58 , 239 - 239 .
Edelmann J, Lu C, Klymenko T, Vilventhraraja E, Estenfelder S, Tausch E, Stilgenbauer S, Mark C et al. ( 2017 ) . p.P2514fs mutant NOTCH1 has longer lasting transcription factor activity due to slower inactivation and degradation . LEUKEMIA & LYMPHOMA . vol. 58 , 67 - 68 .
Di Tullio A, Rouault-Pierre K, Abarrategi A, Mian S, Grey W, Gribben J, Stewart A, Blackwood E et al. ( 2017 ) . The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia . Nat Commun vol. 8 , ( 1 ) 1679 - 1679 .
DAVIES JK, Hassan S, Sarker S, Besley C, Oakervee H, Smith M, Taussig D, Gribben JG et al. ( 2017 ) . Durable graft-versus-leukaemia effects without donor lymphocyte infusions- results of a Phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia . British Journal of Haematology
Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A et al. ( 2017 ) . Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma . Cell vol. 171 , ( 2 ) 481 - 494.e15 .
Munir T, Howard DR, McParland L, Pocock C, Rawstron AC, Hockaday A, Varghese A, Hamblin M et al. ( 2017 ) . Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL . Leukemia vol. 31 , ( 10 ) 2085 - 2093 .
Pinto A, Daly A, Evans S, Almeida MF, Assoun M, Belanger-Quintana A, Bernabei S, Bollhalder S et al. ( 2017 ) . Dietary practices in isovaleric acidemia: A European survey . Molecular Genetics and Metabolism Reports vol. 12 , 16 - 22 .
Passaro D, Di Tullio A, Abarrategi A, Rouault-Pierre K, Foster K, Ariza-McNaughton L, Montaner B, Chakravarty P et al. ( 2017 ) . Increased Vascular Permeability in the Bone Marrow Microenvironment Contributes to Disease Progression and Drug Response in Acute Myeloid Leukemia . Cancer Cell vol. 32 , ( 3 ) 324 - 341.e6 .
Klymenko T, Bloehdorn J, Bahlo J, Robrecht S, Akylzhanova G, Cox K, Estenfelder S, Wang J et al. ( 2017 ) . Lamin B1 regulates somatic mutations and progression of B-cell malignancies . Leukemia vol. 32 , ( 2 ) 364 - 375 .
Bento L, Boumendil A, Finel H, Le Gouill S, Amorim S, Monjanel H, Bouabdallah R, Bay JO et al. ( 2017 ) . Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): A retrospective study of the EBMT Lymphoma Working Party . Bone Marrow Transplantation vol. 52 , ( 8 ) 1120 - 1125 .
Stevens WBC, Mendeville M, Redd R, Clear AJ, Bladergroen R, Calaminici M, Rosenwald A, Hoster E et al. ( 2017 ) . Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: A study by the Lunenburg Lymphoma Biomarker Consortium . Haematologica vol. 102 , ( 8 ) 1413 - 1423 .
Jagasia M, Beohou E, van der Werf S, Niederwieser D, Dreger P, Meijer E, Chevallier P, Sengeloev H et al. ( 2017 ) . Addition of rituximab in reduced intensity conditioning regimens for B-cell malignancies does not influence transplant outcomes: an EBMT registry analyses . BONE MARROW TRANSPLANTATION . vol. 52 , S83 - S83 .
Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K et al. ( 2017 ) . International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) . Annals of Oncology vol. 28 , ( 7 ) 1436 - 1447 .
Dreger P, Boumendil A, Koster L, Scheid C, Passweg J, Veelken H, Cahn Y, Collin M et al. ( 2017 ) . No evidence for an increased GVHD risk associated with post-transplant Idelalisib given for relapse of chronic lymphocytic leukemia or lymphoma: First results of a survey by the EBMT chronic malignancy and lymphoma working parties . BONE MARROW TRANSPLANTATION . vol. 52 , S424 - S425 .
Taylor JG, Seddon T, Alizadeh K, Agrawal C, Kempster L, Gribben JG, Agrawal SG ( 2017 ) . Single centre experience of ZarzioTM biosimilar Granulocyte-colony stimulating factor (GCSF) for the mobilisation of healthy donors demonstrates good leukapheresis yields and safety profile at 24 month median follow-up . BONE MARROW TRANSPLANTATION . vol. 52 , S145 - S146 .
Passaro D, Di Tullio A, Abarrategi A, Rouault-Pierre K, Foster K, Ariza-McNaughton L, Chakravarty P, Bhaw L et al. ( 2017 ) . ACUTE MYELOID LEUKEMIA ALTERS THE PERMEABILITY OF THE BONE MARROW VASCULAR MICROENVIRONMENT, FOSTERING DISEASE PROGRESSION AND DRUG RESISTANCE . HAEMATOLOGICA . vol. 102 , 78 - 78 .
Besley C, Kotsiou E, Petty R, Sangaralingam A, Chelala C, Ghazaly E, LeDieu R, Gribben J et al. ( 2017 ) . ALLORESPONSES OF HUMAN T-CELLS FROM ADULT PERIPHERAL BLOOD AND UMBILICAL CORD BLOOD ARE DIFFERENTIALLY IMPACTED BY LENALIDOMIDE - IMPLICATIONS FOR AHSCT . HAEMATOLOGICA . vol. 102 , 638 - 638 .
Seymour F, Cavenagh J, Gribben J ( 2017 ) . CYTOTOXIC LYMPHOCYTES IN NEWLY DIAGNOSED MYELOMA HAVE REVERSIBLE FUNCTIONAL AND PHENOTYPIC ABNORMALITIES THAT MAY OFFER THERAPUTIC OPPORTUNITIES . HAEMATOLOGICA . vol. 102 , 498 - 498 .
Vilventhraraja E, Gribben J, Braun A ( 2017 ) . INTRACELLULAR CALCIUM AND METABOLISM HAVE CRITICAL ROLES IN DETERMINING ANTI-CD20 ANTIBODY EFFICACY IN DLBCL . HAEMATOLOGICA . vol. 102 , 567 - 567 .
Dokal A, Gribben J, Cutillas P ( 2017 ) . MICROENVIRONMENT SECRETED PROTEINS MEDIATE RESISTANCE TO TARGETED THERAPY IN PRIMARY AML CELLS . HAEMATOLOGICA . vol. 102 , 358 - 358 .
Klymenko T, Bloehdorn J, Bahlo J, Robrecht S, Wang J, Fischer K, Akylzhanova G, Edelmann J et al. ( 2017 ) . NUCLEAR LAMINA REGULATES SOMATIC HYPERMUTATION AND PROGRESSION OF B CELL MALIGNANCIES . HAEMATOLOGICA . Conference: EHA vol. 102 , 228 - 228 .
Casado-Izquierdo P, Wilkes EH, Miraki-Moud F, Hadi MM, Rio-Machin A, Rajeeve V, Pike R, Sameena I et al. ( 2017 ) . PHOSPHOPROTEOMICS AND MASS CYTOMETRY SIGNATURES OF PRIMARY AML CELL DIFFERENTIATION ARE ASSOCIATED WITH SENSITIVITY TO KINASE INHIBITORS . HAEMATOLOGICA . vol. 102 , 203 - 203 .
Hillmen P, Rawstron A, Munir T, Brock K, Vincente SM, Jefferson Y, Paterson K, Fox CP et al. ( 2017 ) . THE INITIAL REPORT OF THE BLOODWISE TAP CLARITY STUDY COMBINING IBRUTINIB AND VENETOCLAX IN RELAPSED, REFRACTORY CLL SHOWS ACCEPTABLE SAFETY AND PROMISING EARLY INDICATIONS OF EFFICACY . HAEMATOLOGICA . vol. 102 , 311 - 311 .
Gribben JG ( 2017 ) . Restoring leukemia cell function from the inside out . Blood vol. 129 , ( 24 ) 3137 - 3138 .
Baptista M, Tapia G, Muñoz‐Marmol A, Muncunill J, Montoto S, Gribben J, Calaminici M, Martinez A et al. ( 2017 ) . APPLICATION OF CELL‐OF‐ORIGIN SUBTYPES DETERMINED BY DIGITAL GENE EXPRESSION IN HIV‐RELATED DIFFUSE LARGE B‐CELL LYMPHOMAS . Hematological Oncology vol. 35 , ( S2 ) 156 - 157 .
Pott C, Belada D, Danesi N, Fingerle‐Rowson GR, Gribben J, Harbron CG, Hoster E, Kahl BS et al. ( 2017 ) . MINIMAL RESIDUAL DISEASE AND OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) IN THE PHASE III GADOLIN TRIAL OF OBINUTUZUMAB AND BENDAMUSTINE VS BENDAMUSTINE . Hematological Oncology vol. 35 , ( S2 ) 216 - 217 .
Radford J, Gribben J, Johnson PW, Malladi R, Neeson S, Asfaw B, O'Regan L, Law A et al. ( 2017 ) . YourTreatmentChoices: FAST ACCESS TO TRIALS PROGRAMME . Hematological Oncology vol. 35 , ( S2 ) 272 - 273 .
Lindsay JO, Allez M, Clark M, Labopin M, Ricart E, Rogler G, Rovira M, Satsangi J et al. ( 2017 ) . Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial . The Lancet Gastroenterology & Hepatology vol. 2 , ( 6 ) 399 - 406 .
Edelmann J, Gribben JG ( 2017 ) . Managing patients with TP53-deficient chronic lymphocytic leukemia . Journal of Oncology Practice vol. 13 , ( 6 ) 371 - 377 .
Gribben JG ( 2017 ) . The role of stem cell transplant for lymphoma in 2017 . Hematological Oncology vol. 35 , 25 - 29 .
Lucas FM, Gribben J ( 2017 ) . Chronic lymphocytic leukemia . Clinical Manual of Blood and Bone Marrow Transplantation ,
Duncan M, Deane J, White PD, Ridge D, Roylance R, Korszun A, Chalder T, Bhui KS et al. ( 2017 ) . A survey to determine usual care after cancer treatment within the United Kingdom National Health Service . BMC Cancer vol. 17 , ( 186 )
Lucas FM, Gribben JG ( 2017 ) . Aberrant Immunological Synapses Driven by Leukemic Antigen-Presenting Cells . Methods Mol Biol vol. 1584 , 533 - 544 .
Edelmann J, Tausch E, Landau DA, Robrecht S, Bahlo J, Fischer K, Fink AM, Bloehdorn J et al. ( 2017 ) . Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: Results from the CLL8 trial . Leukemia vol. 31 , ( 3 ) 734 - 738 .
Van Gelder M, De Wreede LC, Bornhäuser M, Niederwieser D, Karas M, Anderson NS, Gramatzki M, Dreger P et al. ( 2017 ) . Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation . Bone Marrow Transplantation vol. 52 , ( 3 ) 372 - 380 .
Abarrategi A, Foster K, Hamilton A, Mian SA, Passaro D, Gribben J, Mufti G, Bonnet D ( 2017 ) . Versatile humanized niche model enables study of normal and malignant human hematopoiesis . Journal of Clinical Investigation vol. 127 , ( 2 ) 543 - 548 .
Chanan-Khan A, Egyed M, Robak T, Martinelli de Oliveira FA, Echeveste MA, Dolan S, Desjardins P, Blonski JZ et al. ( 2017 ) . Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial) . Leukemia vol. 31 , ( 5 ) 1240 - 1243 .
Gribben JG ( 2017 ) . Clinical Manifestations, Staging, and Treatment of Follicular Lymphoma . Hematology: Basic Principles and Practice ,
Dermit M, Casado P, Rajeeve V, Wilkes EH, Foxler DE, Campbell H, Critchlow S, Sharp TV et al. ( 2016 ) . Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition . Oncogene
Besley C, Kotsiou E, Petty R, Ajanthah S, Chelala C, Ghazaly E, Le Dieu R, Davies J et al. ( 2016 ) . Alloresponses of Human T-Cells from Adult Peripheral Blood and Umbilical Cord Blood Are Differentially Impacted By Lenalidomide . Blood . vol. 128 , 5714 - 5714 .
Casado P, Wilkes E, Hadi MM, Rajeeve V, Miraki-Moud F, Pike R, Del Rio-Machin A, Iqbal S et al. ( 2016 ) . Differentiation Status Revealed By Shotgun Phosphoproteomics Determines Sensitivity of Primary AML Cells to Kinase Inhibitors . Blood . vol. 128 , 840 - 840 .
Edelmann J, Klymenko T, Lu C, Vilventhraraja E, Estenfelder S, Tausch E, Beers SA, Stilgenbauer S et al. ( 2016 ) . In Chronic Lymphocytic Leukemia ΔCT7544-7545 Mutant NOTCH1 Maintains Transcription Factor Activity with Longer Lasting Effects Due to Slower Degradation . Blood . Conference: American Society of Hematology vol. 128 , 971 - 971 .
Zhang J, Reddy A, Love C, Moffitt AB, Rajagopalan D, Leppä S, Pasanen A, Meriranta L et al. ( 2016 ) . Integrative Genetic and Clinical Analysis through Whole Exome Sequencing in 1001 Diffuse Large B Cell Lymphoma (DLBCL) Patients Reveals Novel Disease Drivers and Risk Groups . Blood . vol. 128 , 1087 - 1087 .
Lo Celso C, Hawkins ED, Duarte D, Akinduro O, Khorshed RA, Passaro D, Nowicka M, Straszkowski L et al. ( 2016 ) . Intravital Microscopy Reveals Fundamental Differences in the Interaction of Stem Cells and T Acute Lymphoblastic Leukaemia with the Bone Marrow Microenvironment . Blood . vol. 128 , 5199 - 5199 .
Cheson BD, Trněný M, Bouabdallah K, Dueck G, Gribben J, Lugtenburg PJ, Press O, Salles GA et al. ( 2016 ) . Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study . Blood . vol. 128 , 615 - 615 .
Britton DJ, Wilkes E, Casado P, Rajeeve V, Fitzgibbon J, Gribben J, Cutillas PR ( 2016 ) . Proteomic Analysis Directs Effective Drug Selection in Relapsed AML By Quantifying Drug Targets . Blood . vol. 128 , 5265 - 5265 .
Vilventhraraja E, Klymenko T, Edelmann J, Gribben J, Ivanov A ( 2016 ) . Reduction of Mitochondrial Membrane Potential Leads to Enhancement of Type-II CD20-Antibody Cytotoxicity in Diffuse Large B-Cell Lymphoma . Blood . vol. 128 , 1763 - 1763 .
Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E et al. ( 2016 ) . Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation . Biology of Blood and Marrow Transplantation vol. 22 , ( 12 ) 2117 - 2125 .
Cheson BD, Trask PC, Gribben JG, Dimier N, Kimby E, Lugtenburg PJ, Thieblemont C, Wassner-Fritsch E et al. ( 2016 ) . Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone . Annals of Hematology
Sarker SJ, Smith SK, Chowdhury K, Ganz PA, Zimmerman S, Gribben J, Korszun A ( 2016 ) . Comparison of the impact of cancer between British and US long-term non-Hodgkin lymphoma survivors . Supportive Care in Cancer
Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF, Yu J, Neuberg DS et al. ( 2016 ) . High-level ROR1 associates with accelerated disease-progression in chronic lymphocytic leukemia . Blood vol. 128 , 2931 - 2940 .
Salzer E, Cagdas D, Hons M, Mace EM, Garncarz W, Petronczki Ö, Platzer R, Pfajfer L et al. ( 2016 ) . RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics . Nature Immunology vol. 17 , ( 12 ) 1352 - 1360 .
Hawkins ED, Duarte D, Akinduro O, Khorshed RA, Passaro D, Nowicka M, Straszkowski L, Scott MK et al. ( 2016 ) . T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments . Nature vol. 538 , ( 7626 ) 518 - 522 .
McClanahan F, Sharp TG, Gribben JG ( 2016 ) . Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas? . Haematologica vol. 101 , ( 10 ) 1144 - 1158 .
Navarro-Bailon A, Taylor JG, Matthews J, Montoto S, Gribben JG ( 2016 ) . THE ROLE OF WATCH AND WAIT IN NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA: SINGLE CENTRE DATA FROM THE MODERN ERA . HAEMATOLOGICA . vol. 101 , 64 - 64 .
Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V et al. ( 2016 ) . Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial . The Lancet Oncology vol. 17 , ( 8 ) 1081 - 1093 .
Freeman CL, Dixon M, Houghton R, Kreuzer KA, Fingerle-Rowson G, Herling M, Humphrey K, Böttcher S et al. ( 2016 ) . Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab . Leukemia vol. 30 , ( 8 ) 1763 - 1766 .
Eyre TA, Clifford R, Bloor A, Boyle L, Roberts C, Cabes M, Collins GP, Devereux S et al. ( 2016 ) . NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome . British Journal of Haematology
Hawkey CJ, Lindsay J, Gribben J ( 2016 ) . In reply . JAMA - Journal of the American Medical Association vol. 315 , ( 23 ) 2620 - 2621 .
Schwarzbich MA, McClanahan F, DSc JGR ( 2016 ) . Allogeneic Transplantation for Chronic Lymphocytic Leukemia in the Age of Novel Treatment Strategies . Oncology (Williston Park, N.Y.) vol. 30 , ( 6 )
Vilventhraraja E, Gribben J, Ivanov A ( 2016 ) . EXPLOITING OXIDATIVE PHOSPHORYLATION TO IMPROVE ANTIBODY THERAPY OF LYMPHOMA . HAEMATOLOGICA . vol. 101 , 574 - 575 .
Araf S, Wang J, Pangault C, Kotsiou E, Hoxha E, Iqbal S, Davies J, Johnson P et al. ( 2016 ) . GENOMIC PROFILING REVEALS SPATIAL HETEROGENEITY IN FOLLICULAR LYMPHOMA: IMPLICATIONS FOR PRECISION MEDICINE . HAEMATOLOGICA . vol. 101 , 270 - 270 .
Dokal A, Gribben J, Cutillas P ( 2016 ) . HETEROTYPIC SIGNALLING BETWEEN BONE MARROW STROMAL CELLS AND BLASTS PROVIDES INSIGHT INTO THE CELLULAR COMMUNICATION IN ACUTE MYELOID LEUKAEMIA . HAEMATOLOGICA . vol. 101 , 369 - 369 .
Petty R, Zhang X, Ivan C, Calin G, Gribben J, Le Dieu R ( 2016 ) . MICRORNAS HSA-LET-7A AND MIR-142-3P IN T CELLS IN PATIENTS PRESENTING WITH ACUTE MYELOID LEUKAEMIA-A MEANS OF REPAIRING TUMOUR-INDUCED T CELL DEFECTS? . HAEMATOLOGICA . vol. 101 , 364 - 365 .
Trneny M, Bouabdallah K, Dueck G, Gribben J, Lugtenburg P, Press O, Salles G, Sehn L et al. ( 2016 ) . OBINUTUZUMAB PLUS BENDAMUSTINE VERSUS BENDAMUSTINE ALONE IN PATIENTS WITH RITUXIMAB-REFRACTORY FOLLICULAR LYMPHOMA: RESULTS FROM THE GADOLIN STUDY . HAEMATOLOGICA . vol. 101 , 155 - 156 .
Britton D, Casado P, Rajeeve V, Wilkes E, Smith R, Fitzgibbon J, Gribben J, Cutillas P ( 2016 ) . PROTEOMIC ANALYSIS OF RELAPSE AML IDENTIFIES OPPORTUNITIES FOR THERAPEUTIC INTERVENTION IN INDIVIDUAL PATIENTS . HAEMATOLOGICA . vol. 101 , 373 - 373 .
Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Al Seraihi AF et al. ( 2016 ) . Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma (vol 48, pg 183, 2016) . NATURE GENETICS vol. 48 , ( 6 ) 700 - 700 .
Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Seraihi AFA et al. ( 2016 ) . Corrigendum: Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma . Nat Genet vol. 48 , ( 6 ) 700 - 700 .
Walsh C, Bonner JJ, Johnson TN, Neuhoff S, Ghazaly EA, Gribben JG, Boddy AV, Veal GJ ( 2016 ) . Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer . British Journal of Clinical Pharmacology vol. 81 , ( 5 ) 989 - 998 .
Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, Bollard C, Ansell S et al. ( 2016 ) . Role of the tumor microenvironment in mature B-cell lymphoid malignancies . Haematologica: the hematology journal vol. 101 , ( 5 ) 531 - 540 .
Edelmann J, Gribben JG ( 2016 ) . Obinutuzumab for the treatment of indolent lymphoma . Future Oncol vol. 12 , ( 15 ) 1769 - 1781 .
Kotsiou E, Okosun J, Besley C, Iqbal S, Matthews J, Fitzgibbon J, Gribben J, DAVIES JK ( 2016 ) . TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses . Blood vol. 128 , ( 1 ) 72 - 81 .
Pott C, Belada D, Danesi N, Fingerle-Rowson G, Gribben J, Harbron C, Hoster E, Kahl B et al. ( 2016 ) . Minimal residual disease analysis in patients with follicular lymphoma treated with obinutuzumab plus bendamustine versus bendamustine alone in GADOLIN, a phase III study of relapsed/refractory indolent non-Hodgkin lymphoma . British Journal of Haematology, Supplement . Conference: XXXVI World Congress of the International Society of Hematology ( Glasgow ) from: 18/04/2016 to: 21/04/2016 , vol. 173 , 93 - 94 .
Griessinger E, Anjos-Afonso F, Vargaftig J, Taussig DC, Lassailly F, Prebet T, Imbert V, Nebout M et al. ( 2016 ) . Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients . Cancer Research vol. 76 , ( 8 ) 2082 - 2086 .
Riches JC, Gribben JG ( 2016 ) . Mechanistic and clinical aspects of lenalidomide treatment for chronic lymphocytic leukemia . Current Cancer Drug Targets vol. 16 ,
Kotsiou E, Gribben JG, Davies JK ( 2016 ) . Allospecific Tregs expanded after anergization remain suppressive in inflammatory conditions but lack expression of gut-homing molecules . Molecular therapy : the journal of the American Society of Gene Therapy vol. 24 , ( 6 ) 1126 - 1134 .
Iyengar S, Ariza-Mcnaughton L, Clear A, Taussig D, Auer R, Roe A, Lillington D, Iqbal S et al. ( 2016 ) . Characteristics of human primary mantle cell lymphoma engraftment in NSG mice . British Journal of Haematology vol. 173 , ( 1 ) 165 - 169 .
Bühler A, Wendtner CM, Kipps TJ, Rassenti L, Fraser GAM, Michallet AS, Hillmen P, Dürig J et al. ( 2016 ) . Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: Data from the prospective, multicenter phase-II CLL-009 trial . Blood Cancer Journal vol. 6 ,
Hanna BS, Mcclanahan F, Yazdanparast H, Zaborsky N, Kalter V, Rößner PM, Benner A, Dürr C et al. ( 2016 ) . Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo . Leukemia vol. 30 , ( 3 ) 570 - 579 .
Freeman CL, Gribben JG ( 2016 ) . Immunotherapy in Chronic Lymphocytic Leukaemia (CLL) . Current Hematologic Malignancy Reports vol. 11 , ( 1 ) 29 - 36 .
Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Al Seraihi AF et al. ( 2016 ) . Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma . Nature Genetics vol. 48 , ( 2 ) 183 - 188 .
Vrhovac R, Labopin M, Ciceri F, Finke J, Holler E, Tischer J, Lioure B, Gribben J et al. ( 2016 ) . Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: Analysis of risk factors and treatment outcomes . Bone Marrow Transplantation vol. 51 , ( 2 ) 186 - 193 .
Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, De Wit TD, Eichinger S et al. ( 2016 ) . The european hematology association roadmap for european hematology research: A consensus document . Haematologica vol. 101 , ( 2 ) 115 - 208 .
Wendtner CM, Hallek M, Fraser GA, Michallet AS, Hillmen P, Dürig J, Kalaycio M, Gribben JG et al. ( 2016 ) . Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial . Leukemia and Lymphoma vol. 57 , ( 6 ) 1291 - 1299 .
Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Al Seraihi AF et al. ( 2015 ) . Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma . Nature Genetics .
Hawkey CJ, Allez M, Clark MM, Labopin M, Lindsay JO, Ricart E, Rogler G, Rovira M et al. ( 2015 ) . Autologous hematopoetic stem cell transplantation for refractory Crohn disease a randomized clinical trial . JAMA - Journal of the American Medical Association vol. 314 , ( 23 ) 2524 - 2534 .
Freeman CL, Morschhauser F, Sehn L, Dixon M, Houghton R, Lamy T, Fingerle-Rowson G, Wassner-Fritsch E et al. ( 2015 ) . Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions . Blood vol. 126 , ( 24 ) 2646 - 2649 .
Pott C, Belada D, Danesi N, Fingerle-Rowson G, Gribben J, Harbron C, Hoster E, Kahl BS et al. ( 2015 ) . Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma . Blood . vol. 126 , 3978 - 3978 .
Cui B, Chen L, Rassenti LZ, Ghia EM, Yu J, Zhang L, Neuberg DS, Wierda W et al. ( 2015 ) . High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia . Blood . vol. 126 , 1713 - 1713 .
Norster F, Clear AJ, Matthews J, Hoxha E, Gribben J, Jia L ( 2015 ) . Overexpression of HMGB1 Receptor RAGE Is Associated with Worse Clinical Outcome in Patients with Chronic Lymphocytic Leukemia . Blood . vol. 126 , 617 - 617 .
Cheson BD, Trask PC, Gribben J, Dimier N, Kimby E, Lugtenburg PJ, Thieblemont C, Wassner Fritsch E et al. ( 2015 ) . Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma . Blood . vol. 126 , 1532 - 1532 .
Flinn IW, Brunvand M, Choi MY, Dyer MJS, Gribben J, Hillmen P, Jones J, Li Y et al. ( 2015 ) . Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331) . Blood . vol. 126 , 494 - 494 .
Lucas DM, Ruppert AS, Lozanski G, Dewald GW, Lozanski A, Claus R, Plass C, Flinn IW et al. ( 2015 ) . Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: A long-term follow-up study of the US intergroup phase III trial E2997 . Leukemia and Lymphoma vol. 56 , ( 11 ) 3031 - 3037 .
Conconi A, Lobetti-Bodoni C, Montoto S, Lopez-Guillermo A, Coutinho R, Matthews J, Franceschetti S, Bertoni F et al. ( 2015 ) . Life expectancy of young adults with follicular lymphoma . Annals of Oncology vol. 26 , ( 11 ) 2317 - 2322 .
Taylor JG, Gribben JG ( 2015 ) . Microenvironment abnormalities and lymphomagenesis: Immunological aspects . Seminars in Cancer Biology vol. 34 , 36 - 45 .
Tawana K, Wang J, Renneville A, Bödör C, Hills R, Loveday C, Savic A, Van Delft FW et al. ( 2015 ) . Disease evolution and outcomes in familial AML with germline CEBPA mutations . Blood vol. 126 , ( 10 ) 1214 - 1223 .
Carlotti E, Wrench D, Rosignoli G, Marzec J, Sangaralingam A, Hazanov L, Michaeli M, Hallam S et al. ( 2015 ) . High throughput sequencing analysis of the immunoglobulin heavy chain gene from flow-sorted B cell sub-populations define the dynamics of follicular lymphoma clonal evolution . PLoS ONE vol. 10 , ( 9 )
Gribben JG, Fowler N, Morschhauser F ( 2015 ) . Mechanisms of action of lenalidomide in B-cell non-hodgkin lymphoma . Journal of Clinical Oncology vol. 33 , ( 25 ) 2803 - 2811 .
McClanahan F, Gribben J ( 2015 ) . New insights into hematopoietic stem cell transplantation for chronic lymphocytic leukemia: A 2015 perspective . Clinical Advances in Hematology and Oncology vol. 13 , ( 9 ) 586 - 594 .
Munir T, Cohen D, Pocock C, Rawstron A, Collet L, McParland L, Chalmers A, Varghese A et al. ( 2015 ) . Physical examination and MRD assessment rather than CT-scans is effective to assess responses in patients treated with fludarabine-based chemoimmunotherapy. Analysis of patients in the UK NCRI ADMIRE and ARCTIC trials . LEUKEMIA & LYMPHOMA vol. 56 , 26 - 27 .
Ghazaly EA, Gnanaranjan C, Greenhalf B, Blagden SP, Mullen P, Harrison D, Gribben JG ( 2015 ) . Abstract 3390: Validating the RNAscope for molecular profiling of key biomarkers associated with gemcitabine resistance . Conference: Clinical Research (Excluding Clinical Trials)3390 - 3390 .
McClanahan F, Riches JC, Miller S, Day WP, Kotsiou E, Neuberg D, Croce CM, Capasso M et al. ( 2015 ) . Mechanisms of PD-L1/PD-1 mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eμ-TCL1 CLL mouse model . Blood vol. 126 , ( 2 ) 212 - 221 .
McClanahan F, Hanna B, Miller S, Clear AJ, Lichter P, Gribben JG, Seiffert M ( 2015 ) . PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia . Blood vol. 126 , ( 2 ) 203 - 211 .
Miraki-Moud F, Ghazaly E, Ariza-McNaughton L, Hodby KA, Clear A, Anjos-Afonso F, Liapis K, Grantham M et al. ( 2015 ) . Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo . Blood vol. 125 , ( 26 ) 4060 - 4068 .
Wilkes EH, Terfve C, Gribben JG, Saez-Rodriguez J, Cutillas PR ( 2015 ) . Empirical inference of circuitry and plasticity in a kinase signaling network . Proceedings of the National Academy of Sciences of the United States of America vol. 112 , ( 25 ) 7719 - 7724 .
Sehn LH, Chua NS, Mayer J, Dueck GS, Trneny M, Bouabdallah K, Fowler NH, Delwail V et al. ( 2015 ) . GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma . JOURNAL OF CLINICAL ONCOLOGY . vol. 33 ,
Sehn LH, Chua NS, Mayer J, Dueck GS, Trněný M, Bouabdallah K, Fowler NH, Delwail V et al. ( 2015 ) . GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma . Journal of Clinical Oncology vol. 33 , ( 18_suppl ) lba8502 - lba8502 .
Bernard S, Danglade D, Gardano L, Laguillier C, Lazarian G, Roger C, Thieblemont C, Marzec J et al. ( 2015 ) . Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma . International Journal of Cancer vol. 136 , ( 12 ) 2761 - 2774 .
Hassan S, Davies J, Smith M, Tsitsikas D, Oakervee H, Hallam S, Taussig D, Gribben J et al. ( 2015 ) . DURABLE REMISSIONS AFTER SEQUENTIAL TRANSPLANTATION USING T-REPLETE NON-MYELOABLATIVE CONDITIONING FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASIA . HAEMATOLOGICA . vol. 100 , 278 - 278 .
Sehn L, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah K, Fowler N, Delwail V et al. ( 2015 ) . GADOLIN: PRIMARY RESULTS FROM A PHASE III STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE COMPARED WITH BENDAMUSTINE ALONE IN PATIENTS WITH RITUXIMAB-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA . HAEMATOLOGICA . vol. 100 , 273 - 273 .
Eyre T, Clifford R, Bloor A, Boyle L, Cabes M, Collins G, Devereux S, Follows G et al. ( 2015 ) . SINGLE ARM NCRI FEASIBILITY PHASE II STUDY OF CHOP IN COMBINATION WITH OFATUMUMAB IN INDUCTION AND MAINTENANCE FOR PATIENTS WITH NEWLY DIAGNOSED RICHTER'S SYNDROME . HAEMATOLOGICA . vol. 100 , 109 - 109 .
Gribben JG ( 2015 ) . XV. Clinical aspects of transformed lymphoma . Hematological Oncology vol. 33 , ( S1 ) 80 - 83 .
Blagden SP, Rizzuto I, Stavraka C, O'Shea D, Suppiah P, Patel M, Loyse N, Sukumaran A et al. ( 2015 ) . A first in human Phase I/II study of NUC-1031 in patients with advanced gynecological cancers . Journal of Clinical Oncology . vol. 33 , 2547 - 2547 .
Leonard J, Gribben JG, Trněný M, Scheinberg P, Tobinai K, Fowler NH, Kilavuz N, Fustier P et al. ( 2015 ) . AUGMENT: A randomized, phase 3 trial in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) to compare efficacy and safety of lenalidomide plus rituximab (R 2 ) versus placebo plus rituximab . Journal of Clinical Oncology vol. 33 , ( 15_suppl ) tps8603 - tps8603 .
Leonard J, Gribben JG, Trnen M, Scheinberg P, Tobinai K, Fowler NH, Kilavuz N, Fustier P et al. ( 2015 ) . AUGMENT: A randomized, phase 3 trial in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) to compare efficacy and safety of lenalidomide plus rituximab (R-2) versus placebo plus rituximab . JOURNAL OF CLINICAL ONCOLOGY . vol. 33 ,
Blagden SP, Rizzuto I, Stavraka C, O'Shea D, Suppiah P, Patel M, Sukumaran A, Loyse N et al. ( 2015 ) . Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies . Journal of Clinical Oncology . vol. 33 , 2514 - 2514 .
Sehn LH, Chua NS, Mayer J, Dueck GS, Trnen M, Bouabdallah K, Fowler NH, Delwail V et al. ( 2015 ) . GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma . JOURNAL OF CLINICAL ONCOLOGY . vol. 33 ,
Flinn I, Moreno C, Gill DS, Kipps TJ, Shaw Y, Li Y, Styles LA, James DF et al. ( 2015 ) . Randomized, multicenter, open-label, phase 3 study of the BTK inhibitor ibrutinib in combination with obinutuzumab vs. chlorambucil in combination with obinutuzumab in patients with treatment-naive CLL/SLL (PCYC-1130): iLLUMINATE . JOURNAL OF CLINICAL ONCOLOGY . vol. 33 ,
Flinn I, Moreno C, Gill DS, Kipps TJ, Shaw Y, Li Y, Styles LA, James DF et al. ( 2015 ) . Randomized, multicenter, open-label, phase 3 study of the BTK inhibitor ibrutinib in combination with obinutuzumab vs. chlorambucil in combination with obinutuzumab in patients with treatment-naïve CLL/SLL (PCYC-1130): iLLUMINATE . Journal of Clinical Oncology vol. 33 , ( 15_suppl ) tps7095 - tps7095 .
Hanna B, McClanahan F, Zaborsky N, Duerr C, Kalter V, Egle A, Lichter P, Gribben J et al. ( 2015 ) . Targeting dysfunctional myeloid cells delays disease development and improves immune function in a CLL mouse model . JOURNAL OF IMMUNOLOGY . vol. 194 ,
Taylor JG, Liapis K, Gribben JG ( 2015 ) . The role of the tumor microenvironment in HIV-associated lymphomas . Biomarkers in Medicine vol. 9 , ( 5 ) 473 - 482 .
Hondares E, Brown M, Musset B, Morgan D, Cherny VV, Taubert C, Bhamrah MK, Coe D et al. ( 2015 ) . Enhanced activation of an amino-terminally truncated isoform of voltage-gated proton channel HVCN1 enriched in malignant B cells . ACTA PHYSIOLOGICA vol. 213 , 39 - 39 .
Kotsiou E, Guinan E, Gribben J, Davies J ( 2015 ) . Phenotypic and functional stability of regulatory T cells expanded after alloanergization with costimulatory molecule blockade . BONE MARROW TRANSPLANTATION . vol. 50 , S373 - S373 .
Bento L, Boumendil A, Finel H, Chevallier P, Amorim S, Monjanel H, Blaise D, Bay J-O et al. ( 2015 ) . Radioimmunotherapy and BEAM chemotherapy versus BEAM as the conditioning regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective matched-control study of the LWP-EBMT . BONE MARROW TRANSPLANTATION . vol. 50 , S287 - S288 .
Hondares E, Brown M, Musset B, Morgan D, Cherny VV, Taubert C, Bhamrah MK, Coe D et al. ( 2015 ) . Enhanced Activation of an Amino-Terminally Truncated Isoform of Voltage-Gated Proton Channel HVCN1 Enriched in Malignant B cells . Biophysical Journal vol. 108 , ( 2 )
Nakagawa R, Vukovic M, Tarafdar A, Cosimo E, Dunn K, McCaig AM, Holroyd A, McClanahan F et al. ( 2015 ) . Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKCα subversion induces up-regulation of PKCβII expression in B lymphocytes . Haematologica vol. 100 , ( 4 ) 499 - 510 .
Aguiar A, Ahring K, Almeida MF, Assoun M, Belanger Quintana A, Bigot S, Bihet G, Blom Malmberg K et al. ( 2015 ) . Practices in prescribing protein substitutes for PKU in Europe: No uniformity of approach . Molecular Genetics and Metabolism vol. 115 , ( 1 ) 17 - 22 .
Coutinho R, Clear AJ, Mazzola E, Owen A, Greaves P, Wilson A, Matthews J, Lee A et al. ( 2015 ) . Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: Robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP . Haematologica vol. 100 , ( 3 ) 363 - 369 .
Zhao T, Ren H, Wang X, Liu P, Yan F, Jiang W, Li Y, Li J et al. ( 2015 ) . Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma . Oncotarget vol. 6 , ( 29 ) 27816 - 27831 .
Dreger P, Schetelig J, Andersen N, Corradini P, van Gelder M, Gribben J, Kimby E, Michallet M et al. ( 2014 ) . Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? . Blood vol. 124 , ( 26 ) 3841 - 3849 .
Hondares E, Brown MA, Musset B, Morgan D, Cherny VV, Taubert C, Bhamrah MK, Coe D et al. ( 2014 ) . Enhanced activation of an amino-terminally truncated isoform of the voltage-gated proton channel HVCN1 enriched in malignant B cells . PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA vol. 111 , ( 50 ) 18078 - 18083 .
McClanahan F, Calore F, Zanesi N, Gribben JG, Croce CM ( 2014 ) . Aberrant PD-L1 Expression in CLL As a Result of Adaptive Immune Resistance Mediated By Tumor-Secreted Circulating miRNA Binding to Toll-like Receptor 7 . Blood . vol. 124 , 716 - 716 .
Edelmann J, Saub J, Ibach S, Holzmann K, Tausch E, Bloehdorn J, Mertens D, Zenz T et al. ( 2014 ) . High Resolution Genomic Profiling of Primary “Ultra High Risk” and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial . Blood . vol. 124 , 3288 - 3288 .
Hanna B, McClanahan F, Clear AJ, Miller S, Lichter P, Seiffert M, Gribben JG ( 2014 ) . Immune Checkpoint Blockade with Anti-PD-L1 Prevents Immune Dysfuntion and CLL Development in the TCL1 Adoptive Transfer Mouse Model . Blood vol. 124 , ( 21 ) 717 - 717 .
Sarker S-J, George GE, Chowdhury K, Levitt G, Kingston J, Lister A, Gribben JG, Korszun A ( 2014 ) . Late Effects: An Evaluation of Contrasting Physical and Psychological Experiences Between Child and Adult Hodgkin Survivors . Blood vol. 124 , ( 21 ) 1309 - 1309 .
Besley CM, Kotsiou E, Petty R, Sangaralingum A, Le Dieu R, Gribben JG, Davies JK ( 2014 ) . Lenalidomide Enhances Human Alloresponses By Increasing Proliferation of Effector Memory CD8 T Cells with Enhanced Polyfunctional Effector Capacity and a Unique Gene Expression Profile . Blood . vol. 124 , 1103 - 1103 .
McCarthy A, Clear AJ, Marzec J, Coutinho R, Petty RD, Matthews J, Wilson A, Iqbal S et al. ( 2014 ) . Overexpression of BCL-2 Does Not Inhibit Autophagy in Human Follicular and Diffuse Large B-Cell Lymphomas . Blood . vol. 124 , 3007 - 3007 .
Ghazaly E, Smith P, Gnanaranjan C, Young BD, Joel S, Gribben JG, Taussig DC ( 2014 ) . SKIP Is Underexpressed in AML Leading to Sphingosine Kinase Hypofunction . Blood . vol. 124 , 5324 - 5324 .
Kotsiou E, Okosun J, Clear AJ, Iqbal S, Fitzgibbon J, Gribben JG, Davies JK ( 2014 ) . TNFRSF14 aberrations in Follicular Lymphoma B Cells Result in Increased Alloresponses in Vitro and in Vivo . Blood . vol. 124 , 2426 - 2426 .
Hanna B, McClanahan F, Zaborsky N, Dürr C, Kalter V, Egle A, Gribben JG, Lichter P et al. ( 2014 ) . Targeting Dysfunctional Myeloid Cells Delays Disease Development and Improves Immune Function in a CLL Mouse Model . Blood vol. 124 , ( 21 ) 3298 - 3298 .
Dürr C, Hanna B, McClanahan F, Clear AJ, Zenz T, Stilgenbauer S, Gribben JG, Lichter P et al. ( 2014 ) . The Flavonoid Wogonin Reduces CLL Cell Survival in Vitro and Leukemia Development in Eµ-TCL1 Mice By Targeting Aberrant TNF Receptor Signaling . Blood . vol. 124 , 1966 - 1966 .
McClanahan F, Gribben J ( 2014 ) . Transplantation in chronic lymphocytic leukemia. Does it still matter in the era of novel targeted therapies? . Hematology/Oncology Clinics of North America vol. 28 , ( 6 ) 1055 - 1071 .
Ficz G, Gribben JG ( 2014 ) . Loss of 5-hydroxymethylcytosine in cancer: cause or consequence? . Genomics vol. 104 , ( 5 ) 352 - 357 .
El-Najjar I, Boumendil A, Luan JJ, Bouabdallah R, Thomson K, Mohty M, Colombat P, Biron P et al. ( 2014 ) . The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party . Ann Oncol vol. 25 , ( 11 ) 2224 - 2229 .
Tavora B, Reynolds LE, Batista S, Demircioglu F, Fernandez I, Lechertier T, Lees DM, Wong P-P et al. ( 2014 ) . Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy . Nature vol. 514 , ( 7520 ) 112 - 116 .
JIA L ( 2014 ) . Dysregulation of autophagy in human follicular lymphoma is independent of overexpression of BCL-2 . Oncotarget11653 - 11668 .
Edelmann J, Haferlach C, Saub J, Teleanu V, Florence C, Leblonde V, Delmer A, Buehler A et al. ( 2014 ) . Genomic characterization of primary ultra high-risk and refractory chronic lymphocytic leukemia: Results from the CLL2O trial . ONCOLOGY RESEARCH AND TREATMENT vol. 37 , 220 - 220 .
McClanahan F, Riches JC, Miller S, Ghazaly E, Day W, Capasso M, Gribben J ( 2014 ) . PD-1/PD-L1 mediated T-cell dysfunction in CLL is not absolute and can be at least partially reversed in vivo by the immune-modulatory drug lenalidomide . ONCOLOGY RESEARCH AND TREATMENT vol. 37 , 236 - 236 .
Ghazaly EA, Slusarczyk M, Mason M, Gribben J, McGuigan C, Blagden S ( 2014 ) . Abstract CT401: NUC-1031: A novel ProTide that overcomes the key cancer resistance mechanisms associated with poor survival . Conference: Clinical Trialsct401 - ct401 .
Greaves P, Lister TA, Gribben JG ( 2014 ) . Parenthood in long-term survivors after CHOP with or without etoposide treatment for aggressive lymphoma - response to Meissner et al . Br J Haematol vol. 166 , ( 4 ) 615 - 616 .
Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC et al. ( 2014 ) . Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia . Blood vol. 124 , ( 1 ) 42 - 48 .
Riches JC, Gribben JG ( 2014 ) . Immunomodulation and immune reconstitution in chronic lymphocytic leukemia . Semin Hematol vol. 51 , ( 3 ) 228 - 234 .
Riches JC, O'Donovan CJ, Kingdon SJ, McClanahan F, Clear AJ, Neuberg DS, Werner L, Croce CM et al. ( 2014 ) . Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations . BLOOD vol. 123 , ( 26 ) 4101 - 4110 .
Gribben JG ( 2014 ) . Immune responses and outcome in follicular lymphoma . J Clin Oncol vol. 32 , ( 17 ) 1757 - 1759 .
Hanna B, McClanahan F, Zaborsky N, Duerr C, Gschwend V, Stilgenbauer S, Egle A, Gribben J et al. ( 2014 ) . CLL INDUCES SEVERE SKEWING IN THE MYELOID COMPARTMENT IN PATIENTS AND IN THE TCL1 MOUSE MODEL . HAEMATOLOGICA . vol. 99 , 228 - 229 .
Munir T, Cohen D, Pocock C, Rawstron A, McParland L, Chalmers A, Varghese A, Smith A et al. ( 2014 ) . ORAL FCR INDUCES HIGHER COMPLETE REMISSION RATES AND MRD NEGATIVITY IN UNTREATED CLL THAN PREVIOUS REPORTS OF INTRAVENOUS THERAPY: COMBINED RESULTS OF THE NCRI ADMIRE AND ARCTIC TRIALS . HAEMATOLOGICA . vol. 99 , 54 - 54 .
Leonard J, Gribben JG, Trneny M, Scheinberg P, Kilavuz N, Patturajan M, Fustier P ( 2014 ) . AUGMENT: A phase 3, randomized trial to compare efficacy and safety of lenalidomide plus rituximab versus placebo plus rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL) . Journal of Clinical Oncology . vol. 32 , tps8614 - tps8614 .
Ghazaly EA, Luong P, Chmielewska-Kassassir M, Wozniak L, Bomalaski JS, Gribben JG, Szlosarek PW ( 2014 ) . Metabolomic analysis of pegylated arginine deiminase treatment in patients with malignant pleural mesothelioma . Journal of Clinical Oncology . vol. 32 , 7587 - 7587 .
Besley C, Kotsiou E, Petty R, Sangaralingam A, LeDieu R, Gribben J, Davies J ( 2014 ) . Lenalidomide potentiates human T cell alloresponses by selectively increasing proliferation of alloreactive CD8+cells which exhibit a novel gene expression profile - implications for IMiD therapy after allogeneic haematopoietic stem cell transplant . BRITISH JOURNAL OF HAEMATOLOGY . vol. 165 , 16 - 17 .
Manodoro F, Marzec J, Chaplin T, Miraki-Moud F, Moravcsik E, Jovanovic JV, Wang J, Iqbal S et al. ( 2014 ) . Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukaemia . BRITISH JOURNAL OF HAEMATOLOGY . vol. 165 , 16 - 16 .
Hillmen P, Pettitt A, Schuh A, Milligan D, Bowles K, Bareford D, Riaz JM, Follows G et al. ( 2014 ) . Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted) . BRITISH JOURNAL OF HAEMATOLOGY . vol. 165 , 19 - 20 .
Bloor AJC, Cohen D, Pocock C, Rawstron A, McParland L, Chalmers A, Varghese A, Smith A et al. ( 2014 ) . Results of the randomised phase II NCRI ADMIRE trial of FC-R and FCM-R in previously untreated CLL: oral FCR is highly effective and safe but the addition of mitoxantrone does not improve responses . BRITISH JOURNAL OF HAEMATOLOGY . vol. 165 , 18 - 18 .
Riches JC, O'Donovan C, Kingdon SJ, McClanahan F, Clear AJ, Neuberg DS, Croce CM, Ramsay AG et al. ( 2014 ) . Trisomy 12 chronic lymphocytic leukaemia cells exhibit functional upregulation of integrin signalling that is modulated by NOTCH1 mutations . BRITISH JOURNAL OF HAEMATOLOGY . vol. 165 , 20 - 20 .
Jia L, Gribben JG ( 2014 ) . Dangerous power: mitochondria in CLL cells . Blood vol. 123 , ( 17 ) 2596 - 2597 .
Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, Oscier DG, Dearden CE et al. ( 2014 ) . Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an OpenLabel Phase II Study . JOURNAL OF CLINICAL ONCOLOGY vol. 32 , ( 12 ) 1236 - + .
Griessinger E, Anjos-Afonso F, Pizzitola I, Rouault-Pierre K, Vargaftig J, Taussig D, Gribben J, Lassailly F et al. ( 2014 ) . A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms . Stem Cells Transl Med vol. 3 , ( 4 ) 520 - 529 .
Renaudon-Smith E, Gribben JG, Agrawal SG ( 2014 ) . Primary refractory T-cell prolymphocytic leukaemia treated with daily administration of Alemtuzumab plus high-dose methylprednisolone . Eur J Haematol vol. 92 , ( 4 ) 360 - 361 .
Sander B, de Jong D, Rosenwald A, Xie W, Balague O, Calaminici M, Carreras J, Gaulard P et al. ( 2014 ) . The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium . HAEMATOLOGICA vol. 99 , ( 4 ) 715 - 725 .
Manodoro F, Marzec J, Chaplin T, Miraki-Moud F, Moravcsik E, Jovanovic JV, Wang J, Iqbal S et al. ( 2014 ) . Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia . Blood vol. 123 , ( 13 ) 2066 - 2074 .
Jia L, Clear A, Liu F-T, Matthews J, Uddin N, McCarthy A, Hoxha E, Durance C et al. ( 2014 ) . Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia . Blood vol. 123 , ( 11 ) 1709 - 1719 .
Besley C, Kotsiou E, Petty R, Sangaralingam A, LeDieu R, Gribben J, Davies J ( 2014 ) . LENALIDOMIDE POTENTIATES HUMAN T CELL ALLORESPONSES BY SELECTIVELY INCREASING PROLIFERATION OF ALLOREACTIVE CD8+CELLS WHICH EXHIBIT A NOVEL GENE EXPRESSION PROFILE - IMPLICATIONS FOR IMID THERAPY AFTER ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANT . BONE MARROW TRANSPLANTATION . vol. 49 , S310 - S311 .
Korszun A, Sarker S-J, Chowdhury K, Clark C, Greaves P, Johnson R, Kingston J, Levitt G et al. ( 2014 ) . Psychosocial factors associated with impact of cancer in longterm haematological cancer survivors . Br J Haematol vol. 164 , ( 6 ) 790 - 803 .
Hassan S, Matthews J, Guy A, Farrell M, Taussig D, Smith M, Oakervee H, Cavenagh J et al. ( 2014 ) . REDUCED INTENSITY ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA . BONE MARROW TRANSPLANTATION . vol. 49 , S350 - S351 .
Vrhovac R, Labopin M, Ciceri F, Finke J, Holler E, Tischer J, Lioure B, Gribben J et al. ( 2014 ) . SECOND RIC ALLOGENEIC TRANSPLANT AS A RESCUE STRATEGY FOR ACUTE LEUKAEMIA PATIENTS WHO RELAPSE AFTER AN INITIAL RIC ALLOGENEIC TRANSPLANTATION: ANALYSIS OF RISK FACTORS AND TREATMENT OUTCOMES . BONE MARROW TRANSPLANTATION . vol. 49 , S194 - S195 .
El-Najjar I, Montoto S, McDowell A, Matthews J, Gribben J, Szyszko TA ( 2014 ) . The value of semiquantitative analysis in identifying diffuse bone marrow involvement in follicular lymphoma . Nuclear Medicine Communications vol. 35 , ( 3 ) 311 - 315 .
Liapis K, Taussig D, Cotter FE, Gribben JG ( 2014 ) . Cutaneous cryptococcosis in Hodgkin lymphoma . Br J Haematol vol. 164 , ( 4 )
Greaves P, Sarker SJ, Chowdhury K, Johnson R, Matthews J, Matthews R, Smith M, Korszun A et al. ( 2014 ) . Fertility and sexual function in long-term survivors of haematological malignancy: Using patient-reported outcome measures to assess a neglected area of need in the late effects clinic . British Journal of Haematology vol. 164 , ( 4 ) 526 - 535 .
Greaves P, Sarker S-J, Chowdhury K, Johnson R, Matthews J, Matthews R, Smith M, Korszun A et al. ( 2014 ) . Fertility and sexual function in long-term survivors of haematological malignancy: using patient-reported outcome measures to assess a neglected area of need in the late effects clinic . Br J Haematol vol. 164 , ( 4 ) 526 - 535 .
Okosun J, Bödör C, Wang J, Araf S, Yang CY, Pan C, Boller S, Cittaro D et al. ( 2014 ) . Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma . Nature Genetics vol. 46 , ( 2 ) 176 - 181 .
Okosun J, Bödör C, Wang J, Araf S, Yang C-Y, Pan C, Boller S, Cittaro D et al. ( 2014 ) . Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma . Nat Genet vol. 46 , ( 2 ) 176 - 181 .
Burger JA, Gribben JG ( 2014 ) . The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies . Semin Cancer Biol vol. 24 , 71 - 81 .
Riches JC, Gribben JG ( 2014 ) . Hanging tough: CMV-specific CD8+ T cells in CLL . Blood vol. 123 , ( 5 ) 608 - 609 .
Laurie CC, Laurie CA, Smoley SA, Carlson EE, Flinn I, Fridley BL, Greisman HA, Gribben JG et al. ( 2014 ) . Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants . Cancer Genet vol. 207 , ( 1-2 ) 19 - 30 .
McCarthy A, Marzec J, Clear A, Petty RD, Coutinho R, Matthews J, Wilson A, Iqbal S et al. ( 2014 ) . Dysregulation of autophagy in human follicular lymphoma is independent of overexpression of BCL-2 . Oncotarget vol. 5 , ( 22 ) 11653 - 11668 .
Coutinho R, Clear AJ, Owen A, Wilson A, Matthews J, Lee A, Alvarez R, Gomes da Silva M et al. ( 2013 ) . Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies . Clin Cancer Res vol. 19 , ( 24 ) 6686 - 6695 .
Riches JC, Gribben JG ( 2013 ) . Advances in chimeric antigen receptor immunotherapy for chronic lymphocytic leukemia . Discov Med vol. 16 , ( 90 ) 295 - 302 .
Kotsiou E, Gribben J, Davies J ( 2013 ) . Phenotypic and functional characterisation of alloantigen-specific regulatory T cells expanded after in vitro anergisation with co-stimulatory molecule blockade . IMMUNOLOGY . vol. 140 , 22 - 22 .
Miraki-Moud F, Ariza-McNaughton L, Ghazaly EA, Hodby KA, Luong P, Clear A, Sohrabi F, Bomalaski J et al. ( 2013 ) . Arginine Deprivation With Pegylated Arginine Deiminase Induces Death Of Acute Myeloid Leukaemia Cells In Vivo . Blood . vol. 122 , 1458 - 1458 .
Wrench D, Rizvi H, Wilson A, O'Riain C, Clear A, Matthews J, Laszlo D, Lister TA et al. ( 2013 ) . Concurrent Follicular Lymphoma At Diagnosis Has a Negative Impact On The Outcome Of Patients With Diffuse Large B Cell Lymphoma . Blood vol. 122 , ( 21 ) 4260 - 4260 .
Chen S-S, Herndon TM, Emson C, Riches JC, McClanahan F, Tong T, Yan X-J, Patten PEM et al. ( 2013 ) . Intraclonal Complexity Of CLL Fractions In Cell Proliferation Rates, Gene Expression Signatures, and Responses To Autologous T-Cell Help In Peripheral blood and Secondary Lymphoid Tissues . Blood . vol. 122 , 115 - 115 .
Manodoro F, Marzec J, Wang J, Chaplin T, Jovanovic JV, Eva M, Sameena I, Grimwade D et al. ( 2013 ) . Loss of Imprinting at the 14q32 Domain Leads to MicroRNA Overexpression in Acute Promyelocytic Leukemia . Blood . vol. 122 , 2494 - 2494 .
Riches JC, Sangaralingam A, Chaplin T, McClanahan F, Iqbal S, Agrawal SG, Ramsay AG, Gribben J ( 2013 ) . NK Cells From CLL Patients Exhibit Down-Regulation Of Interferon Response Genes That Can Be Reversed With Lenalidomide . Blood vol. 122 , ( 21 ) 4131 - 4131 .
Korszun A, Sarker S-J, Chowdhury K, Clark C, Greaves P, Johnson R, Kingston J, Levitt G et al. ( 2013 ) . Psychosocial Factors and Impact Of Cancer In British Long-Term Haematological Cancer Survivors . Blood . vol. 122 , 2943 - 2943 .
McClanahan F, Miller S, Riches JC, Ghazaly E, Day WP, Capasso M, Gribben J ( 2013 ) . T-Cell Dysfunction In CLL Is Mediated Not Only By PD-1/PD-L1 But Also By PD-1/PD-L2 Interactions - Partial Functionality Is Maintained In PD-1 Defined CD8 Subsets and This Can Be Further Promoted By Ibrutinib Treatment . Blood vol. 122 , ( 21 ) 4120 - 4120 .
O'Donovan CJ, Ramsay AG, McClanahan F, Rassenti L, Kipps TJ, Gribben J, Riches JC ( 2013 ) . Trisomy 12 CLL Cells Have High Surface Expression Of Integrins Involved In Lymphocyte Trafficking But This Does Not Translate Into Improved LFA-1-Mediated Motility . Blood vol. 122 , ( 21 ) 4159 - 4159 .
Rouault-Pierre K, Lopez-Onieva L, Foster K, Anjos-Afonso F, Lamrissi-Garcia I, Serrano-Sanchez M, Mitter R, Ivanovic Z et al. ( 2013 ) . HIF-2 alpha Protects Human Hematopoietic Stem/Progenitors and Acute Myeloid Leukemic Cells from Apoptosis Induced by Endoplasmic Reticulum Stress . CELL STEM CELL vol. 13 , ( 5 ) 549 - 563 .
Rouault-Pierre K, Lopez-Onieva L, Foster K, Anjos-Afonso F, Lamrissi-Garcia I, Serrano-Sanchez M, Mitter R, Ivanovic Z et al. ( 2013 ) . HIF-2α Protects Human Hematopoietic Stem/Progenitors and Acute Myeloid Leukemic Cells from Apoptosis Induced by Endoplasmic Reticulum Stress . Cell Stem Cell vol. 13 , ( 5 ) 549 - 563 .
Ene-Obong A, Clear AJ, Watt J, Wang J, Fatah R, Riches JC, Marshall JF, Chin-Aleong J et al. ( 2013 ) . Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma . Gastroenterology vol. 145 , ( 5 ) 1121 - 1132 .
Bödör C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K, Marzec J, Araf S et al. ( 2013 ) . EZH2 mutations are frequent and represent an early event in follicular lymphoma . Blood vol. 122 , ( 18 ) 3165 - 3168 .
Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJN, Decker WK, Li S et al. ( 2013 ) . Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity . PLoS ONE vol. 8 , ( 10 )
Greaves P, Clear A, Owen A, Iqbal S, Lee A, Matthews J, Wilson A, Calaminici M et al. ( 2013 ) . Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells . Blood vol. 122 , ( 16 ) 2856 - 2863 .
Gribben JG ( 2013 ) . B-cell receptor pathway inhibitors-rationale and potential . Clin Adv Hematol Oncol vol. 11 Suppl 12 , ( 9 ) 3 - 4 .
Gribben JG ( 2013 ) . The sequence of events in diffuse large B-cell lymphoma . Blood vol. 122 , ( 7 ) 1097 - 1098 .
Miraki-Moud F, Anjos-Afonso F, Hodby KA, Griessinger E, Rosignoli G, Lillington D, Jia L, Davies JK et al. ( 2013 ) . Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation . Proc Natl Acad Sci U S A vol. 110 , ( 33 ) 13576 - 13581 .
Davies JK, Taussig D, Oakervee H, Smith M, Agrawal S, Cavenagh JD, Gribben JG ( 2013 ) . Long-term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non-myeloablative conditioning without T cell depletion . Br J Haematol vol. 162 , ( 4 ) 525 - 529 .
Kiaii S, Clear AJ, Ramsay AG, Davies D, Sangaralingam A, Lee A, Calaminici M, Neuberg DS et al. ( 2013 ) . Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation . J Clin Oncol vol. 31 , ( 21 ) 2654 - 2661 .
Liapis K, Clear A, Owen A, Coutinho R, Greaves P, Lee AM, Montoto S, Calaminici M et al. ( 2013 ) . The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies . Blood vol. 122 , ( 3 ) 424 - 433 .
Greaves P, Wilson A, Matthews J, Gribben J ( 2013 ) . A SIMPLE, ACCESSIBLE NEW TOOL TO DEFINE HIGH RISK PATIENTS IN CLASSICAL HODGKIN LYMPHOMA BASED ON VALIDATION OF PRE-EXISTING BIOMARKERS . HAEMATOLOGICA . vol. 98 , 67 - 68 .
Coutinho R, Flook M, Pria A, Gandhi S, Bailey K, Fields P, Cwynarski K, Wilson A et al. ( 2013 ) . HIV STATUS DOES NOT INFLUENCE THE OUTCOME OF PATIENTS DIAGNOSED WITH DLBCL TREATED WITH R-CHOP IN THE HAART ERA . HAEMATOLOGICA . vol. 98 , 129 - 129 .
Hillmen P, Pocock C, Rawstron A, McParland L, Chalmers A, Varghese A, Smith A, Collett C et al. ( 2013 ) . RESULTS OF THE RANDOMISED PHASE II NCRI ADMIRE TRIAL OF FCR AND FCM-R IN PREVIOUSLY UNTREATED CLL: ORAL FCR IS HIGHLY EFFECTIVE AND SAFE BUT THE ADDITION OF MITOXANTRONE DOES NOT IMPROVE RESPONSES . HAEMATOLOGICA . vol. 98 , 473 - 474 .
Greaves P, Iqbal S, Wilson A, Matthews J, Calaminici M, Gribben J ( 2013 ) . THE TH-INFILTRATE OF HODGKIN LYMPHOMA HAS A UNIQUE PHENOTYPE RICH IN ACTIVATION/PROLIFERATION MARKERS, CENTRAL MEMORY & TH1-POLARISED CELLS, WITHOUT EVIDENCE OF SENESCENCE, SUPPRESSION OR EXHAUSTION . HAEMATOLOGICA . vol. 98 , 221 - 221 .
Ghazaly EA, Joel S, Gribben JG, Mohammad T, Emiloju O, Stavraka C, Hopkins T, Gabra H et al. ( 2013 ) . ProGem1: Phase I first-in-human study of the novel nucleotide NUC-1031 in adult patients with advanced solid tumors . JOURNAL OF CLINICAL ONCOLOGY . vol. 31 ,
Marafioti T, Copie-Bergman C, Calaminici M, Paterson JC, Shende VH, Liu H, Baia M, Ramsay AD et al. ( 2013 ) . Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups . HISTOPATHOLOGY vol. 62 , ( 6 ) 860 - 875 .
Ramsay AG, Evans R, Kiaii S, Svensson L, Hogg N, Gribben JG ( 2013 ) . Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide . Blood vol. 121 , ( 14 ) 2704 - 2714 .
Gribben J ( 2013 ) . Bendamustine for non-Hodgkin lymphoma. Interview by Louise Rishton . Expert Rev Hematol vol. 6 , ( 2 ) 123 - 125 .
Bento L, Anderson D, Davies J, Dark L, Gribben J, Montoto S ( 2013 ) . Capping of body surface area is not necessary for dosing of high dose chemotherapy and autologous stem cell rescue in patients with body surface area > 2m2 . BONE MARROW TRANSPLANTATION . vol. 48 , S230 - S231 .
Burlinson ND, McCloskey D, Gribben J ( 2013 ) . Clinical audit of HLA typing performed on adult patients not receiving an allograft at time of testing . BONE MARROW TRANSPLANTATION . vol. 48 , S100 - S101 .
van Delft FW, Mansur MB, Furness C, Minto L, Irving J, Iqbal S, Noronha E, Colman S et al. ( 2013 ) . Genetics of teenage and young adult t-cell acute lymphoblastic leukaemia . BRITISH JOURNAL OF HAEMATOLOGY vol. 161 , 12 - 12 .
Julve M, Hassan S, Matthews J, Farrell M, Guy A, Popat R, Smith M, Oakervee H et al. ( 2013 ) . Multiple myeloma: a comparison of two melphalan conditioning regimens (200 mg/m2 versus 140 mg/m2) for autologous stem cell transplantation . BONE MARROW TRANSPLANTATION . vol. 48 , S226 - S227 .
Montoto S, Matthews J, Greaves P, Lillington D, Anderson D, Gribben JG, Lister TA ( 2013 ) . Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse . Haematologica vol. 98 , ( 4 ) 620 - 625 .
Greaves P, Sarker S, Chowdhury K, Johnson R, Matthews J, Matthews R, Smith M, Korszun A et al. ( 2013 ) . Self-reported sexual functioning and fertility in long survivors of haematological malignancy: a neglected area of need in the late-effects clinic . BRITISH JOURNAL OF HAEMATOLOGY vol. 161 , 55 - 55 .
Okosun J, Clear A, Iqbal S, Matthews J, Gribben J, Fitzgibbon J, Davies J ( 2013 ) . TNFRSF14 aberrations are associated with death from acute GvHD after reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation for follicular lymphoma . BONE MARROW TRANSPLANTATION . vol. 48 , S169 - S169 .
Riches JC, Gribben JG ( 2013 ) . Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications . Hematol Oncol Clin North Am vol. 27 , ( 2 ) 207 - 235 .
Iyengar S, Clear A, Bödör C, Maharaj L, Lee A, Calaminici M, Matthews J, Iqbal S et al. ( 2013 ) . P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse . Blood vol. 121 , ( 12 ) 2274 - 2284 .
Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, Federico M, Hoskin P et al. ( 2013 ) . ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) . Ann Oncol vol. 24 , ( 3 ) 561 - 576 .
Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, Ramsay AG, Gribben JG ( 2013 ) . T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production . Blood vol. 121 , ( 9 ) 1612 - 1621 .
Gribben J, Coutinho ( 2013 ) . Biomarkers of diffuse large B-cell lymphoma: impact on diagnosis, treatment, and prognosis . Current Biomarker Findings vol. Volume 3 , 17 - 34 .
Brown JR, Kim HT, Armand P, Cutler C, Fisher DC, Ho V, Koreth J, Ritz J et al. ( 2013 ) . Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome . Leukemia vol. 27 , ( 2 ) 362 - 369 .
Greaves P, Gribben JG ( 2013 ) . The role of B7 family molecules in hematologic malignancy . Blood vol. 121 , ( 5 ) 734 - 744 .
Greaves P, Gribben JG ( 2013 ) . A shot in the arm for radiotherapy . Blood vol. 121 , ( 2 ) 246 - 248 .
Greaves P, Clear A, Coutinho R, Wilson A, Matthews J, Owen A, Shanyinde M, Lister TA et al. ( 2013 ) . Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome . J Clin Oncol vol. 31 , ( 2 ) 256 - 262 .
Vallat L, Kemper CA, Jung N, Maumy-Bertrand M, Bertrand F, Meyer N, Pocheville A, III FJW et al. ( 2013 ) . Reverse-engineering the genetic circuitry of a cancer cell with predicted intervention in chronic lymphocytic leukemia . PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA vol. 110 , ( 2 ) 459 - 464 .
Adam S, Almeida MF, Assoun M, Baruteau J, Bernabei SM, Bigot S, Champion H, Daly A et al. ( 2013 ) . Dietary management of urea cycle disorders: European practice . Molecular Genetics and Metabolism vol. 110 , ( 4 ) 439 - 445 .
Gribben JG, Riches JC ( 2013 ) . Immunotherapeutic strategies including transplantation: eradication of disease . Hematology Am Soc Hematol Educ Program vol. 2013 , 151 - 157 .
Greaves P, Gribben JG ( 2012 ) . Laser-capturing the essence of Hodgkin lymphoma . Blood vol. 120 , ( 23 ) 4451 - 4452 .
Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K et al. ( 2012 ) . HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era . J Clin Oncol vol. 30 , ( 33 ) 4111 - 4116 .
Butler T, Montoya A, Clear AJ, Coutinho R, Taussig DC, Cutillas P, Gribben JG ( 2012 ) . Anergic Response to B-Cell Receptor Signaling in Chronic Lymphocytic Leukemia: The Differing Roles of IgD and IgM in the Microenvironment and Peripheral Blood . BLOOD . vol. 120 ,
El Najjar I, Szyszko T, Mc Dowell A, Matthews J, Gribben JG, Montoto S ( 2012 ) . Assessment of Bone Marrow Involvement by FDG-PET in Patients with Follicular Lymphoma . BLOOD . vol. 120 ,
Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, Ramsay AG, Gribben JG ( 2012 ) . Characterizing Immunophenotypic and Functional Pseudo-Exhaustion in T Cells From CLL Patients: The Impact of Lenalidomide . Blood vol. 120 , ( 21 ) 564 - 564 .
Van Delft FW, Furness CL, Mansur MB, Minto L, Irving J, Iqbal S, Noronha E, Colman S et al. ( 2012 ) . Genetics of Teenage and Young Adult Acute Lymphoblastic T-Cell Leukaemia . Blood vol. 120 , ( 21 ) 2521 - 2521 .
Al-Malti A, Gribben JG, Jia L ( 2012 ) . HMGB1 Activates TLR9/RAGE Signalling Pathway and Sustains Chronic Lymphocytic Leukemic Cell in Vitro Survival . Blood vol. 120 , ( 21 ) 3860 - 3860 .
Böodöor C, Vera G, Kohlmann A, Tan K, Okosun J, Popov N, Araf S, Marzec J et al. ( 2012 ) . High Incidence of EZH2 Mutations with Variable Mutation Load in Follicular Lymphoma and Its Consequences for EZH2 Targeted Therapy . Blood vol. 120 , ( 21 ) 545 - 545 .
Iyengar S, Ariza-McNaughton L, Clear AJ, Roe A, Lillington D, Taussig DC, Gribben JG, Joel S et al. ( 2012 ) . Human Primary Mantle Cell Lymphoma Can Be Established in NOD/SCID/IL2R gamma-Null Mice . BLOOD . vol. 120 ,
Maharaj L, Popat R, Gribben JG, Joel S ( 2012 ) . IL-6, IL-8 and VEGF Neutralisation Restores Drug Sensitivity to Conventional and Novel Treatment Combinations in a Multiple Myeloma Bone Marrow Micro-Environment Model . BLOOD . vol. 120 ,
Kiaii S, Clear AJ, Gribben JG ( 2012 ) . Impact of Tumor Infiltrating T Cells in Patients with Diffuse Large B-Cell Lymphoma . BLOOD . vol. 120 ,
Iyengar S, Clear AJ, Boedor C, Maharaj L, Matthews J, Auer R, Iqbal S, Gribben JG et al. ( 2012 ) . Increased Tonic PI3K Signaling Through p110 alpha Can Limit the Efficacy of P110 delta -Selective Inhibition in Mantle Cell Lymphoma, Particularly with Multiple Relapse . BLOOD . vol. 120 ,
McCarthy A, Yeung V, Gribben JG, Jia L ( 2012 ) . Inhibition of Autophagy by Chloroquine Sensitises Lymphoma Cells to ABT-737-Induced Apoptosis . BLOOD . vol. 120 ,
McClanahan F, Ghirelli C, Greaves P, Riches JC, Coutinho R, Ramsay AG, Gribben JG ( 2012 ) . Inhibitory Ligands CD200, CD270, CD274 and CD276 Are Expressed On E mu-TCL1 Transgenic Mouse Splenocytes and Are of Potential Relevance to Impaired T-Cell Function in Vivo . BLOOD . vol. 120 ,
El-Najjar I, Matthews J, Wilson A, Gribben JG, Montoto S ( 2012 ) . The Clinical Course of Patients with Follicular Lymphoma in the Rituximab Era: A Paradigm Shift . BLOOD . vol. 120 ,
Coutinho R, Newman AM, Rossignoli G, Day W, Miraki-Moud F, Chaplin T, Marzec J, Petty RD et al. ( 2012 ) . The Diffuse Large B-Cell Lymphoma Infiltrating Macrophage Transcriptome Signature Is Enriched for Both M1 and M2 Genes and Provides an Excellent Platform for Functional Validation of Macrophage Biology in DLBCL . BLOOD . vol. 120 ,
Korszun A, Johnson R, Sarker S-J, Kashfia C, Clark C, Greaves P, Kingston J, Levitt G et al. ( 2012 ) . The Relationship of Depression and Anxiety and Impact of Cancer in Long-Term Survivors of Haematological Malignancy . Blood vol. 120 , ( 21 ) 3174 - 3174 .
Claus R, Ruppert AS, Lucas DM, Zucknick M, Rassenti LZ, Greaves A, Neuberg DS, Wierda WG et al. ( 2012 ) . The Relative Significance of ZAP-70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set . Blood vol. 120 , ( 21 ) 3865 - 3865 .
Okosun J, Boedoer C, Wang J, Araf S, Marzec J, Iqbal S, Matthews J, Calaminici M et al. ( 2012 ) . Whole Genome Sequencing in Sequential Biopsies Reveals the Genetic Evolution of Follicular Lymphoma to Transformed Follicular Lymphoma . BLOOD . vol. 120 ,
McClanahan F, Gribben JG ( 2012 ) . Immunotherapeutic Approaches Have the Potential to Brighten the Future Not Only for Patients With del(17p13.1), but for All CLL Patients THE STEPHENS/BYRD ARTICLE REVIEWED . ONCOLOGY-NEW YORK vol. 26 , ( 11 ) 1055 - + .
McClanahan F, Gribben JG ( 2012 ) . Immunotherapeutic approaches have the potential to brighten the future not only for patients with del(17p13.1), but for all CLL patients . Oncology (Williston Park) vol. 26 , ( 11 ) 1055 - 1058 .
Nagler A, Labopin M, Shimoni A, Mufti GJ, Cornelissen JJ, Blaise D, Janssen JJWM, Milpied N et al. ( 2012 ) . Mobilized peripheral blood stem cells compared with bone marrow from HLA-identical siblings for reduced-intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT . EUROPEAN JOURNAL OF HAEMATOLOGY vol. 89 , ( 3 ) 206 - 213 .
Lozanski G, Ruppert AS, Heerema NA, Lozanski A, Lucas DM, Gordon A, Gribben JG, Morrison VA et al. ( 2012 ) . Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study . LEUKEMIA & LYMPHOMA vol. 53 , ( 9 ) 1743 - 1748 .
Ramsay AG, Clear AJ, Fatah R, Gribben JG ( 2012 ) . Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer . Blood vol. 120 , ( 7 ) 1412 - 1421 .
Riches JC, Gribben JG ( 2012 ) . Less expensive CARs? . Cytotherapy vol. 14 , ( 7 ) 773 - 774 .
El-Najjar I, Szyszko T, Mc Dowell A, Matthews J, Gribben J, Montoto S ( 2012 ) . ASSESSMENT OF BONE MARROW INVOLVEMENT BY FDG-PET/CT IN PATIENTS WITH FOLLICULAR LYMPHOMA . HAEMATOLOGICA . vol. 97 , 664 - 664 .
Liu F, Jia L, Farren T, Gribben J, Agrawal S ( 2012 ) . AUTOCRINE IL-6 PRODUCTION CORRELATED WITH SURVIVAL OF CHRONIC LYMPHOCYTIC LEUKAEMIA CELLS . HAEMATOLOGICA . vol. 97 , 517 - 517 .
Greaves P, Iqbal S, Rosignoli G, Matthews J, Wilson A, Taussig D, Gribben J ( 2012 ) . DOMINANCE OF NAIVE AND CENTRAL MEMORY CD4+T CELLS IN THE CLASSICAL HODGKIN LYMPHOMA MICROENVIRONMENT PROVIDES A DISTINCTIVE SIGNATURE WITH IMPLICATIONS FOR PATHOGENESIS AND CLINICAL DIAGNOSIS . HAEMATOLOGICA . vol. 97 , 81 - 81 .
Riches J, Davies J, McClanahan F, Iqbal S, Fatah R, Agrawal S, Ramsay A, Gribben J ( 2012 ) . IDENTIFICATION OF AN EXPANDED POPULATION OF TERMINALLY DIFFERENTIATED CD8+T CELLS WITH A NOVEL PHENOTYPIC AND FUNCTIONAL PROFILE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA . HAEMATOLOGICA . vol. 97 , 451 - 451 .
Hassan S, Montoto S, Gribben J, De Vos J ( 2012 ) . LOW-DOSE ETOPOSIDE AND CYTARABINE: A PALLIATIVE TREATMENT OPTION IN PATIENTS WITH REFRACTORY/RELAPSED DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR INTENSIVE SALVAGE CHEMOTHERAPY . HAEMATOLOGICA . vol. 97 , 654 - 654 .
Ramsay G, Clear A, Fatah R, Gribben J ( 2012 ) . MULTIPLE INHIBITORY LIGANDS INDUCE T CELL IMMUNOLOGICAL SYNAPSE DYSFUNCTION IN HEMATOLOGIC MALIGNANCY THAT CAN BE BLOCKED WITH LENALIDOMIDE - DEFINING A REVERSIBLE IMMUNE EVASION MECHANISM IN CANCER . HAEMATOLOGICA . vol. 97 , 230 - 230 .
Butler T, Taussig D, Cutillas P, Gribben J ( 2012 ) . PHOSPHOPROTEOMIC ANALYSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA AND B-CELL RECEPTOR SIGNALING SUGGESTS NOVEL THERAPEUTIC TARGETS . HAEMATOLOGICA . vol. 97 , 49 - 49 .
Greaves P, Clear A, Owen A, Wilson A, Matthews J, Calaminici M, Gribben J ( 2012 ) . THE MICROENVIRONMENT IN CLASSICAL HODGKIN LYMPHOMA SHOWS EVIDENCE OF A TH1 AND NOT TH2 RESPONSE WITH TBET EXPRESSION BEING ASSOCIATED WITH IMPROVED SURVIVAL AND EBV STATUS . HAEMATOLOGICA . vol. 97 , 455 - 455 .
Patel S, Cavenagh J, Gribben J, De Vos J ( 2012 ) . USE OR RITUXIMAB IN ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD) POST ALLOGENEIC HEMATOPOIETIC CELL-TRANSPLANTATION . HAEMATOLOGICA . vol. 97 , 726 - 727 .
Claus R, Lucas DM, Stilgenbauer S, Ruppert AS, Yu L, Zucknick M, Mertens D, Bühler A et al. ( 2012 ) . Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia . J Clin Oncol vol. 30 , ( 20 ) 2483 - 2491 .
Delage B, Luong P, Maharaj L, O'Riain C, Syed N, Crook T, Hatzimichael E, Papoudou-Bai A et al. ( 2012 ) . Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis . Cell Death Dis vol. 3 ,
Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP, Cymbalista F, Eichhorst B et al. ( 2012 ) . ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia . LEUKEMIA vol. 26 , ( 7 ) 1458 - 1461 .
Auer RL, MacDougall F, Oakervee HE, Taussig D, Davies JK, Syndercombe-Court D, Agrawal S, Cavenagh JD et al. ( 2012 ) . T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies . Br J Haematol vol. 157 , ( 5 ) 580 - 585 .
Zenz T, Gribben JG, Hallek M, Doehner H, Keating MJ, Stilgenbauer S ( 2012 ) . Risk categories and refractory CLL in the era of chemoimmunotherapy . BLOOD vol. 119 , ( 18 ) 4101 - 4107 .
Joshi NM, Hassan S, Jasani P, Dixon S, Cavenagh JD, Oakervee HE, Smith M, Agrawal SA et al. ( 2012 ) . Bile acid malabsorption in patients with graft-versus-host disease of the gastrointestinal tract . Br J Haematol vol. 157 , ( 3 ) 403 - 407 .
Mounier N, Canals C, Gisselbrecht C, Cornelissen J, Foa R, Conde E, Maertens J, Attal M et al. ( 2012 ) . High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry . Biology of Blood and Marrow Transplantation vol. 18 , ( 5 ) 788 - 793 .
White RE, Raemer PC, Naresh KN, Meixlsperger S, Pinaud L, Rooney C, Savoldo B, Coutinho R et al. ( 2012 ) . EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors . JOURNAL OF CLINICAL INVESTIGATION vol. 122 , ( 4 ) 1487 - 1502 .
Greaves P, Wilson A, Matthews J, Brown DLP, Auer R, Montoto S, Lister TA, Gribben JG ( 2012 ) . Early relapse and refractory disease remain risk factors in the anthracycline and autologous transplant era for patients with relapsed/refractory classical Hodgkin lymphoma: a single centre intention-to-treat analysis . Br J Haematol vol. 157 , ( 2 ) 201 - 204 .
Vargaftig J, Taussig DC, Griessinger E, Anjos-Afonso F, Lister TA, Cavenagh J, Oakervee H, Gribben J et al. ( 2012 ) . Frequency of leukemic initiating cells does not depend on the xenotransplantation model used . Leukemia vol. 26 , ( 4 ) 858 - 860 .
Orkin C, Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M et al. ( 2012 ) . HIV Status does not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era . HIV MEDICINE vol. 13 , 5 - 5 .
Wrench D, Matthews J, Montoto S, Gribben JG, Lister TA ( 2012 ) . Management without radiotherapy may be an acceptable approach for stage 1 follicular lymphoma . BRITISH JOURNAL OF HAEMATOLOGY . vol. 157 , 52 - 52 .
El-Najjar I, Boumendil A, Luan J, Thieblemont C, Blaise D, Thomson K, Mohty M, Colombat P et al. ( 2012 ) . The outcome of patients with follicular lymphoma in the rituximab era treated with autologous stem cell transplant according to the high-dose regimen received. A retrospective study of the EBMT Lymphoma Working Party . BONE MARROW TRANSPLANTATION . vol. 47 , S3 - S4 .
Jasani PD, MacDougall F, Smith MLW, Cavenagh JD, Lister TA, Gribben JG, Taussig DC, Oakervee HE ( 2012 ) . Treatment of acute myeloid leukaemia in the elderly: a retrospective analysis . BRITISH JOURNAL OF HAEMATOLOGY . vol. 157 , 64 - 65 .
Wendtner C-M, Hillmen P, Mahadevan D, Buehler A, Uharek L, Coutre S, Frankfurt O, Bloor A et al. ( 2012 ) . Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia . LEUKEMIA & LYMPHOMA vol. 53 , ( 3 ) 417 - 423 .
Riches JC, Ramsay AG, Gribben JG ( 2012 ) . Immune reconstitution in chronic lymphocytic leukemia . Curr Hematol Malig Rep vol. 7 , ( 1 ) 13 - 20 .
JIA L, Gopinathan G, Sukumar JT, Gribben JG ( 2012 ) . Blocking Autophagy Prevents Bortezomib-Induced NF-kappaB Activation by Reducing I-kappaBalpha Degradation in Lymphoma Cells . PLoS One vol. 7 , ( 2 ) Article e32584 ,
DAVIES JK, Gribben JG ( 2012 ) . Blockade of chemotaxis in graft-versus-host disease . New England Journal of Medicine vol. 367 , ( 17 )
Decker WK, Shah N, Xing D, Lapushin R, Li S, Robinson SN, Yang H, Parmar S et al. ( 2012 ) . Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC . PLoS One vol. 7 , ( 12 )
Riches JC, Ramsay AG, Gribben JG ( 2012 ) . Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy . Curr Pharm Des vol. 18 , ( 23 ) 3389 - 3398 .
Gribben JG ( 2012 ) . Transplant in chronic lymphocytic leukemia: to do it or not and if so, when and how? . Am Soc Clin Oncol Educ Book399 - 404 .
Montserrat E, Gribben JG ( 2011 ) . Autografting CLL: The game is over! . Blood vol. 118 , ( 26 )
Jia L, Uddin N, Gribben JG ( 2011 ) . Activation of Mitochondrial STAT3 Increases Mitochondrial Respiration and Inhibits Oxidative Stress in Chronic Lymphocytic Leukemic Cells . BLOOD . vol. 118 , 133 - 133 .
Liu F, Jia L, Farren TW, Gribben JG, Agrawal SG ( 2011 ) . Autocrine IL-6 Production Indicates the Level of Activated STAT3 and NF-Kb of Chronic Lymphocytic Leukemia Cells . Blood vol. 118 , ( 21 ) 1784 - 1784 .
Xing D, Ramsay AG, Decker W, Lee DA, Robinson S, Shah N, Parmar S, Bollard CM et al. ( 2011 ) . CD137L Reverse the Immunological Synapse Defects of Natural Killer Cells in Acute Myeloid Leukemia . BLOOD . vol. 118 , 112 - 112 .
Ramsay AG, Clear AJ, Davenport A, Fatah R, Gribben JG ( 2011 ) . Chronic Lymphocytic Leukemia Cells Co-Opt CD200, CD270, CD274 and CD276 to Induce Impaired Actin Polarization At the T Cell Immune Synapse . Blood vol. 118 , ( 21 ) 802 - 802 .
Ramsay AG, Clear AJ, Davenport A, Fatah R, Gribben JG ( 2011 ) . Chronic Lymphocytic Leukemia Cells Co-Opt CD200,.CD270, CD274 and CD276 to Induce Impaired Actin Polarization At the T Cell Immune Synapse . BLOOD . vol. 118 , 364 - 365 .
Taussig DC, Gribben JG ( 2011 ) . Continuous CD4+ T Cell Lines Derived From the Classical Hodgkin Lymphoma Microenvironment: A Challenge to the Assumption of Anergy . BLOOD . vol. 118 , 1556 - 1557 .
Greaves P, Iqbal S, Taussig DC, Gribben JG ( 2011 ) . Continuous CD4+ T Cell Lines Derived From the Classical Hodgkin Lymphoma Microenvironment: A Challenge to the Assumption of Anergy, . Blood vol. 118 , ( 21 ) 3645 - 3645 .
Coutinho R, Clear AJ, Owen DA, Greaves P, Hallam SL, Wilson A, Matthews J, Calaminici M et al. ( 2011 ) . Exploring the Immune Microenvironment of Diffuse Large B Cell Lymphoma in a Tissue Microarray: Predicting Survival with a Score That Incorporates Macrophages, Cytotoxic and Regulatory T Cells . BLOOD . vol. 118 , 434 - 435 .
Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K et al. ( 2011 ) . HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era . BLOOD . vol. 118 , 1557 - 1557 .
Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K et al. ( 2011 ) . HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era, . Blood vol. 118 , ( 21 ) 3646 - 3646 .
Riches JC, Sangaralingam A, Kiaii S, Chaplin T, Cekdemir D, Iqbal S, Ramsay AG, Gribben JG ( 2011 ) . Impact of Lenalidomide on Gene Expression Profiles of Malignant and Immune Cells in Patients with Chronic Lymphocytic Leukemia . BLOOD . vol. 118 , 446 - 446 .
Kiaii S, Clear AJ, Sangaralingam A, Gribben JG ( 2011 ) . Impact of Tumor Infiltrating T Cells in Patients with Follicular Lymphoma At Diagnosis . BLOOD . vol. 118 , 349 - 349 .
Xing D, Ramsay AG, Robinson S, Bollard CM, Shah N, Champlin R, Gribben JG, Shpall EJ ( 2011 ) . Lenalidomide Treatment Enhances Immunological Synapse Formation of Cord Blood Natural Killer Cells with B Cells Derived From Chronic Lymphocytic Leukemia . BLOOD . vol. 118 , 783 - 783 .
Hallam SL, Candido J, Coutinho R, Maniati E, Thompson RG, van Rooijen N, Hagemann T, Gribben JG ( 2011 ) . Manipulating Tumor Associated Macrophages (TAM) in a Mouse Model of B-Cell Non-Hodgkin Lymphoma (NHL) . Blood vol. 118 , ( 21 ) 1657 - 1657 .
El-Najjar I, Matthews J, Gribben J, Montoto S ( 2011 ) . Neither the FLIPI Nor the FLIPI2 Accurately Segregates Low- Risk From Intermediate- Risk Follicular Lymphoma Patients in Terms of Progression-Free Survival . BLOOD . vol. 118 , 1144 - 1144 .
Iyengar S, Clear AJ, Owen A, Maharaj L, Matthews J, Calaminici M, Auer R, Ghazaly E et al. ( 2011 ) . PI3K Inhibition with GDC-0941 Has Greater Efficacy Compared to p110 delta-Selective Inhibition with CAL-101 in Mantle Cell Lymphoma and May Be Particularly Advantageous in Multiply Relapsed Patients . BLOOD . vol. 118 , 719 - 719 .
Iyengar S, Clear AJ, Owen A, Maharaj L, Matthews J, Calaminici M, Auer R, Ghazaly E et al. ( 2011 ) . PI3K Inhibition with GDC-0941 Has Greater Efficacy Compared to p110δ-Selective Inhibition with CAL-101 in Mantle Cell Lymphoma and May Be Particularly Advantageous in Multiply Relapsed Patients . Blood vol. 118 , ( 21 ) 1654 - 1654 .
Riches JC, Davies J, Iqbal S, Fatah R, Agrawal S, Ramsay AG, Gribben JG ( 2011 ) . T-Cells From Patients with CLL Exhibit Phenotypic and Transcription Factor Profiles of Exhaustion Independent of CMV Serostatus . Blood vol. 118 , ( 21 ) 1780 - 1780 .
Greaves P, Clear AJ, Owen A, Wilson A, Matthews J, Calaminici M, Gribben JG ( 2011 ) . The PD1/PD-L1 Axis in the Classical Hodgkin Lymphoma Microenvironment: PD-1 Is Rarely Expressed but Identifies Patients with High-Risk Disease . BLOOD . vol. 118 , 678 - 678 .
El-Najjar I, Boumendil A, Luan JJ, Thieblemont C, Blaise D, Thomson K, Le Gouill S, Lissandre S et al. ( 2011 ) . The Role of Total Body Irradiation (TBI) in the High-Dose Regimen of Patients with Follicular Lymphoma (FL) Treated with Autologous Stem Cell Transplant (ASCT) in the Rituximab Era. A Retrospective Study of the EBMT Lymphoma Working Party . BLOOD . vol. 118 , 234 - 235 .
Ramsay AG, Gribben JG ( 2011 ) . The kiss of death in FL . Blood vol. 118 , ( 20 ) 5365 - 5366 .
Jia L, Uddin N, Gribben JG ( 2011 ) . 2.17 Activation of STAT3 Increases Mitochondrial Respiration and Protects Mitochondria from Oxidative Damage in Chronic Lymphocytic Leukemia . Clinical Lymphoma Myeloma & Leukemia vol. 11 , s170 - s171 .
Liu F, Jia L, Farren T, Gribben J, Agrawal S ( 2011 ) . 2.21 Autocrine Interleukin-6 Production Correlated with Survival of Chronic Lymphocytic Leukaemia Cells . Clinical Lymphoma Myeloma & Leukemia vol. 11 ,
Liu F, Jia L, Farren T, Gribben J, Agrawal S ( 2011 ) . 2.46 Signal Transducer and Activator of Transcription 3 and Nuclear Factor κB Activation Regulate Autocrine Interleukin-6 Production and Indicate the Prognosis of CLL . Clinical Lymphoma Myeloma & Leukemia vol. 11 , s188 - s189 .
Riches JC, Ramsay AG, Gribben JG ( 2011 ) . Chronic lymphocytic leukemia: an update on biology and treatment . Curr Oncol Rep vol. 13 , ( 5 ) 379 - 385 .
Farren TW, Giustiniani J, Liu F-T, Tsitsikas DA, Macey MG, Cavenagh JD, Oakervee HE, Taussig D et al. ( 2011 ) . Differential and tumor-specific expression of CD160 in B-cell malignancies . Blood vol. 118 , ( 8 ) 2174 - 2183 .
Gribben JG ( 2011 ) . Are prognostic factors in CLL overrated? . Oncology vol. 25 , ( 8 ) 1 - 3 .
Perrot A, Pionneau C, Nadaud S, Davi F, Leblond V, Jacob F, Merle-Beral H, Herbrecht R et al. ( 2011 ) . A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia . BLOOD vol. 118 , ( 4 ) E1 - E15 .
Gribben JG ( 2011 ) . Are Prognostic Factors in CLL Overrated? THE MOUGALIAN/O'BRIEN ARTICLE REVIEWED . ONCOLOGY-NY vol. 25 , ( 8 ) 703 - 706 .
Gribben JG ( 2011 ) . Are prognostic factors in CLL overrated? . Oncology (Williston Park) vol. 25 , ( 8 ) 703 - 706 .
Montserrat E, Gribben JG ( 2011 ) . Autografting CLL: the game is over! . Blood vol. 117 , ( 23 ) 6057 - 6058 .
Kiaii S, Clear AJ, Davis D, Ramsay AG, Sangaralingam A, Gribben JG ( 2011 ) . DEFECTS AND ABNORMALITIES IN INFILTRATING T CELLS IN PATIENTS WITH FOLLICULAR LYMPHOMA AT DIAGNOSIS . ANNALS OF ONCOLOGY . vol. 22 , 84 - 84 .
Gribben J ( 2011 ) . NEW EVIDENCE FOR MECHANISM OF ACTION OF IMIDS (R) IN LYMPHOMAS, FOCUS ON MCL . ANNALS OF ONCOLOGY . vol. 22 , 254 - 255 .
Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, Oscier DG, Dearden CE et al. ( 2011 ) . RITUXIMAB PLUS CHLORAMBUCIL (R-CHLORAMBUCIL) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): FINAL ANALYSIS OF AN OPEN-LABEL PHASE II STUDY . ANNALS OF ONCOLOGY . vol. 22 , 123 - 123 .
Montoto S, Matthews J, Anderson D, Lister A, Gribben J ( 2011 ) . THE NUMBER OF PREVIOUS TREATMENT LINES HAS NO IMPACT ON THE OUTCOME AFTER HIGH-DOSE THERAPY WITH AUTOLOGOUS STEM CELL RESCUE WITH BEAM FOR RELAPSED FOLLICULAR LYMPHOMA . ANNALS OF ONCOLOGY . vol. 22 , 115 - 115 .
Greaves P, Clear A, Owen A, Matthews J, Macdougall F, Wilson A, Lister A, Calaminici M et al. ( 2011 ) . TOTAL NUMBER OF B CELLS, BUT NOT T CELLS AT DIAGNOSIS IN THE CLASSICAL HODGKIN LYMPHOMA MICROENVIRONMENT IS PREDICTIVE OF SURVIVAL . ANNALS OF ONCOLOGY . vol. 22 , 153 - 153 .
Montoto S, Matthews J, Anderson D, Lister TA, Gribben JG ( 2011 ) . Outcome after high-dose therapy with autologous stem cell rescue with BEAM for relapsed follicular lymphoma . J Clin Oncol vol. 29 , ( 15_suppl )
Woyach JA, Ruppert AS, Heerema NA, Peterson BL, Gribben JG, Morrison VA, Rai KR, Larson RA et al. ( 2011 ) . Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712 . J Clin Oncol vol. 29 , ( 10 ) 1349 - 1355 .
Bödör C, O'Riain C, Wrench D, Matthews J, Iyengar S, Tayyib H, Calaminici M, Clear A et al. ( 2011 ) . EZH2 Y641 mutations in follicular lymphoma . Leukemia vol. 25 , ( 4 ) 726 - 729 .
El-Najjar I, Szyszko T, Matthews J, Gribben J, Avril N, Montoto S ( 2011 ) . FDG-PET/CT staging in follicular lymphoma: effect on FLIPI score . BRITISH JOURNAL OF HAEMATOLOGY . vol. 153 , 48 - 48 .
Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, Oscier DG, Dearden CE et al. ( 2011 ) . Final response assessment of the CLL208 trial: an open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL) . BRITISH JOURNAL OF HAEMATOLOGY . vol. 153 , 21 - 21 .
Johnson R, Greaves P, Powell M, Vinnicombe S, Wilson A, Sarker S, Gribben J, Lister A ( 2011 ) . Survey of breast screening in long-term survivors treated with supra-diaphragmatic irradiation for lymphoma . BRITISH JOURNAL OF HAEMATOLOGY . vol. 153 , 47 - 47 .
Wrench D, Leighton P, Skibola CF, Conde L, Cazier J-B, Matthews J, Iqbal S, Carlotti E et al. ( 2011 ) . SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma . Blood vol. 117 , ( 11 ) 3147 - 3150 .
Greaves PJ, Gribben JG ( 2011 ) . Demonstration of durable graft versus lymphoma effects in Hodgkin's lymphoma . J Clin Oncol vol. 29 , ( 8 ) 952 - 953 .
Gribben JG, O'Brien S ( 2011 ) . Update on therapy of chronic lymphocytic leukemia . J Clin Oncol vol. 29 , ( 5 ) 544 - 550 .
Hallam S, Gribben JG ( 2011 ) . The Role of Stem-Cell Transplantation in Chronic Lymphocytic Leukemia . Leukemias: Principles and Practice of Therapy ,
Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning M, Rassenti LZ, Greaves AW et al. ( 2011 ) . Self-Administered, Subcutaneous Alemtuzumab to Treat Residual Disease in Patients With Chronic Lymphocytic Leukemia . CANCER-AM CANCER SOC vol. 117 , ( 1 ) 116 - 124 .
Gribben JG, Hosing C, Maloney DG ( 2011 ) . Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia . Biol Blood Marrow Transplant vol. 17 , ( 1 Suppl ) S63 - S70 .
Riches JC, Davies J, Iqbal S, Fatah R, Agrawal S, Ramsay AG, Gribben JG ( 2011 ) . T-cells from Patients With CLL Exhibit Phenotypic and Transcription Factor Profiles Of Exhaustion Independent of CMV Serostatus . Blood . vol. 118 , 1780 - 1783 .
Riches JC, Ramsay AG, Gribben JG ( 2010 ) . T-cell function in chronic lymphocytic leukaemia . Semin Cancer Biol vol. 20 , ( 6 ) 431 - 438 .
Tsitsikas DA, Sibony DW, Oakervee HE, Agrawal SG, Smith M, Taussig DC, de Vos J, Stewart E et al. ( 2010 ) . A Phase II Trial of Sequential Treatment with Cytoreductive Therapy and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukaemia, High Risk MDS and Other High Risk Myeoid Malignancies An Interim Report . BLOOD . vol. 116 , 1430 - 1430 .
Tsitsikas DA, Warcel-Sibony D, Oakervee HE, Agrawal SG, Smith M, Taussig DC, de Vos J, Stewart E et al. ( 2010 ) . A Phase II Trial of Sequential Treatment with Cytoreductive Therapy and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukaemia, High-Risk MDS and Other High Risk Myeoid Malignancies: An Interim Report . BLOOD . vol. 116 , 1430 - 1430 .
Tsitsikas DA, Warcel-Sibony D, Oakervee HE, Agrawal SG, Smith M, Taussig DC, de Vos J, Stewart E et al. ( 2010 ) . A Phase II Trial of Sequential Treatment with Cytoreductive Therapy and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukaemia, High-Risk MDS and Other High Risk Myeoid Malignancies: An Interim Report . Blood vol. 116 , ( 21 ) 3480 - 3480 .
Greaves P, Wilson A, Matthews J, Brown DLP, Montoto S, Gribben JG, Lister A ( 2010 ) . A Single-Centre Analysis by Intention to Treat with High Dose Chemotherapy and Autologous Stem Cell Rescue Following Second-Line Treatment In Patients with Hodgkin Lymphoma . BLOOD . vol. 116 , 989 - 990 .
Greaves P, Clear AJ, Owen DA, Macdougall F, Wilson A, Lister A, Calaminici M, Gribben JG ( 2010 ) . An Immunohistochemical Score Based On CD68 and FOXP3 Expression In the Tumour Microenvironment at Diagnosis Defines Prognostic Groups In Both Early and Advanced Stage Classical Hodgkin Lymphoma . BLOOD . Conference: 52nd Annual Meeting of the American-Society-of-Hematology (ASH) ( Orlando, FL ) from: 04/12/2010 to: 07/12/2010 , vol. 116 , 330 - 330 .
Liu F, Jia L, Farren T, Gribben JG, Agrawal S ( 2010 ) . Autocrine IL6/STAT3 Signaling Enhances Survival of Chronic Lymphocytic Leukaemia Cells . Blood vol. 116 , ( 21 ) 3598 - 3598 .
Ramsay AG, Evans R, Svensson L, Kiati S, Hogg N, Gribben JG ( 2010 ) . Defective LFA 1 Mediated T Cell Motility In Chronic Lymphocytic Leukemia Is Mediated by Defects In the Rho GTPase Signaling Pathway . BLOOD . vol. 116 , 403 - 403 .
Ramsay AG, Evans R, Svensson L, Kiaii S, Hogg N, Gribben JG ( 2010 ) . Defective LFA-1 Mediated T Cell Motility In Chronic Lymphocytic Leukemia Is Mediated by Defects In the Rho GTPase Signaling Pathway . BLOOD . vol. 116 , 403 - 403 .
Kiaii S, Clear AJ, Ramsay AG, Sangaralingam A, Gribben JG ( 2010 ) . Differential Gene Expression Profile Identifies Defects and Abnormalities In Infiltrating T Cells In Patients With Follicular Lymphoma at Diagnosis . BLOOD . Conference: 52nd Annual Meeting of the American-Society-of-Hematology (ASH) ( Orlando, FL ) from: 04/12/2010 to: 07/12/2010 , vol. 116 , 66 - 67 .
Kiaii S, Clear AJ, Ramsay AG, Sangaralingam A, Gribben JG ( 2010 ) . Differential Gene Expression Profile Identifies Defects and Abnormalities In Infiltrating T Cells In Patients with Follicular Lymphoma at Diagnosis . BLOOD . vol. 116 , 66 - 67 .
Wendtner C, Hillmen P, Mahadevan D, Stilgenbauer S, Uharek L, Coutre S, Frankturt O, Bloor A et al. ( 2010 ) . Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL 001 Study) . BLOOD . vol. 116 , 591 - 592 .
Wendtner C, Hillmen P, Mahadevan D, Stilgenbauer S, Uharek L, Coutre S, Frankfurt O, Bloor A et al. ( 2010 ) . Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study) . BLOOD . vol. 116 , 591 - 592 .
Ramsay AG, Clear AJ, Davenport A, Fatah R, Gribben JG ( 2010 ) . Functional Screening Studies Identify Combinational Activity of PD L1 and CD200 In Mediating Dysfunctional T Cell Immunological Synapse Formation In Chronic Lymphocytic Leukemia . BLOOD . Conference: 52nd Annual Meeting of the American-Society-of-Hematology (ASH) ( Orlando, FL ) from: 04/12/2010 to: 07/12/2010 , vol. 116 , 306 - 307 .
Ramsay AG, Clear AJ, Davenport A, Fatah R, Gribben JG ( 2010 ) . Functional Screening Studies Identify Combinational Activity of PD-L1 and CD200 In Mediating Dysfunctional T Cell Immunological Synapse Formation In Chronic Lymphocytic Leukemia . BLOOD . vol. 116 , 306 - 307 .
Smith MR, Neuberg D, Flinn IW, Grever MR, Bennett JM, Dewald G, Paietta EM, Litzow MR et al. ( 2010 ) . Increased Incidence of Therapy Related Myeloid Neoplasia (t MN) After Initial Therapy for CLL with Fludarabine Cyclophosphamide (FC) Vs Fludarabine (F) Long Term Follow up of US Intergroup Study E2997 . BLOOD . vol. 116 , 408 - 409 .
Smith MR, Neuberg D, Flinn IW, Grever MR, Bennett JM, Dewald G, Paietta EM, Litzow MR et al. ( 2010 ) . Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997 . BLOOD . vol. 116 , 408 - 409 .
Butler T, Gribben JG, Hodgson A ( 2010 ) . Physician Scientists In Hematology: Hematologists' Experiences of Research and Recruitment to Academia - A Mixed Methods, Qualitative Approach . BLOOD . vol. 116 , 1063 - 1064 .
Jia L, Gopinathan G, Sukumar JT, Gribben JG ( 2010 ) . Potentiation of Bortezomib Induced Killing of Lymphoma Cells by Inhibition of Autophagy and Prevention of I kappa B alpha Degradation . BLOOD . Conference: 52nd Annual Meeting of the American-Society-of-Hematology (ASH) ( Orlando, FL ) from: 04/12/2010 to: 07/12/2010 , vol. 116 , 57 - 57 .
Jia L, Gopinathan G, Sukumar JT, Gribben JG ( 2010 ) . Potentiation of Bortezomib-Induced Killing of Lymphoma Cells by Inhibition of Autophagy and Prevention of I-kappa B alpha Degradation . BLOOD . vol. 116 , 57 - 57 .
Jia L, Gopinathan G, Sukumar JT, Gribben JG ( 2010 ) . Potentiation of Bortezomib-Induced Killing of Lymphoma Cells by Inhibition of Autophagy and Prevention of I-κBα Degradation . Blood . vol. 116 , 116 - 116 .
Greaves P, Montoto S, Matthews J, Wilson A, Brown DLP, Lillington D, Gribben JG, Lister A ( 2010 ) . Prospective Use of a Triple FISH Probe to Predict sMDS/AML Following High Dose Therapy with Autologous Stem Cell Rescue for Lymphoma . BLOOD . vol. 116 , 1420 - 1420 .
Greaves P, Montoto S, Matthews J, Wilson A, Brown DLP, Lillington D, Gribben JG, Lister A ( 2010 ) . Prospective Use of a Triple FISH Probe to Predict sMDS/AML Following High Dose Therapy with Autologous Stem Cell Rescue for Lymphoma . Blood vol. 116 , ( 21 ) 3459 - 3459 .
Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, Oscier DG, Deanden CE et al. ( 2010 ) . Rituximab Plus Chlorambucil In Patients with CD20-Positive B Cell Chronic Lymphocytic Leukemia (CLL) Final Response Analysis of An Open Label Phase H Study . BLOOD . Conference: 52nd Annual Meeting of the American-Society-of-Hematology (ASH) ( Orlando, FL ) from: 04/12/2010 to: 07/12/2010 , vol. 116 , 307 - 307 .
Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, Oscier DG, Dearden CE et al. ( 2010 ) . Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study . BLOOD . vol. 116 , 307 - 307 .
Wrench D, Sangaralingam A, Tayyib H, Kang MK, Riain C, Gupta M, Carlotti E, Bodor C et al. ( 2010 ) . TNERSF14 and EZH2 Mutations, Chr2p Gain and Copy Number Changes Targeting Genes Whose Proteins Interact with the Microenviroment In Transformed Follicular Lymphoma . BLOOD . Conference: 52nd Annual Meeting of the American-Society-of-Hematology (ASH) ( Orlando, FL ) from: 04/12/2010 to: 07/12/2010 , vol. 116 , 349 - 349 .
Wrench D, Sangaralingam A, Tayyib H, Kang M-K, O'Riain C, Gupta M, Carlotti E, Bodor C et al. ( 2010 ) . TNFRSF14 and EZH2 Mutations, Chr2p Gain and Copy Number Changes Targeting Genes Whose Proteins Interact with the Microenvironment In Transformed Follicular Lymphoma . Blood vol. 116 , ( 21 ) 799 - 799 .
Xing DX, Decker W, Li SF, Robinson S, Shah N, Yang H, Champlin RE, Parmar S et al. ( 2010 ) . Targeting Chronic Lymphocytic Leukemia with Cord Blood NK Cells In NSG Model . BLOOD . vol. 116 , 1018 - 1019 .
Buchner M, Brantner P, Stickel N, Prinz G, Burger M, Bar C, Dierks C, Pfeifer D et al. ( 2010 ) . The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia-CXCR4 antagonists as potential adjuvants for monoclonal antibodies . BRIT J HAEMATOL vol. 151 , ( 2 ) 167 - 178 .
Gribben JG ( 2010 ) . Chronic lymphocytic leukemia: planning for an aging population . Expert Rev Anticancer Ther vol. 10 , ( 9 ) 1389 - 1394 .
Xing D, Ramsay AG, Gribben JG, Decker WK, Burks JK, Munsell M, Li S, Robinson SN et al. ( 2010 ) . Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion . J Immunother vol. 33 , ( 7 ) 684 - 696 .
Gribben JG ( 2010 ) . Implications of the tumor microenvironment on survival and disease response in follicular lymphoma . CURR OPIN ONCOL vol. 22 , ( 5 ) 424 - 430 .
Czuczman M, Straus D, Gribben J, Bredenfeld H, Friedberg J, Bollard C ( 2010 ) . Management options, survivorship, and emerging treatment strategies for follicular and Hodgkin lymphomas . LEUKEMIA & LYMPHOMA . vol. 51 , 41 - 49 .
Gribben J, Rosenwald A, Gascoyne R, Lenz G ( 2010 ) . Targeting the microenvironment . Leuk Lymphoma vol. 51 Suppl 1 , 34 - 40 .
Clear AJ, Lee AM, Calaminici M, Ramsay AG, Morris KJ, Hallam S, Kelly G, Macdougall F et al. ( 2010 ) . Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment . Blood vol. 115 , ( 24 ) 5053 - 5056 .
O'Riain C, Smith P, Clear A, Wrench D, Gupta M, Bodor C, Matolcsy A, Calaminici M et al. ( 2010 ) . EZH2 MUTATION IN FOLLICULAR LYMPHOMA . HAEMATOLOGICA . vol. 95 , 167 - 167 .
Wrench J, Skibola C, Matthews J, Cazier JB, Iqbal S, Carlotti E, Calaminici M, Davies A et al. ( 2010 ) . SNP RS6457327 ON CHROMOSOME 6P PREDICTS TRANSFORMATION OF FOLLICULAR LYMPHOMA . HAEMATOLOGICA . vol. 95 , 170 - 171 .
Taussig D, Miraki-Moud F, Lister A, Bonnet D, Gribben J ( 2010 ) . BONE MARROW FAILURE IN ACUTE MYELOID LEUKEMIA IS INDUCED BY A BLOCK IN DIFFERENTIATION OF NORMAL HEMATOPOIETIC STEM CELLS . HAEMATOLOGICA-THE HEMATOLOGY JOURNAL . vol. 95 , 13 - 13 .
O' Riain C, Smith P, Clear A, Wrench D, Gupta M, Bodor C, Matolcsy A, Calaminici M et al. ( 2010 ) . EZH2 MUTATION IN FOLLICULAR LYMPHOMA . HAEMATOLOGICA-THE HEMATOLOGY JOURNAL . vol. 95 , 167 - 167 .
Wrench J, Skibola C, Matthews J, Cazier JB, Iqbal S, Carlotti E, Calaminici M, Davies A et al. ( 2010 ) . SNP RS6457327 ON CHROMOSOME 6P PREDICTS TRANSFORMATION OF FOLLICULAR LYMPHOMA . HAEMATOLOGICA-THE HEMATOLOGY JOURNAL . vol. 95 , 170 - 171 .
Sziosarek PW, Delage B, O'Riain C, Hatzimichael E, Crook T, Calaminici M, Gribben JG, Lemoine N et al. ( 2010 ) . Effect of inactivation of argininosuccinate synthetase on sensitivity of lymphomas to caspase-dependent apoptosis following treatment with arginine deiminase . JOURNAL OF CLINICAL ONCOLOGY vol. 28 , ( 15 )
Streetly MJ, Maharaj L, Joel S, Schey SA, Gribben JG, Cotter FE ( 2010 ) . GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death . BLOOD vol. 115 , ( 19 ) 3939 - 3948 .
Hillmen P, Gribben JG, Follows GA, Milligan DW, Sayala HA, Moreton P, Oscier D, Dearden CE et al. ( 2010 ) . An open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL): On behalf of the NCRI CLL sub-group . BRITISH JOURNAL OF HAEMATOLOGY . vol. 149 , 2 - 2 .
Butler T, Gribben JG ( 2010 ) . Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia . Blood Rev vol. 24 , ( 3 ) 135 - 141 .
Auer RL, MacDougall F, Oakervee HE, Cavenagh JC, Gribben JG, Lister TA ( 2010 ) . Fludarabine/cyclophosphamide non-myeloablative allogeneic stem cell transplantation for lymphoid malignancies . BRITISH JOURNAL OF HAEMATOLOGY . vol. 149 , 70 - 70 .
Jueliger S, Maharaj L, Iyengar S, Ghazaly E, Cutillas P, Auer R, Rommel C, Li L et al. ( 2010 ) . Abstract 4489: The activity of novel, potent, selective PI3K/mTOR pathway inhibitors in B-cell malignancies . Cancer Research . vol. 70 , 4489 - 4489 .
Liu F-T, Giustiniani J, Farren T, Jia L, Bensussan A, Gribben JG, Agrawal SG ( 2010 ) . CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia . Blood vol. 115 , ( 15 ) 3079 - 3088 .
Ramsay AG, Gribben JG ( 2010 ) . The 3 Rs in CLL immune dysfunction . Blood vol. 115 , ( 13 ) 2563 - 2564 .
Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, Luke T, Lillington D, Oakervee H et al. ( 2010 ) . Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction . Blood vol. 115 , ( 10 ) 1976 - 1984 .
Gribben JG ( 2010 ) . Detection of Minimal Residual Disease in Hematological Malignancies . Molecular Hematology: Third Edition ,
Letai AG, Gribben JG ( 2010 ) . Lymphoma Genetics . Molecular Hematology: Third Edition ,
Provan D, Gribben JG ( 2010 ) . Molecular Hematology: Third Edition .
Gilliland DG, Gribben JG ( 2010 ) . Secondary Myelodysplasia/Acute Myelogenous Leukemia: Assessment of Risk . Molecular Hematology: Third Edition ,
Nagler A, Labopin M, Shimoni A, Mufti G, Cornelissen JJ, Blaise D, Janssen JJWM, Milpied N et al. ( 2010 ) . Mobilized peripheral blood stem cells compared with bone marrow for related reduced-intensity transplantation in acute myeloid leukaemia in complete remission: a retrospective analysis from the ALWP of EBMT . BONE MARROW TRANSPLANTATION . vol. 45 , S21 - S22 .
Hallam S, Gribben JG ( 2010 ) . Stem cell transplantation in chronic lymphocytic leukaemia - steering a safe course over shifting sands . Best Pract Res Clin Haematol vol. 23 , ( 1 ) 109 - 119 .
Cheson BD, Wendtner CM, Pieper A, Dreyling M, Friedberg J, Hoelzer D, Moreau P, Gribben J et al. ( 2010 ) . Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel . CL LYMPH MYELOM LEUK vol. 10 , ( 1 ) 21 - 27 .
Gribben JG ( 2010 ) . How I treat CLL up front . Blood vol. 115 , ( 2 ) 187 - 197 .
Dieu RL, Gribben JG ( 2009 ) . Chronic lymphocytic leukemia . Hematopoietic Stem Cell Transplantation in Clinical Practice ,
Rai KR, Knauf WU, Gribben JG ( 2009 ) . Recent advances in chronic lymphocytic leukemia: A post-iwCLL 2009 discussion . Clinical Advances in Hematology and Oncology . vol. 7 , 1 - 15 .
Hillmen P, Gribben JG, Follows GA, Milligan DW, Sayala HA, Moreton P, Oscier D, Dearden CE et al. ( 2009 ) . An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL) . BLOOD . vol. 114 , 1331 - 1332 .
Farren TW, Liu F-T, Stephens C, Tsitsikas D, Macey MG, Jenner M, Gribben JG, Agrawal SG ( 2009 ) . CD160 Expression in B-Cell Lymphoproliferative Disorders: Derivation and Validation of a New Three-Antigen Scoring System Improving Diagnostic Precision in B-Cell Malignancies . Blood vol. 114 , ( 22 ) 4382 - 4382 .
Mohty M, Labopin M, Janssen JJWM, Mufti GJ, Cornelissen JJ, Milpied NJ, Sengeloev H, Blaise D et al. ( 2009 ) . Comparison of Low Dose Total Body Irradiation (TBI)-Based Reduced Intensity Conditioning (RIC) Vs. Chemotherapy-Based RIC Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1): a Retrospective Analysis of 1200 Patients From the Acute Leukemia Working Party of EBMT . BLOOD . vol. 114 , 489 - 489 .
Xing DX, Ramsay AG, Decker W, Li SF, Robinson S, Yang H, Shah N, Hosing C et al. ( 2009 ) . Dramatic Reduction of Chronic Lymphocytic Leukemia (CLL) Cells Following Adoptive Transfer of Cord Blood (CB) Natural Killer (NK) Cells Using CB-Engrafted NOD-SCID IL2R gamma(null) (NSG) Mice as a Model . BLOOD . vol. 114 , 936 - 936 .
Xing D, Ramsay AG, Decker W, Li S, Robinson S, Yang H, Shah N, Hosing C et al. ( 2009 ) . Dramatic Reduction of Chronic Lymphocytic Leukemia (CLL) Cells Following Adoptive Transfer of Cord Blood (CB) Natural Killer (NK) Cells Using CB-Engrafted NOD-SCID IL2Rγnull (NSG) Mice as a Model . Blood vol. 114 , ( 22 ) 2370 - 2370 .
Xing DX, Ramsay AG, Decker W, Li SF, Robinson S, Yang H, Bollard CM, Gribben JG et al. ( 2009 ) . Ex Vivo IL-2 Expansion of CB-NK Cells Promotes Synergistic LFA-1 and CD2 Engagement at the NK Cell Lytic Immune Synapse; Implications for Adoptive CB-NK Cell Therapy in Acute Myeloid Leukemia . BLOOD . vol. 114 , 1180 - 1181 .
Butler T, Wiseman C, Farren T, Gribben JG, Agrawal SG ( 2009 ) . Expression of Surface IgG Is High in Chronic Lymphocytic Leukaemia, and Co-Expression with IgM Confers a Worse Prognosis . Blood vol. 114 , ( 22 ) 4371 - 4371 .
Xing DX, Ramsay AG, Decker W, Li SF, Robinson S, Yang H, Gribben JG, Shpall EJ ( 2009 ) . Impaired Natural Killer Cells Immune Synapse Formation in Acute Myeloid Leukemia . BLOOD . vol. 114 , 1044 - 1044 .
Xing D, Ramsay AG, Decker W, Li S, Robinson S, Yang H, Gribben JG, Shpall EJ ( 2009 ) . Impaired Natural Killer Cells Immune Synapse Formation in Acute Myeloid Leukemia . Blood vol. 114 , ( 22 ) 2663 - 2663 .
Liu F-T, Jia L, Farren T, Giustiniani J, Bensussan A, Gribben JG, Agrawal SG ( 2009 ) . Spontaneous in Vitro Death of CLL Cells Can Be Prevented by Mitochondrial Stabilization Via CD160 Signaling . Blood vol. 114 , ( 22 ) 4372 - 4372 .
Woyach JA, Ruppert AS, Heerema NA, Peterson B, Gribben JG, Morrison VA, Rai KR, Larson RA et al. ( 2009 ) . Treatment with Fludarabine and Rituximab Produces Extended Overall Survival (OS) and Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) without Increased Risk of Second Malignancy: Long-Term Follow up of CALGB Study 9712 . BLOOD . vol. 114 , 226 - 226 .
Woyach JA, Ruppert AS, Heerema NA, Peterson B, Gribben JG, Morrison VA, Rai KR, Larson RA et al. ( 2009 ) . Treatment with Fludarabine and Rituximab Produces Extended Overall Survival (OS) and Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) without Increased Risk of Second Malignancy: Long-Term Follow up of CALGB Study 9712 . Blood vol. 114 , ( 22 ) 539 - 539 .
Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, Macdougall F, Lister TA, Lee AM et al. ( 2009 ) . Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy . Blood vol. 114 , ( 21 ) 4713 - 4720 .
Riches JC, Gribben JG ( 2009 ) . Interesting times in the diagnosis and treatment of CLL . Oncology (Williston Park) vol. 23 , ( 12 ) 1043 - 1046 .
O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki AB, Koziner B, Chanan-Khan AA, Seymour JF et al. ( 2009 ) . 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen . J Clin Oncol vol. 27 , ( 31 ) 5208 - 5212 .
Le Dieu R, Taussig DC, Ramsay AG, Mitter R, Miraki-Moud F, Fatah R, Lee AM, Lister TA et al. ( 2009 ) . Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts . Blood vol. 114 , ( 18 ) 3909 - 3916 .
Gribben JG ( 2009 ) . One step back but 2 steps forward . Blood vol. 114 , ( 16 ) 3359 - 3360 .
Carlotti E, Gribben JG ( 2009 ) . Stem cell mimicry: key to transformation? . Blood vol. 114 , ( 15 ) 3133 - 3134 .
O'Riain C, O'Shea DM, Yang Y, Le Dieu R, Gribben JG, Summers K, Yeboah-Afari J, Bhaw-Rosun L et al. ( 2009 ) . Array-based DNA methylation profiling in follicular lymphoma . Leukemia vol. 23 , ( 10 ) 1858 - 1866 .
Ramsay AG, Gribben JG ( 2009 ) . Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug . HAEMATOL-HEMATOL J vol. 94 , ( 9 ) 1198 - 1202 .
Tsitsikas DA, Oakervee H, Cavenagh JD, Gribben J, Agrawal SG, Mattes FM ( 2009 ) . Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience . Br J Haematol vol. 146 , ( 5 ) 574 - 576 .
Le Dieu R, Taussig D, Lister TA, Gribben JG ( 2009 ) . Negative immunomagnetic selection of T cells from peripheral blood of presentation AML specimens . J Immunol Methods vol. 348 , ( 1-2 ) 95 - 100 .
Buchner M, Fuchs S, Prinz G, Pfeifer D, Bartholome K, Burger M, Chevalier N, Vallat L et al. ( 2009 ) . Spleen Tyrosine Kinase Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia . CANCER RES vol. 69 , ( 13 ) 5424 - 5432 .
Wendtner CM, Mahadevan D, Coutre S, Hillmen P, Stilgenbauer S, Frankfurt O, Bloor A, Bosch F et al. ( 2009 ) . A PHASE I DOSE-ESCALATION OF LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA . HAEMATOLOGICA-THE HEMATOLOGY JOURNAL . vol. 94 , 371 - 372 .
Cotter F, Smith DA, Boyd TE, Richards DA, Alemany C, Loesch D, Salogub G, Tidmarsh GF et al. ( 2009 ) . Single-agent activity of GCS-100, a first-in-class galectin-3 antagonist, in elderly patients with relapsed chronic lymphocytic leukemia . JOURNAL OF CLINICAL ONCOLOGY . vol. 27 ,
Cotter F, Smith DA, Boyd TE, Richards DA, Alemany C, Loesch D, Salogub G, Tidmarsh GF et al. ( 2009 ) . Single-agent activity of GCS-100, a first-in-class galectin-3 antagonist, in elderly patients with relapsed chronic lymphocytic leukemia . J Clin Oncol vol. 27 , ( 15_suppl )
Gorgun G, Ramsay AG, Holderried TAW, Zahrieh D, Le Dieu R, Liu F, Quackenbush J, Croce CM et al. ( 2009 ) . E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction . Proc Natl Acad Sci U S A vol. 106 , ( 15 ) 6250 - 6255 .
Gorgun G, Ramsay AG, Holderried TAW, Zahrieh D, Dieu RL, Liu F, Quackenbush J, Croce CM et al. ( 2009 ) . Eμ- TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction . Proceedings of the National Academy of Sciences of the United States of America vol. 106 , ( 15 ) 6250 - 6255 .
Carlotti E, Wrench D, Matthews J, Iqbal S, Davies A, Norton A, Hart J, Lai R et al. ( 2009 ) . Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone . Blood vol. 113 , ( 15 ) 3553 - 3557 .
O'Shea D, O'Riain C, Gupta M, Waters R, Yang Y, Wrench D, Gribben J, Rosenwald A et al. ( 2009 ) . Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation . Blood vol. 113 , ( 10 ) 2298 - 2301 .
Gribben JG ( 2009 ) . Removal of Tumor Cells from the Hematopoietic Graft . Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition ,
Messmer BT, Raphael BJ, Aerni SJ, Widhopf GF, Rassenti LZ, Gribben JG, Kay NE, Kipps TJ ( 2009 ) . Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia . Leuk Res vol. 33 , ( 3 ) 368 - 376 .
Gribben JG, Hallek M ( 2009 ) . Rediscovering alemtuzumab: current and emerging therapeutic roles . Br J Haematol vol. 144 , ( 6 ) 818 - 831 .
Tsitsikas DA, Oakervee H, Cavenagh J, Agrawal S, Gribben J, Mattes F ( 2009 ) . Treatment of respiratory syncytial virus infection with nebulised ribavirin and the humanised monoclonal antibody palivizumab in eight haemopoietic stem cell transplant recipients . BONE MARROW TRANSPLANTATION . vol. 43 , S252 - S253 .
Xing D, Ramsary AG, Gribben JG, Decker WK, Li S, Robinson SN, Yang H, David S et al. ( 2009 ) . DEFECTIVE IMMUNE SYNAPSE FORMATION OF UMBILICAL CORD BLOOD-DERIVED NATURAL KILLER CELL S IS ABROGATED BY EX VIVO EXPANSION . BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION . vol. 15 , 117 - 118 .
Decker WK, Li S, Xing D, Robinson SN, Yang H, Steiner D, Lapusbin R, Ramsay AG et al. ( 2009 ) . GENERATION OF CLL-SPECIFIC CTL EFFECTORS FROM PARTIALLY HLA-MATCHED UMBILICAL CORD BLOOD GRAFTS USING CD154-TRANSDUCED CLL CELL S AS APCS . BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION . vol. 15 , 123 - 123 .
Elter T, Vehreschild J, Gribben J, Cornely O, Engert A, Hallek M ( 2009 ) . Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab . ANN HEMATOL vol. 88 , ( 2 ) 121 - 132 .
Le Dieu R, Gribben JG ( 2009 ) . CHAPTER 10 Chronic lymphocytic leukemia . Hematopoietic Stem Cell Transplantation in Clinical Practice ,
Wrench D, Waters R, Carlotti E, Iqbal S, Matthews J, Calaminici M, Gribben J, Lister TA et al. ( 2009 ) . Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma . HAEMATOL-HEMATOL J vol. 94 , ( 1 ) 148 - 150 .
Gribben JG ( 2009 ) . Stem cell transplantation in chronic lymphocytic leukemia . Biol Blood Marrow Transplant . vol. 15 , 53 - 58 .
Hallam S, Gribben JG ( 2009 ) . Transplantation in chronic lymphocytic leukemia: timing and expectations . Clin Lymphoma Myeloma vol. 9 Suppl 3 , S186 - S193 .
Ramsay AG, Gorgun G, Holderried TAW, Zahrieh D, Liu F, Quackenbush J, Croce CM, Gribben JG ( 2008 ) . A Mouse Model for Immunotherapeutic Reversal of Leukemia-Induced T Cell Dysfunction . Blood vol. 112 , ( 11 ) 30 - 30 .
Brown JR, Rassenti L, Neuberg D, Greaves A, Byrd JC, Grever MR, Gribben JG, Kay NE et al. ( 2008 ) . Characteristics of Familial CLL Evaluated in the CLL Research Consortium Cohort . BLOOD . vol. 112 , 1071 - 1072 .
Ramsay AG, Clear AJ, Fatah R, Gribben JG ( 2008 ) . Co-Treatment with Panobinostat Enhances Bortezomib-Induced Unfolded Protein Response, Endoplasmic Reticulum Stress and Apoptosis of Human Mantle Cell Lymphoma Cells . BLOOD . vol. 112 , 327 - 327 .
Brown JR, Stevenson K, Kim HT, Armand P, Cutler C, Fisher DC, Ho V, Koreth J et al. ( 2008 ) . Comparative Outcome of Myeloablative and Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia . BLOOD . vol. 112 , 357 - 358 .
Ramsay AG, Xing D-X, Decker WK, Burks JK, Wierda WG, Gribben JG, Shpall EJ ( 2008 ) . Compared to Adult Peripheral Blood T Cells, Cord Blood T Cells Show Enhanced Immunological Recognition of Chronic Lymphocytic Leukemia Tumor Cells . Blood vol. 112 , ( 11 ) 2333 - 2333 .
Ramsay AG, Svensson L, Hogg N, Gribben JG ( 2008 ) . Defective T Cell Migration in Chronic Lymphocytic Leukemia Is Repaired by Lenalidomide . BLOOD . vol. 112 , 1069 - 1069 .
Le Dieu R, Ramsay AG, Taussig D, Mitter R, Gribben JG ( 2008 ) . Differential Gene Expression Profile Identifies the Nature of T Cell Defects in AML Patients at Diagnosis . BLOOD . vol. 112 , 433 - 433 .
Le Dieu R, Ramsay AG, Taussig D, Mitter R, Gribben JG ( 2008 ) . Differential Gene Expression Profile Identifies the Nature of T Cell Defects in AML Patients at Diagnosis . Blood . vol. 112 , 1186 - 1186 .
Agrawal SG, Liu FT, Giustiniani J, Jia L, Gribben JG, Bensussan A ( 2008 ) . Dual Action of CD160 on CLL Cells: Giving Life to Prepare for Death! . BLOOD . vol. 112 , 726 - 726 .
Agrawal SRG, Liu F-T, Giustiniani J, Jia L, Gribben JG, Bensussan A ( 2008 ) . Dual Action of CD160 on CLL Cells: Giving Life to Prepare for Death! . Blood vol. 112 , ( 11 ) 2088 - 2088 .
Xing DX, Ramsay AG, Gribben JG, Decker WK, Burt JK, Li SF, Simon SN, Yang H et al. ( 2008 ) . Ex Vivo Expansion of Cord Blood Natural Killer Cells Overcomes Impaired Immune Synapse Formation and Effector Function in Acute Myeloid Leukemia . BLOOD . vol. 112 , 999 - 999 .
Clear AJ, Lee AM, Morris KJ, Calaminici M, Macdougall F, Goff LK, Lister TA, Gribben JG ( 2008 ) . Extended Focal Imaging Reveals An Improved Gauge of Angiogenic Activity and Highlights the Role of Angiogenesis in Survival and Time to Transformation in Follicular Lymphoma . Blood vol. 112 , ( 11 ) 2822 - 2822 .
Clear AJ, Lee AM, Morris KJ, Calaminici M, Macdougall F, Goff LK, Lister TA, Gribben JG ( 2008 ) . Extended Focal Imaging Reveals An Improved Gauge of Angiogenic Activity and Highlights the Role of Angiogenesis in Survival and Time to Transformation in Follicular Lymphoma . BLOOD . vol. 112 , 975 - 975 .
Ramsay AG, Clear AJ, Fatah R, Gribben JG ( 2008 ) . Lenalidomide Repairs Suppressed T Cell Immunological Synapse Formation in Follicular Lymphoma . Conference: 50th Annual Meeting of the American- Society-of-Hematology ( San Francisco, CA ) from: 06/12/2008 to: 09/12/2008 ,
Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Rassenti LZ, Greaves AW, Neuberg D et al. ( 2008 ) . Plasma Alemtuzumab Levels at End of Treatment Correlate with Response and Response Duration in Patients with CLL Receiving Treatment for Residual Disease . Blood vol. 112 , ( 11 ) 2109 - 2109 .
Wendtner CM, Mahadevan D, Stilgenbauer S, Frankfurt O, Bloor A, Bosch F, Uharek L, Furman RR et al. ( 2008 ) . Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL- 001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia . Blood vol. 112 , ( 11 ) 2104 - 2104 .
Wendtner CM, Mahadevan D, Stilgenbauer S, Frankfurt O, Bloor A, Bosch F, Uharek L, Furman RR et al. ( 2008 ) . Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL-001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic-Lymphocytic-Leukemia . BLOOD . vol. 112 , 732 - 732 .
Buchner M, Fuchs S, Prinz G, Pfeifer D, Bartholomee K, Chevalier N, Vallat L, Timmer J et al. ( 2008 ) . Spleen Tyrosine Kinase (SYK) Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia . BLOOD . vol. 112 , 203 - 203 .
Liu F-T, Agrawal SG, Movasaghi Z, Wyatt PB, Rehman IU, Gribben JG, Newland AC, Jia L ( 2008 ) . Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib . Blood vol. 112 , ( 9 ) 3835 - 3846 .
Gribben JG ( 2008 ) . Role of allogeneic hematopoietic stem-cell transplantation in chronic lymphocytic leukemia . J Clin Oncol vol. 26 , ( 30 ) 4864 - 4865 .
O'Shea D, O'Riain C, Taylor C, Waters R, Carlotti E, Macdougall F, Gribben J, Rosenwald A et al. ( 2008 ) . The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival . Blood vol. 112 , ( 8 ) 3126 - 3129 .
Wrench D, Gribben JG ( 2008 ) . Stem cell transplantation for non-Hodgkin's lymphoma . Hematol Oncol Clin North Am vol. 22 , ( 5 ) 1051 - xi .
Davies JK, Gribben JG, Brennan LL, Yuk D, Nadler LM, Guinan EC ( 2008 ) . Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies . Blood vol. 112 , ( 6 ) 2232 - 2241 .
Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR et al. ( 2008 ) . Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia . BLOOD vol. 112 , ( 5 ) 1923 - 1930 .
Ramsay AG, Gribben JG ( 2008 ) . Vaccine therapy and chronic lymphocytic leukaemia . Best Pract Res Clin Haematol vol. 21 , ( 3 ) 421 - 436 .
Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C, Lillington D, Oakervee H et al. ( 2008 ) . Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells . Blood vol. 112 , ( 3 ) 568 - 575 .
Proto-Siqueira R, Panepucci RA, Careta FP, Lee A, Clear A, Morris K, Owen C, Rizzatti EG et al. ( 2008 ) . SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL . BLOOD vol. 112 , ( 2 ) 394 - 397 .
Ramsay AG, Johnson AJ, Lee AM, Gorgün G, Le Dieu R, Blum W, Byrd JC, Gribben JG ( 2008 ) . Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug . J Clin Invest vol. 118 , ( 7 ) 2427 - 2437 .
de Jong D, Lee AM, Hauptmann M, Heisterkamp S, Calaminici M, Gribben JG, Kerst M, Lister TA ( 2008 ) . Changes in follicular lymphoma are related to time to transformation to diffuse large B-cell lymphoma . ANNALS OF ONCOLOGY . vol. 19 , 111 - 111 .
Cotter FE, Gribben J, Streetly M, Auer R, Smith D, Alemany C, Loesch D, Boyd TE et al. ( 2008 ) . Clinical caspase activation in CLL by GCS-100, a novel carbohydrate, in a phase 2 study . ANNALS OF ONCOLOGY . vol. 19 , 90 - 90 .
Lee AM, Clear AJ, Morris KJ, Calaminici MR, Matthews J, Gribben JG, Lister TA ( 2008 ) . Examination of changes in tumour microenvironment of follicular lymphoma using serial sample tissue microarrays . ANNALS OF ONCOLOGY . vol. 19 , 179 - 179 .
Wrench D, Waters R, Matthews J, Calaminici M, Carlotti E, Iqbal S, Gribben J, Lister A et al. ( 2008 ) . MDM2 309 and TP53 ARG72PRO SNP genotypes do not predict clinical outcome of follicular lymphoma . ANNALS OF ONCOLOGY . vol. 19 , 178 - 178 .
O'Riain C, O'Shea D, Yang Y, Gribben J, Afari J, Mein CA, Crook T, Smith P et al. ( 2008 ) . Methylation profiling in 158 cases of previously untreated follicular lymphoma (FL) . ANNALS OF ONCOLOGY . vol. 19 , 101 - 101 .
Gribben JG ( 2008 ) . New agents in chronic lymphocytic leukemia . Clin Adv Hematol Oncol vol. 6 , ( 6 ) 409 - 468 .
O'Shea D, O'Riain C, MacDougall F, Gribben J, Young BD, Rosenwald A, Rimsza L, Roberts R et al. ( 2008 ) . SNP array genotyping in 182 diagnostic follicular lymphoma cases identifies sites of AUPD associated with overall survival and risk of transformation . ANNALS OF ONCOLOGY . vol. 19 , 111 - 111 .
Lee AM, Clear AJ, Morris KJ, Calaminici MR, Matthews J, Gribben JG, Lister TA ( 2008 ) . The impact of tumour microenvironment in diagnostic follicular lymphoma samples using tissue microarrays . ANNALS OF ONCOLOGY . vol. 19 , 126 - 126 .
Gribben J ( 2008 ) . Transforming the outlook for CLL patients . ANNALS OF ONCOLOGY . vol. 19 , 262 - 262 .
Ghia EM, Jain S, Widhopf GF, Rassenti LZ, Keating MJ, Wierda WG, Gribben JG, Brown JR et al. ( 2008 ) . Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection . BLOOD vol. 111 , ( 10 ) 5101 - 5108 .
Gilleece MH, Pearce R, Linch DC, Wilson M, Towlson K, Mackinnon S, Potter M, Kazmi M et al. ( 2008 ) . The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study . Hematology vol. 13 , ( 2 ) 119 - 127 .
Widhopf GF, Goldberg CJ, Toy TL, Rassenti LZ, Wierda WG, Byrd JC, Keating MJ, Gribben JG et al. ( 2008 ) . Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3 . BLOOD vol. 111 , ( 6 ) 3137 - 3144 .
Liu F-T, Agrawal SG, Gribben JG, Ye H, Du M-Q, Newland AC, Jia L ( 2008 ) . Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL . Blood vol. 111 , ( 5 ) 2797 - 2805 .
Agrawal SG, Liu FT, Wiseman C, Shirali S, Liu H, Lillington D, Du MQ, Syndercombe-Court D et al. ( 2008 ) . Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia . BLOOD vol. 111 , ( 5 ) 2790 - 2796 .
Davies J, Gribben J, Brennan L, Nadler L, Guinan E ( 2008 ) . ALLOANERGIZED HLA-MISMATCHED BONE MARROW TRANSPLANTATION - LOW INCIDENCE OF CLINICALLY SIGNIFICANT GVHD AND VIRAL INFECTION RESULTING IN LONG TERM DISEASE FREE SURVIVAL . BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION . Conference: Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation ( San Diego, CA ) from: 13/02/2008 to: 17/02/2008 , vol. 14 , 16 - 17 .
Ramsay AG, Gorgun G, Holderried TAW, Zahrieh D, Liu FL, Quackenbush J, Croce CM, Gribben JG ( 2008 ) . A Mouse Model for Immunotherapeutic Reversal of Leukemia-induced T Cell Dysfunction . Conference: 50th ASH Annual Meeting and Exposition ( Moscone Center, San Francisco, CA ) from: 06/12/2008 to: 09/12/2008 ,
Butler T, Gribben JG ( 2008 ) . Biologic prognostic markers and their application in clinical trials and management of chronic lymphocytic leukaemia patients . Expert Opinion on Medical Diagnostics vol. 2 , ( 1 ) 101 - 112 .
Le Dieu R, Gribben JG ( 2008 ) . Chronic Lymphocytic Leukaemia . Hematopoietic Stem Cell Transplantation , Editors: Soiffer, RJ , Edition. 1 , Springer
O’Brien S, Gribben JG ( 2008 ) . Chronic lymphocytic leukemia .
Gribben JG ( 2008 ) . Chronic lymphocytic leukemia: an historical perspective . Hematology Am Soc Hematol Educ Program
Gribben JG ( 2008 ) . Molecular profiling in CLL . Hematology Am Soc Hematol Educ Program444 - 449 .
O’Brien SM, Gribben JG ( 2008 ) . Preface .
Buske C, Gisselbrecht C, Gribben J, Letai T, McLaughlin P, Wilson W ( 2008 ) . Refining the treatment of follicular lymphoma . LEUKEMIA & LYMPHOMA . vol. 49 , 18 - 26 .
Gribben JG ( 2008 ) . Stem cell transplantation in CLL . Chronic Lymphocytic Leukemia ,
Dieu RL, Gribben JG ( 2008 ) . Transplantation in Chronic Lymphocytic Leukemia . Hematopoietic Stem Cell Transplantation ,
Stevens JM, Syndercombe-Court D, Oakervee HE, McCloskey D, Jenner MJ, Gribben JG, Cavenagh JD ( 2007 ) . Development of original donor cell leukemia after successful engraftment from a second donor . BLOOD vol. 110 , ( 13 ) 4621 - 4622 .
Auer RL, Gribben J, Cotter FE ( 2007 ) . Emerging therapy for chronic lymphocytic leukaemia . Br J Haematol vol. 139 , ( 5 ) 635 - 644 .
Gribben JG, Parreira A ( 2007 ) . Haematologica Meeting Reports: Editorial . Haematologica Meeting Reports vol. 1 , ( 4 ) 1 - 2 .
Doffman SR, Griffiths LJ, Lim C, Vinnicombe S, Wilks M, Gribben JG, Griffiths MJ, Agrawal SG ( 2007 ) . A Novel Non-Invasive Method of Detecting Galactomannan in Suspected Pulmonary Aspergillosis . Blood vol. 110 , ( 11 ) 3862 - 3862 .
Doffman SR, Griffiths LJ, Lim C, Vinnicombe S, Wilks M, Gribben JG, Griffiths MJ, Agrawal SG ( 2007 ) . A novel non-invasive method of detecting galactomannan in suspected pulmonary aspergillosis . BLOOD . vol. 110 , 33B - 33B .
Clear AJ, Lee AM, Morris KJ, Calaminici M, Macdougall F, Proto-Siqueira R, Goff LK, Lister TA et al. ( 2007 ) . Angiogenesis Assessed in Tissue Microarrays of Diagnostic Follicular Lymphoma Correlates with Outcome . Blood vol. 110 , ( 11 ) 2609 - 2609 .
Clear AJ, Lee AM, Morris KJ, Calaminici M, Macdougall F, Proto-Siqueira R, Goff LK, Lister TA et al. ( 2007 ) . Angiogenesis assessed in tissue microarrays of diagnostic follicular lymphoma correlates with outcome . BLOOD . vol. 110 , 768A - 768A .
Agrawal SG, Liu FT, Wiseman C, Shirali S, Liu H, Lillington D, Du MQ, Court DS et al. ( 2007 ) . Bax degradation activity is a novel poor prognosis marker of chronic lymphocytic leukemia . BLOOD . vol. 110 , 908A - 908A .
Le Dieu R, Taussig D, MacDougal F, Lister A, Gribben JG ( 2007 ) . CD3+/CD56+ Cells, but Not Natural Killer T Cells, Are Increased in Peripheral Blood of Untreated Patients with Leukemia . Blood vol. 110 , ( 11 ) 1815 - 1815 .
Le Dieu R, Taussig D, MacDougal F, Lister A, Gribben JG ( 2007 ) . CD3+/CD56+cells, but not natural killer T cells, are increased in peripheral blood of untreated patients with leukemia . BLOOD . vol. 110 , 538A - 538A .
Giustiniani J, Wiseman C, Farren T, Gribben JG, Agrawal SG ( 2007 ) . CLL cell proliferation and IL-6 production are regulated by CD160-MHC class I interactions offering new therapeutic targets . BLOOD . vol. 110 , 342A - 342A .
Carlotti E, Wrench D, Iqbal S, O’Shea D, Davies A, Virappane P, Hart J, Lai R et al. ( 2007 ) . Determining the Mechanism of Transformation of Follicular Lymphoma into Diffuse Large B Cell Lymphoma . Blood vol. 110 , ( 11 ) 181 - 181 .
Carlotti E, Wrench D, Iqbal S, O'Shea D, Davies A, Virappane P, Hart J, Lai R et al. ( 2007 ) . Determining the mechanism of transformation of follicular lymphoma into diffuse large B cell lymphoma . BLOOD . vol. 110 , 61A - 61A .
Wiseman C, Giustiniani J, Mikkelsen L, Macey M, Goff L, Gribben J, Agrawal S ( 2007 ) . High frequency of surface immunoglobulin IgG in B-Cell chronic lymphocytic leukaemia . BLOOD . vol. 110 , 245B - 245B .
Ramsay AG, Lee AM, Gribben JG ( 2007 ) . Impaired actin polymerization results in defective immunological synapse formation in T cells in chronic lymphocytic leukemia . BLOOD . vol. 110 , 106A - 107A .
Proto-Siqueira R, Panepucci RA, Careta FP, Rizzatti EG, Lee A, Clear A, Morris K, Falcao RP et al. ( 2007 ) . SAGE analysis demonstrates increased expression of TOSO contributing to Fas mediated resistance in CLL . BLOOD . vol. 110 , 340A - 340A .
Ghia EM, Rassenti LZ, Widhopf GF, Silverman GJ, Neuberg DS, Keating MJ, Wierda WG, Gribben JG et al. ( 2007 ) . Stereotypic IGHV3-21/IGLV3-21 Antibodies Expressed in High-Risk Chronic Lymphocytic Leukemia Bind Peptostreptococcus Magnus Protein L . Blood vol. 110 , ( 11 ) 740 - 740 .
Ghia LEM, Rassenti LZ, Widhopf GF, Silverman GJ, Neuberg DS, Keating MJ, Wierda WG, Gribben JG et al. ( 2007 ) . Stereotypie IGHV3-21/IGLV3-21 antibodies expressed in high-risk chronic lymphocytic leukemia bind peptostreptococcus magnus protein . BLOOD . vol. 110 , 227A - 228A .
Vallat L, Pionneau C, Jacob F, Davi F, Leblond V, Gribben JG, Merle-Beral H ( 2007 ) . Temporal Proteomic Analysis of CLL B Cell Response to Antigen Receptor Stimulation . Blood vol. 110 , ( 11 ) 1134 - 1134 .
Vallat L, Pionneau C, Jacob F, Davi F, Leblond V, Gribben JG, Merle-Beral H ( 2007 ) . Temporal proteomic analysis of CLL B cell response to antigen receptor stimulation . BLOOD . vol. 110 , 344A - 344A .
Gribben JG ( 2007 ) . Do we need allogeneic transplantation in HL? . HAEMATOLOGICA-THE HEMATOLOGY JOURNAL . vol. 92 , 19 - 19 .
Gribben JG ( 2007 ) . Management of Haematological Malignancies . The Cancer Handbook ,
Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P, Nadler LM, Freedman AS ( 2007 ) . Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission . Biol Blood Marrow Transplant vol. 13 , ( 9 ) 1057 - 1065 .
Zhou J, Goldwasser MA, Li A, Dahlberg SE, Neuberg D, Wang H, Dalton V, McBride KD et al. ( 2007 ) . Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01 . Blood vol. 110 , ( 5 ) 1607 - 1611 .
Gribben JG ( 2007 ) . Stem-cell transplantation in chronic lympocytic leukaernia . BEST PRACT RES CL HA vol. 20 , ( 3 ) 513 - 527 .
Rohatiner AZS, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J, Gribben JG, Mauch PM et al. ( 2007 ) . Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up . J Clin Oncol . vol. 25 , 2554 - 2559 .
Gribben JG ( 2007 ) . How I treat indolent lymphoma . BLOOD vol. 109 , ( 11 ) 4617 - 4626 .
Vallat LD, Park Y, Li C, Gribben JG ( 2007 ) . Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells . Blood vol. 109 , ( 9 ) 3989 - 3997 .
Wallis LC, Streetly MJ, Auer R, Gribben J, Zhang D, Hankins WD, Zadeh SM, Cotter FE ( 2007 ) . Dynamic assessment of apoptosis for in vitro design of bortezomib combination therapies for lymphoid malignancies . BRITISH JOURNAL OF HAEMATOLOGY . vol. 137 , 63 - 63 .
Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, Flinn IW, Tallman MS et al. ( 2007 ) . Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997 . J Clin Oncol vol. 25 , ( 7 ) 799 - 804 .
Le Dieu R, Gribben JG ( 2007 ) . Transplantation in chronic lymphocytic leukemia . Curr Hematol Malig Rep vol. 2 , ( 1 ) 56 - 63 .
Zirlik KM, Zahrieh D, Neuberg D, Gribben JG ( 2006 ) . Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide . Blood vol. 108 , ( 12 ) 3865 - 3870 .
Gribben JG ( 2006 ) . Transplantation for low-grade lymphoma . Haematologica Reports vol. 2 , ( 7 ) 94 - 95 .
Lee AM, Clear A, Calaminici M, Macdougall F, Goff L, Gribben JG ( 2006 ) . Increased CD69 and decreased CD4 expressing cells in tissue microarray (TMA) in diagnostic lymph node biopsies are associated with poor outcome in CLL/SLL . BLOOD . vol. 108 , 787A - 787A .
Brown JR, Gribben JG, Feng Y, Neuberg D, Mauch P, Nadler LM, Freedman AS ( 2006 ) . Long-term follow-up of autologous bone marrow transplantation for follicular lymphoma in first remission: Bone marrow involvement at harvest and PCR detectable disease after ex vivo purging predict relapse . BLOOD . vol. 108 , 865A - 865A .
Rassenti LZ, Neuberg DS, Huynh L, Wierda WG, Gribben JG, Brown JR, Flinn IW, Rai KR et al. ( 2006 ) . Relative value of CD38 and ZAP-70 versus immunoglobutin mutation status in predicting early disease progression in chronic lymphocytic leukemia . BLOOD . vol. 108 , 786A - 787A .
Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning ML, Rassenti L, Greaves A et al. ( 2006 ) . Self-administered, subcutaneous (SQ) alemtuzumab to eliminate residual disease in patients (pts) with CLL . BLOOD . vol. 108 , 804A - 804A .
Zirlik K, Burger M, Brantner P, Prinz G, Buchner M, Gribben JG, Veelken H ( 2006 ) . Stromal cells protect B-CLL cells from killing by antigen-specific cytotoxic T cells . BLOOD . vol. 108 , 796A - 797A .
Ghia EM, Rassenti LZ, Widhopf GF, Neuberg DS, Keating MJ, Wierda WG, Gribben JG, Brown JR et al. ( 2006 ) . Study of VH3-21 in a large cohort of chronic lymphocytic leukemia patients reveals evidence for antigen selection and confirms its predictive value for early disease progression . BLOOD . vol. 108 , 785A - 785A .
Gilleece MH, Pearce R, Linen DC, Wilson M, Towlson K, Mackinnon S, Potter M, Kamzi M et al. ( 2006 ) . Utilisation of stem cell transplantation for lymphoplasmacytic lymphoma in the UK . BLOOD . vol. 108 , 844A - 845A .
Wallis LC, Streetly MJ, Auer R, Gribben J, Zhang D, Hankins WD, Zadeh SM, Cotter FE ( 2006 ) . Dynamic Assessment of Apoptosis for In Vitro Design of Bortezomib Combination Therapies for Lymphoid Malignancies . Blood . vol. 108 , 2494 - 2494 .
Lee AM, Clear AJ, Calaminici M, Davies AJ, Jordan S, MacDougall F, Matthews J, Norton AJ et al. ( 2006 ) . Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome . J Clin Oncol . vol. 24 , 5052 - 5059 .
Brown JR, Kim HT, Li S, Stephans K, Fisher DC, Cutler C, Ho V, Lee SJ et al. ( 2006 ) . Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia . Biol Blood Marrow Transplant vol. 12 , ( 10 ) 1056 - 1064 .
Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O'Brien S, Sheng SH, Esseltine DL et al. ( 2006 ) . Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia . CANCER vol. 107 , ( 5 ) 916 - 924 .
Gribben JG ( 2006 ) . Of mice and men.. . BLOOD vol. 108 , ( 4 ) 1115 - 1116 .
Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR ( 2006 ) . Infectious complications associated with alemtuzumab use for lymphoproliferative disorders . Clin Infect Dis vol. 43 , ( 1 ) 16 - 24 .
Grever MR, Dewald GW, Neuberg DS, Reed JC, Kitada S, Flinn IW, Appelbaum FR, Larson RA et al. ( 2006 ) . Select high risk genetic features predict earlier progression following chemotherapy in chronic lymphocytic leukemia: Prospective randomized trial (Intergroup E2997) to evaluate justification for risk-adapted therapy . JOURNAL OF CLINICAL ONCOLOGY . vol. 24 , 342S - 342S .
Davies JK, Taussig DC, Oakervee H, Davies AJ, Agrawal SG, Gribben JG, Lister TA, Cavenagh JD ( 2006 ) . Long-term follow-up after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia/myelodysplastic syndrome: late CNS relapses despite graft-versus-host disease . J Clin Oncol vol. 24 , ( 14 ) e23 - e25 .
Ho VT, Kim HT, Liney D, Milford E, Gribben J, Cutler C, Lee SJ, Antin JH et al. ( 2006 ) . HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation . BONE MARROW TRANSPLANTATION . vol. 37 , 845 - 850 .
Le Dieu R, Gribben J ( 2006 ) . Vaccine- and immune-based therapy in chronic lymphocytic leukemia . Semin Oncol vol. 33 , ( 2 ) 220 - 229 .
Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, Lampson B, Larson RA et al. ( 2006 ) . Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy . J Clin Oncol vol. 24 , ( 3 ) 437 - 443 .
Le Dieu R, Gribben JG ( 2006 ) . Allogeneic Stem Cell Transplantation for Non-Hodgkin's and Hodgkin's Lymphoma . The lymphomas , Editors: Canellos, GP, Lister, TA, Young, BD , Edition. 2 , W B Saunders Co
Le Dieu R, Gribben JG ( 2006 ) . Chapter 14 Allogeneic Stem Cell Transplantation for Non-Hodgkin's and Hodgkin's Lymphoma . The Lymphomas ,
Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC, Freedman AS, Mauch P et al. ( 2005 ) . Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia . Blood vol. 106 , ( 13 ) 4389 - 4396 .
Faderl S, Coutré S, Byrd JC, Dearden C, Denes A, Dyer MJS, Gregory SA, Gribben JG et al. ( 2005 ) . The evolving role of alemtuzumab in management of patients with CLL . Leukemia vol. 19 , ( 12 ) 2147 - 2152 .
Gorgun G, Holderried TAW, Ledieu R, Zahrieh D, Gribben JG ( 2005 ) . CLL Cells in TCL1 Transgenic Mice Induce Similar Defects in CD4 and CD8 T Cells to Those Observed in Patients with CLL . Blood vol. 106 , ( 11 ) 50 - 50 .
Gorgun G, Holderried TAW, Ledieu R, Zahrieh D, Gribben JG ( 2005 ) . CLL cells in TCL1 transgenic mice induce similar defects in CD4 and CD8 T cells to those observed in patients with CLL . BLOOD . vol. 106 , 19A - 19A .
Goff LK, Lee AM, Clear A, Calaminici M, Davies AJ, Jordan S, Macdougall F, Matthews J et al. ( 2005 ) . Discrimination of Long and Short Survival in Follicular Lymphoma (FL) Patients by Incidence of FOXP3 and Perifollicular Incidence of CD4 and CD7 Using Immunohistochemistry on Tissue Microarray (TMA) of Diagnostic Lymph Nodes (LN) . Blood vol. 106 , ( 11 ) 603 - 603 .
Fukuda T, Neuberg DS, Huynh L, Rassenti LZ, Toy TL, Rai KR, Keating MJ, Gribben JG et al. ( 2005 ) . Expression of T Cell Co-Stimulator (ICOS) and Its Ligand and Disease Progression in B-Cell Chronic Lymphocytic Leukemia . Blood vol. 106 , ( 11 ) 2943 - 2943 .
Fukuda T, Neuberg DS, Huynh L, Rassenti LZ, Toy TL, Rai KR, Keating MJ, Gribben JG et al. ( 2005 ) . Expression of T cell co-stimulator (ICOS) and its ligand and disease progression in B-cell chronic lymphocytic leukemia . BLOOD . vol. 106 , 826A - 826A .
Gribben J, Stephans K, Marshal B ( 2005 ) . Fludarabine and Alemtuzumab Versus Fludarabine and Rituximab in the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia: Results from a Phase II Study . Blood vol. 106 , ( 11 ) 5046 - 5046 .
Gribben J, Stephans K, Marshal B ( 2005 ) . Fludarabine and alemtuzumab versus fludarabine and rituximab in the treatment of relapsed B-cell chronic lymphocytic leukemia: Results from a phase II study . BLOOD . vol. 106 , 343B - 343B .
Ho VT, Kim HT, Windawi S, Liney D, Milford E, Gribben J, Cutler C, Lee SJ et al. ( 2005 ) . HLA-C Mismatch Is Associated with Inferior Outcome after Unrelated Donor Non-Myeloablative Hematopoietic Stem Cell Transplantation . Blood vol. 106 , ( 11 ) 835 - 835 .
Brown JR, Li S, Kim H, Fisher DC, Cutler C, Ho V, Lee SJ, Ritz J et al. ( 2005 ) . High Levels of Early Donor Chimerism and Treatment-Responsive Disease Predict Improved Progression-Free Survival Following Non-Myeloablative Transplantation for Advanced CLL . Blood vol. 106 , ( 11 ) 560 - 560 .
Brown JR, Li SL, Kim H, Fisher DC, Cutler C, Ho V, Lee SJ, Ritz J et al. ( 2005 ) . High levels of early donor chimerism and treatment-responsive disease predict improved progression-free survival following non-myeloablative transplantation for advanced CLL . BLOOD . vol. 106 , 166A - 167A .
Ledieu R, Gorgun G, Gribben JG ( 2005 ) . In vivo demonstration of donor idiotype specific T cells that kill primary CLL cells post allogeneic transplant . BLOOD . vol. 106 , 23A - 23A .
Guinan EC, Gribben JG, Brennan LL, Nadler LM ( 2005 ) . Patients (Pts) Surviving Haploidentical Stem Cell Transplantation (SCT) after Ex Vivo Costimulatory Blockade To Induce Anergy Experience Few Long-Term Complications . Blood vol. 106 , ( 11 ) 599 - 599 .
Guinan EC, Gribben JG, Brennan LL, Nadler LM ( 2005 ) . Patients (Pts) surviving haploidentical stem cell transplantation (SCT) after ex vivo costimulatory blockade to induce anergy experience few long-term complications . BLOOD . vol. 106 , 178A - 178A .
Mauerer K, Gorgun G, Zahrieh D, Gribben JG ( 2005 ) . Successful Generation of Cytotoxic T-Cells That Kill CLL Cells Using Heteroclitic Peptides Is Independent of the Native Peptide Binding Affinity to HLA-A*0201 . Blood vol. 106 , ( 11 ) 54 - 54 .
Mauerer K, Gorgun G, Zahrieh D, Gribben JG ( 2005 ) . Successful generation of cytotoxic T-cells that kill CLL cells using heteroclitic peptides is independent of the native peptide binding affinity to HLA-A*0201 . BLOOD . vol. 106 , 20A - 21A .
Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D, Larson RA, Rai K et al. ( 2005 ) . Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity . LEUKEMIA RES vol. 29 , ( 11 ) 1253 - 1257 .
Li A, Goldwasser MA, Zhou J, Armstrong SA, Wang H, Dalton V, Fletcher JA, Sallan SE et al. ( 2005 ) . Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias . Br J Haematol vol. 131 , ( 2 ) 185 - 192 .
Le Dieu R, Gribben J ( 2005 ) . CD40 activation: lessons for HIV immunotherapy from malignancies? . J HIV Ther vol. 10 , ( 3 ) 51 - 55 .
Görgün G, Holderried TAW, Zahrieh D, Neuberg D, Gribben JG ( 2005 ) . Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells . J Clin Invest vol. 115 , ( 7 ) 1797 - 1805 .
Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U et al. ( 2005 ) . Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy . Clin Cancer Res vol. 11 , ( 12 ) 4430 - 4436 .
Gribben JG, Stephenson JJ, Bartlett NL, Milder MS, Boccia RV, Redfern C, Mizuno VM, Hillson J et al. ( 2005 ) . A phase II study of Xcellerated T Cells in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL) . JOURNAL OF CLINICAL ONCOLOGY . vol. 23 , 168S - 168S .
Gribben JG, Stephenson JJ, Bartlett NL, Milder MS, Boccia RV, Redfern C, Mizuno VM, Hillson J et al. ( 2005 ) . A phase II study of Xcellerated T Cells in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (NHL) . Journal of Clinical Oncology vol. 23 , ( 16_suppl ) 2510 - 2510 .
Gribben JG ( 2005 ) . Combination therapy with MabCampath (R): Moving forward . ANNALS OF ONCOLOGY . vol. 16 , 255 - 255 .
Darby A, Gribben JG ( 2005 ) . Follicular Lymphoma . Lymphoma , vol. 115 ,
Mauerer K, Zahrieh D, Gorgun G, Li A, Zhou J, Ansén S, Rassenti LZ, Gribben JG ( 2005 ) . Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia . Br J Haematol vol. 129 , ( 4 ) 499 - 510 .
Zhou J, Mauerer K, Farina L, Gribben JG ( 2005 ) . The role of the tumor microenvironment in hematological malignancies and implication for therapy . Front Biosci vol. 10 , 1581 - 1596 .
Craiu A, Saito Y, Limon A, Eppich HM, Olson DP, Rodrigues N, Adams GB, Dombkowski D et al. ( 2005 ) . Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function . BLOOD vol. 105 , ( 5 ) 2235 - 2238 .
Davies AJ, Gribben JG ( 2005 ) . Hematopoietic stem cell transplantation in non-Hodgkin lymphoma . CURR OPIN ORGAN TRAN vol. 10 , ( 1 ) 35 - 39 .
Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ, Lee SJ, Windawi S et al. ( 2005 ) . Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age . BLOOD vol. 105 , ( 4 ) 1810 - 1814 .
Gribben JG, Bartlett NL, Stephenson JJ, Milder MS, Boccia RV, Redfern C, Mizuno VM, Berenson RJ et al. ( 2005 ) . A phase II study of Xcellerated T cells (TM) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL) . BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION . vol. 11 , 76 - 76 .
Darby A, Gribben JG ( 2005 ) . Follicular lymphoma: quantitation of minimal residual disease by PCR of the t(14;18) translocation . Methods Mol Med vol. 115 , 315 - 331 .
Ledieu R, Gorgun G, Gribben J ( 2005 ) . In vivo demonstration of donor idiotype specific T cells that kill primary CLL cells post allogeneic transplant . Conference: ASH from: 11/2005
Gribben JG ( 2005 ) . Salvage therapy for CLL and the role of stem cell transplantation . Hematology Am Soc Hematol Educ Program292 - 298 .
Zhou J, Mauerer K, Farina L, Gribben JG ( 2005 ) . The role of the tumor microenvironment in hematological malignancies and implication for therapy . Frontiers in Bioscience vol. 10 , ( 2 ) 1581 - 1596 .
Gricks CS, Zahrieh D, Zauls AJ, Gorgun G, Drandi D, Mauerer K, Neuberg D, Gribben JG ( 2004 ) . Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells . Blood vol. 104 , ( 13 ) 4002 - 4009 .
Bartlett NL, Gribben JG, Boccia RV, Milder MS, Aboulafia DM, Castro J, Flinn I, Hayes-Lattin B et al. ( 2004 ) . A Phase II Study of Xcellerated T Cells™ in Patients with Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma (NHL) . Blood vol. 104 , ( 11 ) 4640 - 4640 .
Freedman AS, Gribben JG, Neuberg D, Li S, Kim H, Mauch P, Nadler LM ( 2004 ) . Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Long Term Follow up of Two Sequential Trials with Standard Dose and High Dose CHOP Induction . Blood vol. 104 , ( 11 ) 5243 - 5243 .
Freedman AS, Gribben JG, Neuberg D, Li S, Kim H, Mauch P, Nadler LM ( 2004 ) . Autologous bone marrow transplantation for follicular lymphoma in first remission: Long term follow up of two sequential trials with standard dose and high dose CHOP induction . BLOOD . vol. 104 , 396B - 396B .
Rassenti LZ, Neuberg DS, Keating MJ, Gribben JG, Flinn IW, Rai KR, Byrd JC, Kay NE et al. ( 2004 ) . CD38 Compared with ZAP-70 or Immmunoglobulin Mutation Status as Predictor of Disease Progression in Chronic Lymphocytic Leukemia . Blood vol. 104 , ( 11 ) 2805 - 2805 .
Rassenti LZ, Neuberg DS, Keating MJ, Gribben JG, Flinn IW, Rai KR, Byrd JC, Kay NE et al. ( 2004 ) . CD38 compared with ZAP-70 or immmunoglobulin mutation status as predictor of disease progression in chronic lymphocytic leukemia . BLOOD . vol. 104 , 767A - 768A .
Holderried TAW, Gorgun G, Gribben JG ( 2004 ) . Cell contact with CLL cells induces defects in T cell differentiation and effector pathways: Impact of silencing specific cytokine production . BLOOD . vol. 104 , 273A - 274A .
Kitada S, Reed JC, David MLI, Neuberg DS, Gribben JG, Dewald GW, Flinn IW, Appelbaum FR et al. ( 2004 ) . Critical molecular studies to strategically plan therapy in chronic lymphocytic leukemia (CLL): Correlating cellular proteins with defined prognostic patient subsets and their response to treatment . BLOOD . vol. 104 , 274A - 274A .
Mauerer K, Zahrieh D, Gorgun G, Li AH, Zhou JB, Rassenti L, Gribben JG ( 2004 ) . Distinct VDJ-H gene usage between mutated and unmutated patients in B-CLL: Implications for pathogenesis and correlation with clinical outcome . BLOOD . vol. 104 , 278A - 278A .
Rizouli V, Zahrieh D, Gorgun G, Holderried TAW, Croce C, Gribben JG ( 2004 ) . Gene expression profiling identifies similar CD4(+) and CD8(+) T cell defects in TCL1 transgenic mice after development of CLL to those observed in patients with CLL . BLOOD . vol. 104 , 55A - 55A .
Alyea EP, Li S, Kim H, Ho VT, Cutler C, Lee SJ, Gribben J, Stone RM et al. ( 2004 ) . High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS . Blood vol. 104 , ( 11 ) 185 - 185 .
Zhou JB, Xia ZN, Li AH, Gribben JG ( 2004 ) . Mapping low molecular weight plasma proteome of chronic lymphoblastic leukemia patients using MALDI-TOF mass spectrometry . BLOOD . vol. 104 , 528A - 528A .
Li A, Zhou J, Wang H, Goldwasser MA, Lyons C, Sallan SE, Silverman LB, Gribben JG ( 2004 ) . Molecular Analysis of T-Cell Receptor Gene Rearrangements in Children with T-Cell Acute Lymphoblast Leukemia on DFCI ALL Consortium Protocol 95-01 . Blood vol. 104 , ( 11 ) 1084 - 1084 .
Li AH, Zhou JB, Wang HJ, Goldwasser MA, Lyons C, Sallan SE, Silverman LB, Gribben JG ( 2004 ) . Molecular analysis of T-cell receptor gene rearrangements in children with T-cell acute lymphoblast leukemia on DFCI ALL consortium protocol 95-01 . BLOOD . vol. 104 , 308A - 308A .
Grever MR, Lucas DM, Dewald GW, Neuberg DS, Flinn IW, Appelbaum FR, Larson RA, Tallman MS et al. ( 2004 ) . Outcome of treatment with fludarabine versus fludarabine and cyclophosphamide in chronic lymphocytic leukemia (CLL) is adversely impacted by high risk genetic features: Results from ECOG 2997 . BLOOD . vol. 104 , 950A - 951A .
Faderl S, Rai KR, Gribben J, Flinn I, Byrd JC, McConkey D, Schenkein D, Esseltine D et al. ( 2004 ) . Phase 2 Study of Three Doses of Single Agent Bortezomib in Patients with Fludarabine-Refractory B-Cell CLL . Blood vol. 104 , ( 11 ) 4841 - 4841 .
Zhou JB, Li AH, Goldwasser MA, Wang HJ, Dalton V, Lyons C, McBride KD, Sallan SE et al. ( 2004 ) . Quantitative analysis of minimal residual disease at the completion of induction therapy predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL consortium protocol 95-01 . BLOOD . vol. 104 , 96A - 96A .
Vallat LD, Kemper CA, Park Y, Rassenti LZ, Fisher JW, Gribben JG ( 2004 ) . Reprogramming the Transcriptional Response of Chronic Lymphocytic Leukemia (CLL) Cells: Influencing the Temporal Gene Regulatory Network . Blood vol. 104 , ( 11 ) 1128 - 1128 .
Vallat LD, Kemper CA, Park Y, Rassenti LZ, Fisher JW, Gribben JG ( 2004 ) . Reprogramming the transcriptional response of chronic lymphocytic leukemia (CLL) cells: Influencing the temporal gene regulatory network . BLOOD . vol. 104 , 319A - 320A .
Byrd JC, Gribben JG, Peterson B, Grever MR, Lozanski G, Lucas DM, Larson RA, Caligiuri MA et al. ( 2004 ) . Select High Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy with Fludarabine and Rituximab in Chronic Lymphocytic Leukemia (CLL): Preliminary Justification for Risk-Adapted Therapy . Blood vol. 104 , ( 11 ) 476 - 476 .
Byrd JC, Gribben JG, Peterson B, Grever MR, Lozanski G, Lucas DM, Larson RA, Caligiuri MA et al. ( 2004 ) . Select high risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia (CLL): Preliminary justification for risk-adapted therapy . BLOOD . vol. 104 , 139A - 139A .
Alyea EP, Kim H, Cutler C, Ho VT, Gribben J, DeAngelo DJ, Lee SJ, Windawi S et al. ( 2004 ) . Similar Outcome of Non-Myeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients Greater Than Fifty Years of Age . Blood vol. 104 , ( 11 ) 300 - 300 .
Alyea EP, Li S, Kim H, Cutler C, Ho V, Lee SJ, Gribben J, Ritz J et al. ( 2004 ) . Sirolimus, Tacrolimus and Reduced-Dose Methotrexate as Graft Versus Host Disease (GVHD)Prophylaxis after Non-Myeloablative Stem Cell Transplantation: Low Incidence of Acute GVHD Compared with Tacrolimus/Methotrexate or Cyclosporine/Prednisone . Blood vol. 104 , ( 11 ) 730 - 730 .
Mauerer K, Zahrieh D, Ansen S, Li AH, Xia ZN, Gribben JG ( 2004 ) . Somatic hypermutation does not increase the binding affinity of Ig derived peptides to MHC class I or II - Implications for Ig peptide vaccination strategies . BLOOD . vol. 104 , 275A - 275A .
Vallat LD, Park Y, Rassenti L, Gribben JG ( 2004 ) . Temporal Gene Expression after BCR-Crosslinking Based upon Zap70 Related Genomic Features . Blood vol. 104 , ( 11 ) 2795 - 2795 .
Vallat LD, Park Y, Rassenti L, Gribben JG ( 2004 ) . Temporal gene expression after BCR-crosslinking based upon Zap70 related genomic features . BLOOD . vol. 104 , 765A - 765A .
Widhopf GF, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps TJ ( 2004 ) . Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins . Blood vol. 104 , ( 8 ) 2499 - 2504 .
Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW et al. ( 2004 ) . ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia . N Engl J Med vol. 351 , ( 9 ) 893 - 901 .
Gribben JG ( 2004 ) . Killing malignant but not normal B cells . BLOOD vol. 104 , ( 3 ) 601 - 601 .
Rizouli V, Gribben Jg JG ( 2004 ) . The role of stem cell transplantation in chronic lymphocytic leukemia . Semin Hematol vol. 41 , ( 3 ) 246 - 253 .
Li AH, Rue M, Zhou JB, Wang HJ, Goldwasser MA, Neuberg D, Dalton V, Zuckerman D et al. ( 2004 ) . Utilization of Ig heavy chain variable, diversity, and joining gene segments in children with B-lineage acute lymphoblastic leukemia: implications for the mechanisms of VDJ recombination and for pathogenesis . BLOOD vol. 103 , ( 12 ) 4602 - 4609 .
von Bergwelt-Baildon M, Maecker B, Schultze J, Gribben JG ( 2004 ) . CD40 activation: potential for specific immunotherapy in B-CLL . Ann Oncol vol. 15 , ( 6 ) 853 - 857 .
Gribben JG ( 2004 ) . Graft purging in autologous bone marrow transplantation: A promise not quite fulfilled - The Alvarnas/Forman article reviewed . ONCOLOGY-NY vol. 18 , ( 7 ) 876 - 877 .
Gribben JG ( 2004 ) . The Alvarnas/Forman article reviewed . ONCOLOGY vol. 18 , ( 7 ) 876 - 877 .
Armstrong SA, Mabon ME, Silverman LB, Li AH, Gribben JG, Fox EA, Sallan SE, Korsmeyer SJ ( 2004 ) . FLT3 mutations in childhood acute lymphoblastic leukemia . BLOOD vol. 103 , ( 9 ) 3544 - 3546 .
Letestu R, Ugo V, Valensi F, Radford-Weiss I, Nataf J, Levy V, Gribben JG, Troussard X et al. ( 2004 ) . Prognostic impact of p27KIP1 expression in cyclin D1 positive lymphoproliferative disorders . LEUKEMIA vol. 18 , ( 5 ) 953 - 961 .
Brown JR, Gaudet G, Friedberg JW, Neuberg D, Mauch P, Kutok JL, Takvorian T, Fisher DC et al. ( 2004 ) . Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma . LEUKEMIA LYMPHOMA vol. 45 , ( 2 ) 315 - 320 .
Zubair AC, Zahrieh D, Daley H, Schott D, Gribben JG, Alyea EP, Schlossman R, Freedman A et al. ( 2004 ) . Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy . Transfusion vol. 44 , ( 2 ) 253 - 261 .
Friedberg JW, Dong DA, Li SG, Kim H, Stephans K, Noonan K, Neuberg D, Gribben JG et al. ( 2004 ) . Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo . LEUKEMIA RESEARCH . vol. 28 , 139 - 147 .
Gribben JG ( 2004 ) . Death of follicular lymphoma cells - the long and the short of it . BLOOD vol. 103 , ( 2 ) 374 - 374 .
Li A, Zhou J, Zuckerman D, Rue M, Dalton V, Lyons C, Silverman LB, Sallan SE et al. ( 2003 ) . Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection . Blood vol. 102 , ( 13 ) 4520 - 4526 .
Alyea E, Weller E, Schlossman R, Canning C, Mauch P, Ng A, Fisher D, Gribben J et al. ( 2003 ) . Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect . BONE MARROW TRANSPL vol. 32 , ( 12 ) 1145 - 1151 .
O'Brien SM, Gribben JG, Thomas DA, Albitar M, Wierda W, Ferrajoli A, Lerner S, Kantarjian HM et al. ( 2003 ) . Alemtuzumab for minimal residual disease in CLL . BLOOD . vol. 102 , 109A - 109A .
Zhou JB, Li AH, Diller L, Gribben JG ( 2003 ) . Application of molecular markers for minimal residual disease detection in neuroblastoma using real-time PCR technology . BLOOD . vol. 102 , 215B - 216B .
Drandi D, Lee C, Dal Cin P, Gribben JG ( 2003 ) . Array-based comparative genomic hybridization identifies deletion at 14q32 as a new prognostic marker in chronic lymphocytic leukemia (CLL) . BLOOD . vol. 102 , 186A - 186A .
Gorgun G, Zahrieh D, Drandi D, Neuberg D, Gribben J ( 2003 ) . Gene expression profiling reveals defects in genes regulating T cell diffentiation and effector pathways in T cells in patients with CLL . BLOOD . vol. 102 , 232A - 232A .
Rassenti LZ, Toy TL, Huynh L, Greaves A, Gribben JG, Keating MJ, Rai KR, Flinn IW et al. ( 2003 ) . High similarity between familial and sporadic cases of chroni lymphocytic leukemia . BLOOD . vol. 102 , 670A - 670A .
Mauerer K, Gorgun G, Drandi D, Gribben JG ( 2003 ) . Impact of binding affinity to HLA*A0201 on both generation of cytotoxic T cells and their effector function to kill peptide pulsed APCs and CLL cells . BLOOD . vol. 102 , 230A - 231A .
Gribben JG, Sequist L, Zahrieh D, Neuberg D, Alyea EP, Fisher DC, Freedman AS, Schlossman RL et al. ( 2003 ) . Outcome following autologous or allogeneic stem cell transplantation in chronic lymphocytic leukemia . BLOOD . vol. 102 , 980A - 981A .
Li AH, Armstrong S, Rue M, Wang HJ, Zhou JB, Silverman LB, Sallan SE, Gribben JG ( 2003 ) . V-H gene usage, incomplete DJ(H) recombinations and MLL rearrangements in infant with B-lineage acute lymphoblastic leukemia: Implications for leukemic transformation occurring at an earlier stage of B cell development . BLOOD . vol. 102 , 140A - 140A .
Grever MR, Dewald GW, Lucas DM, Neuberg DS, Baird ME, Paternoster SF, Brockman SR, Lozanski G et al. ( 2003 ) . ZAP-70 protein expression varies by interphase cytogenetic group and may predict disease progression to requirement of treatment among select genetic groups in patients with chronic lymphocytic leukemia (CLL) . BLOOD . vol. 102 , 73A - 73A .
Rassenti LZ, Huynh L, Toy TL, Gribben JG, Keating MJ, Rai KR, Flinn IW, Byrd JC et al. ( 2003 ) . Zap-70 is a more reliable marker of disease progression risk than immunoglobulin mutation status in chronic lymphocytic leukemia . BLOOD . vol. 102 , 34A - 34A .
Gribben JG ( 2003 ) . Indolent B-cell malignancies: Immune recognition and antiself . LEUKEMIA & LYMPHOMA . vol. 44 , S77 - S83 .
Lee C, Drandi D, Dal Cin P, Gribben J ( 2003 ) . Prognostic markers in CLL by array-based comparative genomic hybridization . AMERICAN JOURNAL OF HUMAN GENETICS . vol. 73 , 218 - 218 .
Friedberg JW, Kim H, Li S, Neuberg D, Boyd K, Daley H, Fisher DC, Gribben JG et al. ( 2003 ) . Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma . Bone Marrow Transplant vol. 32 , ( 7 ) 681 - 686 .
Battle TE, Castro-Malaspina H, Gribben JG, Frank DA ( 2003 ) . Sustained complete remission of CLL associated with the use of a Chinese herbal extract: case report and mechanistic analysis . LEUKEMIA RES vol. 27 , ( 9 ) 859 - 863 .
Rizouli V, Gribben JG ( 2003 ) . Role of autologous stem cell transplantation in chronic lymphocytic leukemia . CURR OPIN HEMATOL vol. 10 , ( 4 ) 306 - 311 .
Zubair A, Zahrieh D, Daley H, Schott D, Gribben JG, Freedman A, Ritz J ( 2003 ) . Early neutrophil engraftment following autologous BMT provides a functional predictor of long-term hematopoietic reconstitution . Transfusion vol. 43 , ( 5 ) 614 - 621 .
Gricks CS, Gribben JG ( 2003 ) . Cytotoxic T cell responses against immunoglobulin in malignant and normal B cells: implications for tumor immunity and autoimmunity . Curr Pharm Des vol. 9 , ( 23 ) 1889 - 1903 .
Grupp SA, Ash S, Donovan J, Temel J, Zuckerman A, Fang J, Pierson G, Ross A et al. ( 2003 ) . Successful Purging of Stem Cell Products Using CD34 Selection . Transplantation in Hematology and Oncology II ,
Gricks CS, Zauls AJ, Zahrieh D, Chiaretti S, Krackhardt AM, Neuberg D, Gribben JG ( 2002 ) . Gene expression profiling demonstrates differential regulation of genes controlling cell cycle progression following CD40 activation in healthy B cells compared to CLL cells . BLOOD . vol. 100 , 99A - 99A .
Gorgun G, Gribben JG ( 2002 ) . Induction of autologous Th1 response against CLL cells by addition of exogenous interferon during generation of antigen presenting cells gamma . BLOOD . vol. 100 , 591A - 591A .
Savage KJ, Weng AP, Kutok JL, Pinkus G, Gribben JG ( 2002 ) . Loss of CD20 expression following treatment with anti-CD20 monoclonal antibody in chronic lymphocytic leukemia . BLOOD . vol. 100 , 364B - 364B .
Friedberg JW, Dong DA, Li SG, Kim H, Stephans K, Noonan K, Neuberg D, Gribben JG et al. ( 2002 ) . Oral fludarabine (FMP) is highly active in patients (pts) with previously untreated chronic lymphocytic leukemia (CLL), and leads to increased STAT1 levels in vivo . BLOOD . vol. 100 , 388A - 388A .
Li AH, Zuckerman D, Zuckerman A, Silverman LB, Sallan SE, Gribben JG ( 2002 ) . Sequence analysis of clonal IgH and TCR gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: Implications for clinical utility of PCR based methods of minimal residual disease detection . BLOOD . vol. 100 , 68A - 68A .
Ricca I, Compagno M, Ladetto M, Dell'Aquila M, Bandesan P, Omede P, Rocci A, D'antico S et al. ( 2002 ) . Telomere length loss in hematopoietic stem cells following two consecutive chemotherapy-induced mobilizing regimens . BLOOD . vol. 100 , 146B - 146B .
Li AH, Neuberg D, Zuckerman D, Zuckerman A, Silverman LB, Sallan SE, Gribben JG ( 2002 ) . Utilization of Ig heavy-chain variable, diversity and joining gene segments in childhood acute lymphoblastic leukemia . BLOOD . vol. 100 , 760A - 761A .
Krackhardt AM, Witzens M, Harig S, Hodi FS, Zauls AJ, Chessia M, Barrett P, Gribben JG ( 2002 ) . Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX . BLOOD vol. 100 , ( 6 ) 2123 - 2131 .
Andersen NS, Donovan JW, Zuckerman A, Pedersen L, Geisler C, Gribben JG ( 2002 ) . Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma . Exp Hematol vol. 30 , ( 7 ) 703 - 710 .
Krackhardt AM, Harig S, Witzens M, Broderick R, Barrett P, Gribben JG ( 2002 ) . T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy . Blood vol. 100 , ( 1 ) 167 - 173 .
Friedberg JW, Neuberg D, Gribben JG, Fisher DC, Canning C, Koval M, Poor CM, Green LM et al. ( 2002 ) . Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma . BRIT J HAEMATOL vol. 117 , ( 4 ) 828 - 834 .
Ladetto M, Omede P, Sametti S, Donovan JW, Astolfi M, Drandi D, Volpato F, Giaccone L et al. ( 2002 ) . Real-time polymerase chain reaction in multiple myeloma: Quantitative analysis of tumor contamination of stem cell harvests . EXP HEMATOL vol. 30 , ( 6 ) 529 - 536 .
Gribben JG ( 2002 ) . Monitoring disease in lymphoma and CLL patients using molecular techniques . Best Pract Res Clin Haematol vol. 15 , ( 1 ) 179 - 195 .
Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, Shipp MA ( 2002 ) . Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival . J Clin Oncol vol. 20 , ( 5 ) 1288 - 1294 .
Gribben JG ( 2002 ) . Autologous hematopoietic transplantation for low-grade lymphomas . Cytotherapy vol. 4 , ( 3 ) 205 - 215 .
Alyea EP, Weller E, Fisher DC, Freedman AS, Gribben JG, Lee S, Schlossman RL, Stone RM et al. ( 2002 ) . Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation . Biol Blood Marrow Transplant vol. 8 , ( 11 ) 601 - 607 .
Alyea E, Neuberg D, Mauch P, Marcus K, Freedman A, Webb I, Anderson K, Schlossman R et al. ( 2002 ) . Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation . Biol Blood Marrow Transplant vol. 8 , ( 3 ) 139 - 144 .
Webb IJ, Friedberg NW, Gribben JG, Fisher DC, Spitzer T, Neuberg D, Jallow H, Kim H et al. ( 2002 ) . Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma . Biol Blood Marrow Transplant vol. 8 , ( 8 ) 429 - 434 .
Gilliland DG, Gribben JG ( 2002 ) . Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation . BIOL BLOOD MARROW TR vol. 8 , ( 1 ) 9 - 16 .
Gribben JG ( 2002 ) . Immunotherapy in the B-cell lymphomas . Cytotherapy vol. 4 , ( 5 ) 439 - 440 .
Ke XY, Gribben J, Wang J, Wang DB ( 2002 ) . The identical effects of B7-1 and B7-2 on regulation of human IL-2 gene transcription factors NF-kappa B and AP-1 . Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology vol. 10 , ( 6 ) 512 - 518 .
Vonderheide RH, Dutcher JP, Anderson JE, Eckhardt SG, Caron DA, Gribben JG ( 2001 ) . Cd40 ligand therapy of lymphoma patients - Reply . J CLIN ONCOL vol. 19 , ( 23 ) 4352 - 4353 .
Younes A, Vonderheide RH, Dutcher JP, Anderson JE, Eckhardt EG, Caron DA, Gribben JG ( 2001 ) . Cd40 ligand therapy of lymphoma patients [3] . Journal of Clinical Oncology vol. 19 , ( 23 ) 4351 - 4353 .
Krackhardt AM, Witzens M, Zauls AJ, Barrett P, Chessia M, Gribben JG ( 2001 ) . Differential expression of newly identified CLL-associated antigenes: Ientification of a novel antigen with cancer-testis like expression pattern and genes with tumor-restricted splice variants . BLOOD vol. 98 , ( 11 ) 731A - 731A .
Rai KR, Coutre S, Rizzieri D, Gribben JG, Flinn I, Rabinowe S, Keating MJ, Campath Study Grp ( 2001 ) . Efficacy and safety of alemtuzumab (Campath-1H) in refractory B-CLL patients treated on a compassionate basis . BLOOD vol. 98 , ( 11 ) 365A - 365A .
Coutre S, Rai KR, Keating MJ, Gribben JG, Flinn I, Rabinowe S, Rizzieri D, Campath Study Grp ( 2001 ) . Efficacy and safety of alemtuzumab (Campath-1H) used on a compassionate basis in refractory T-PLL . BLOOD vol. 98 , ( 11 ) 366A - 366A .
Krackhardt AM, Witzens M, Zauls AJ, Barrett P, Gribben JG ( 2001 ) . Identification of novel tumor-associated antigens in CLL - Implications for immunotherapy in CLL . BLOOD vol. 98 , ( 11 ) 807A - 807A .
Zubair AC, Freedman AS, Gribben JG, Friedberg J, Ritz J, Webb IJ ( 2001 ) . Neutrophil engraftment is a better predictor of long-term hematopoietic function than number of CD34 positive cells infused . BLOOD vol. 98 , ( 11 ) 323B - 323B .
Ladetto M, Omede P, Sametti S, Donovan JW, Drandi D, Giaccone L, Volpato F, Astolfi M et al. ( 2001 ) . Real time PCR in multiple myeloma: Quantitative analysis of tumor contamination of stem cell harvests . BLOOD vol. 98 , ( 11 ) 300B - 300B .
Lin TS, Zahrieh D, Weller E, Alyea ER, Fisher DC, Gribben JG, Freedman AS, Schlossman RL et al. ( 2001 ) . Risk factors for CMV reactivation after T-cell depleted allogeneic bone marrow transplantation . BLOOD vol. 98 , ( 11 ) 480A - 481A .
Harig S, Witzens M, Krackhardt AM, Trojan A, Barrett P, Broderick R, Zauls AJ, Gribben JG ( 2001 ) . Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues . BLOOD vol. 98 , ( 10 ) 2999 - 3005 .
Vonderheide RH, Butler MO, Liu JF, Battle TE, Hirano N, Gribben JG, Frank DA, Schultze JL et al. ( 2001 ) . CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity . Int J Oncol vol. 19 , ( 4 ) 791 - 798 .
Alyea E, Weller E, Schlossman R, Canning C, Webb I, Doss D, Mauch P, Marcus K et al. ( 2001 ) . T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect . Blood vol. 98 , ( 4 ) 934 - 939 .
Vonderheide RH, Dutcher JP, Anderson JE, Eckhardt SG, Stephans KF, Razvillas B, Garl S, Butine MD et al. ( 2001 ) . Phase I study of recombinant human CD40 ligand in cancer patients . JOURNAL OF CLINICAL ONCOLOGY . vol. 19 , 3280 - 3287 .
Trojan A, Witzens M, Schultze JL, Vonderheide RH, Harig S, Krackhardt AM, Stahel RA, Gribben JG ( 2001 ) . Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule . Cancer Res vol. 61 , ( 12 ) 4761 - 4765 .
Schultze JL, Anderson KC, Gilleece MH, Gribben JG, Nadler LM ( 2001 ) . A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2 . BRIT J HAEMATOL vol. 113 , ( 2 ) 455 - 460 .
Soiffer RJ, Weller E, Alyea EP, Mauch P, Webb IL, Fisher DC, Freedman AS, Schlossman RL et al. ( 2001 ) . CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors . J Clin Oncol vol. 19 , ( 4 ) 1152 - 1159 .
Ladetto M, Sametti S, Donovan JW, Ferrero D, Astolfi M, Mitterer M, Ricca I, Drandi D et al. ( 2001 ) . A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients . Exp Hematol vol. 29 , ( 2 ) 183 - 193 .
Donovan J, Temel J, Zuckerman A, Gribben J, Fang J, Pierson G, Ross A, Diller L et al. ( 2000 ) . CD34 selection as a stem cell purging strategy for neuroblastoma: Preclinical and clinical studies . Medical and Pediatric Oncology . vol. 35 , 677 - 682 .
Ash S, Donovan JW, Temel J, Zuckerman A, Grupp SA, Diller L, Gribben JG ( 2000 ) . Detection of minimal residual disease and assessment of stem cell purging by taqman real time PCR quantitation of gage expression in patients with neuroblastoma . Blood vol. 96 , ( 11 PART I )
Freedman A, Friedberg JW, Gribben J ( 2000 ) . High-dose therapy for follicular lymphoma . ONCOLOGY vol. 14 , ( 3 ) 321 - 329 .
Grdisa M, Tang RP, Delmer A, Levy V, Gribben JG, Ajchenbaum-Cymbalista F ( 2000 ) . Ligation of cd40 on B-CELL chronic lymphocytic leukemia (B-CLL) cells promotes increased survival but does not impair fludarabine induced apoptosis . Blood vol. 96 , ( 11 PART I )
Witzens M, Krackhardt AM, Harig S, Donovan JW, Gribben JG ( 2000 ) . Overexpression of ribosomal proteins in chronic lymphocytic leukemia identified by subtractive hybridization . Blood vol. 96 , ( 11 PART II )
Ladetto M, Sametti POS, Donovan JW, Astolfi M, Giaccone L, Giaretta F, Volpato F, Bringhen S et al. ( 2000 ) . Real time quantitative pcr shows that peripheral blood stem cell (pbpc) harvests are significantly less contaminated than bone marrow (bm) in multiple myeloma patients (mm) . Blood vol. 96 , ( 11 PART I )
Ladetto M, Sametti S, Donovan JW, Ferrero D, Astolfi M, Mitterer M, Ricca I, Drandi D et al. ( 2000 ) . An extensively valitaded real-time quantitative PCR approach shows a correlation between tumour burden (tb) and successful ex vivo purging in follicular lymphoma (FL) patients . BLOOD vol. 96 , ( 11 ) 583A - + .
Donovan JW, Zuckerman A, Waters S, Silverman L, Sallan S, Gribben JG ( 2000 ) . Analysis of residual disease levels in pediatric acute lymphoblastic leukemia by TaqMan quantitative PCR . BLOOD vol. 96 , ( 11 ) 314A - 314A .
Witzens M, Krackhardt AM, Harig S, Zauls AJ, Donovan JW, Gribben JG ( 2000 ) . Chronic lymphocytic leukemia antigens elicit specific immune responses in the autologous host . BLOOD vol. 96 , ( 11 ) 513A - 513A .
Soiffer RJ, Weller E, Lee SJ, Alyea EP, Schlossman RL, Gribben JG, Ritz J, Antin JH ( 2000 ) . Comparative outcomes of cyclosporine/methotrexate and CD6+T cell depletion (TCD) as graft-vs-host disease (GVHD) prophylaxis for allogeneic bone marrow transplantation (BMT) from unrelated donors (URD) . BLOOD vol. 96 , ( 11 ) 415A - 415A .
Ash S, Donovan JW, Temel J, Zuckerman A, Grupp SD, Diller L, Gribben JG ( 2000 ) . Detection of minimal residual disease and assessment of stem cell purging by TaqMan real time PCR quantitation of GAGE expression in patients with neuroblastoma . BLOOD vol. 96 , ( 11 ) 187A - 187A .
Krackhardt AM, Witzens M, Donovan JW, Chessia M, Harig S, Gribben JG ( 2000 ) . Identification of tumor associated genes in CLL by subtractive hybridization . BLOOD vol. 96 , ( 11 ) 165B - 165B .
Harig S, Witzens M, Trojan A, Krackhardt AM, Broderick R, Barrett P, Donovan JW, Gribben JG ( 2000 ) . Induction of cytotoxic T-cell responses against immunoglobulin derived peptides modified at HLA-A2 binding residues . BLOOD vol. 96 , ( 11 ) 830A - 830A .
Krackhardt AM, Witzens M, Donovan JW, Chessia M, Harig S, Gribben JG ( 2000 ) . JM1, isolation and characterization of a novel CLL antigen recognized by autologous and syngeneic IgG antibodies . BLOOD vol. 96 , ( 11 ) 513A - 513A .
Widhopf GF, Marathe CM, Rassenti LZ, Byrd JC, Flinn IW, Gribben JG, Kipps TJ ( 2000 ) . Lack of correlation between immunoglobulin somatic mutation and expression of CD38 in chronic lymphocytic leukemia . BLOOD vol. 96 , ( 11 ) 367A - 367A .
Grdisa M, Tang RP, Delmer A, Levy V, Gribben JG, Ajchenbaum-Cymbalista F ( 2000 ) . Ligation of CD40 on B-cell chronic lymphocytic leukemia (B-CLL) cells promotes increased survival but does not impair fludarabine induced apoptosis . BLOOD vol. 96 , ( 11 ) 159A - 159A .
Witzens M, Krackhardt AM, Harig S, Donovan JW, Gribben JG ( 2000 ) . Overexpression of ribosomal proteins in chronic lymphocytic leukemia identified by subtractive hybridization . BLOOD vol. 96 , ( 11 ) 168B - 168B .
Friedberg JW, Neuberg D, Gribben JG, Canning C, Daley JF, Kuhlman C, Koval M, Donovan J et al. ( 2000 ) . Phase II study of combination immunotherapy with interleukin-2 (IL-2) and rituximab in patients with relapsed or refractory follicular non-Hodgkin's lymphoma (NHL) . BLOOD vol. 96 , ( 11 ) 730A - 731A .
Ladetto M, Omede P, Sametti S, Donovan JW, Astolfi M, Giaccone L, Giaretta F, Volpato F et al. ( 2000 ) . Real time quantitative PCR shows that peripheral blood stem cell (PBPC) harvests are significantly less contaminated than bone marrow (BM) in multiple myeloma patients (MM) . BLOOD vol. 96 , ( 11 ) 154A - 154A .
Krackhardt AM, Harig S, Witzens M, Barrett P, Broderick R, Gribben JG ( 2000 ) . T cell responses in CLL: Superiority of TH2 responses might contribute to reduced cytotoxic autologous antitumor responses . BLOOD vol. 96 , ( 11 ) 28A - 28A .
Trojan A, Schultze JL, Witzens M, Vonderheide RH, Ladetto M, Donovan JW, Gribben JG ( 2000 ) . Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies . Nature Medicine vol. 6 , ( 6 ) 667 - 672 .
Longo DL, Duffey PL, Gribben JG, Jaffe ES, Curti BD, Gause BL, Janik JE, Braman VM et al. ( 2000 ) . Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: Results of a phase II study . Cancer Journal vol. 6 , ( 3 ) 146 - 150 .
Donovan JW, Ladetto M, Zou G, Neuberg D, Poor C, Bowers D, Gribben JG ( 2000 ) . Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia . Blood vol. 95 , ( 8 ) 2651 - 2658 .
Schultze JL, Gribben JG ( 2000 ) . Molecular immunological modulation of target cells to enhance the GVL effect . Allogeneic Immunotherapy for Malignant Diseases ,
Ladetto M, Donovan JW, Harig S, Weller E, Trojan A, Poor C, Schlossman R, Anderson KC et al. ( 2000 ) . Real-Time Polymerase Chain Reaction of Immunoglobulin Rearrangements for Quantitative Evaluation of Minimal Residual Disease in Multiple Myeloma . Biology of Blood and Marrow Transplantation vol. 6 , ( 3 ) 241 - 253 .
Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC, Schlossman R, Alyea EP et al. ( 1999 ) . Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma . Blood vol. 94 , ( 10 ) 3325 - 3333 .
Krackhardt A, Gribben JG ( 1999 ) . Stem cell transplantation for indolent lymphoma . Current Opinion in Hematology vol. 6 , ( 6 ) 388 - 393 .
Gribben JG ( 1999 ) . Stem-cell transplantation for indolent lymphoma . Seminars in Hematology . vol. 36 , 18 - 25 .
Grossbard ML, Multani PS, Freedman AS, O'Day S, Gribben JG, Rhuda C, Neuberg D, Nadler LM ( 1999 ) . A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non- Hodgkin's lymphoma . Clinical Cancer Research vol. 5 , ( 9 ) 2392 - 2398 .
Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, Gribben JG ( 1999 ) . Transplantation of anergic histoincompatible bone marrow allografts . New England Journal of Medicine vol. 340 , ( 22 ) 1704 - 1714 .
Gribben JG ( 1999 ) . Bone marrow transplant for lymphoma: Where is the field going? . Biochimica et Biophysica Acta - Reviews on Cancer vol. 1423 , ( 3 )
Schultze JL, Michalak S, Lowne J, Wong A, Gilleece MH, Gribben JG, Nadler LM ( 1999 ) . Human non-germinal center B cell interleukin (IL)-12 production is primarily regulated by T cell signals CD40 ligand, interferon γ, and IL-10: Role of B cells in the maintenance of T cell responses . Journal of Experimental Medicine vol. 189 , ( 1 ) 1 - 11 .
Friedberg JW, Neuberg D, Gribben JG, Mauch P, Anderson KC, Soiffer RJ, Takvorian T, Fisher DC et al. ( 1999 ) . Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies . Biology of Blood and Marrow Transplantation vol. 5 , ( 4 ) 262 - 268 .
Schultze JL, Donovan JW, Gribben JG ( 1999 ) . Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia . Journal of Molecular Medicine vol. 77 , ( 2 ) 259 - 265 .
Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A, Mauch PM, Gribben JG et al. ( 1999 ) . Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma . Journal of Clinical Oncology vol. 17 , ( 10 ) 3128 - 3135 .
Boussiotis VA, Freeman GJ, Gribben JG, Hayes DF, Nadler LM ( 1998 ) . No evidence for muc 1-induced apoptosis [4] . Nature Medicine vol. 4 , ( 10 )
Gribben JG ( 1998 ) . Molecular basis for stem cell transplantation in indolent lymphomas . Cancer Journal from Scientific American vol. 4 , ( SUPPL. 2 )
Mach-Pascual S, Legare RD, Lu D, Kroon M, Neuberg D, Tantravahi R, Stone RM, Freedman AS et al. ( 1998 ) . Predictive Value of Clonality Assays in Patients With Non-Hodgkin's Lymphoma Undergoing Autologous Bone Marrow Transplant: A Single Institution Study . Blood vol. 91 , ( 12 ) 4496 - 4503 .
Mach-Pascual S, Legare RD, Lu D, Kroon M, Neuberg D, Tantravahi R, Stone RM, Freedman AS et al. ( 1998 ) . Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: A single institution study . Blood vol. 91 , ( 12 ) 4496 - 4503 .
Freeman GJ, Boussiotis VA, Gribben JG, Sharpe AH, Nadler LM ( 1998 ) . B7 (CD80 and CD86) . Encyclopedia of Immunology ,
Soiffer RJ, Freedman AS, Neuberg D, Fisher DC, Alyea EP, Gribben J, Schlossman RL, Bartlett-Pandite L et al. ( 1998 ) . CD6<sup>+</sup> T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma . Bone Marrow Transplantation vol. 21 , ( 12 ) 1177 - 1181 .
Freedman AS, Gribben JG, Nadler LM ( 1998 ) . High dose therapy and autologous stem cell transplantation in follicular non-Hodgkin's lymphoma . Leukemia and Lymphoma vol. 28 , ( 3-4 ) 219 - 230 .
Freedman AS, Neuberg D, Gribben JG, Mauch P, Soiffer RJ, Fisher DC, Anderson KC, Andersen N et al. ( 1998 ) . High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: No evidence for long-term remission . Journal of Clinical Oncology vol. 16 , ( 1 ) 13 - 18 .
Uglialoro AM, Turbay D, Pesavento PA, Delgado JC, McKenzie FE, Gribben JG, Hartl D, Yunis EJ et al. ( 1998 ) . Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-α gene promoter . Tissue Antigens vol. 52 , ( 4 ) 359 - 367 .
Schultze JL, Gribben JG, Nadler LM ( 1998 ) . Tumor-specific adoptive T-cell therapy for CD40+ B-cell malignancies . Current Opinion in Oncology vol. 10 , ( 6 ) 542 - 547 .
Ghia P, Boussiotis VA, Schultze JL, Cardoso AA, Dorfman DM, Gribben JG, Freedman AS, Nadler LM ( 1998 ) . Unbalanced expression of bcl-2 family proteins in follicular lymphoma: Contribution of CD40 signaling in promoting survival . Blood vol. 91 , ( 1 ) 244 - 251 .
Freedman A, Neuberg D, Mauch P, Gribben J, Soiffer R, Anderson K, Robertson M, Fisher DC et al. ( 1997 ) . Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Dose Intensification With Granulocyte Colony-Stimulating Factor Markedly Depletes Stem Cell Reserve for Autologous Bone Marrow Transplantation . Blood vol. 90 , ( 12 ) 4996 - 5001 .
Freedman A, Neuberg D, Mauch P, Gribben J, Soiffer R, Anderson K, Robertson M, Fisher DC et al. ( 1997 ) . Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation . Blood vol. 90 , ( 12 ) 4996 - 5001 .
Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, Delgado JC, Gribben JG et al. ( 1997 ) . CD40-activated human B cells: An alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy . Journal of Clinical Investigation vol. 100 , ( 11 ) 2757 - 2765 .
Dorfman DM, Schultze JL, Shahsafaei A, Michalak S, Gribben JG, Freeman GJ, Pinkus GS, Nadler LM ( 1997 ) . In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation . Blood vol. 90 , ( 11 ) 4297 - 4306 .
Andersen NS, Donovan JW, Borus JS, Poor CM, Neuberg D, Aster JC, Nadler LM, Freedman AS et al. ( 1997 ) . Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease . Blood vol. 90 , ( 10 ) 4212 - 4221 .
Boussiotis VA, Lee BJ, Freeman GJ, Gribben JG, Nadler LM ( 1997 ) . Induction of T Cell Clonal Anergy Results in Resistance, whereas CD28-Mediated Costimulation Primes for Susceptibility to Fas- and Bax-Mediated Programmed Cell Death . Journal of Immunology vol. 159 , ( 7 ) 3156 - 3167 .
Legare RD, Gribben JG, Maragh M, Hermanowski-Vosatka A, Roach S, Tantravahi R, Nadler LM, Gilliland DG ( 1997 ) . Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma . American Journal of Hematology vol. 56 , ( 1 ) 45 - 51 .
Cardoso AA, Seamon MJ, Afonso HM, Ghia P, Boussiotis VA, Freeman GJ, Gribben JG, Sallan SE et al. ( 1997 ) . Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells . Blood vol. 90 , ( 2 ) 549 - 561 .
Schultze JL, Seamon MJ, Michalak S, Gribben JG, Nadler LM ( 1997 ) . Autologous Tumor Infiltrating T Cells Cytotoxic for Follicular Lymphoma Cells Can Be Expanded In Vitro . Blood vol. 89 , ( 10 ) 3806 - 3816 .
Schultze JL, Seamon MJ, Michalak S, Gribben JG, Nadler LM ( 1997 ) . Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro . Blood vol. 89 , ( 10 ) 3806 - 3816 .
Voena C, Ladetto M, Astolfi M, Provan D, Gribben JG, Boccadoro M, Pileri A, Corradini P ( 1997 ) . A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors . Leukemia vol. 11 , ( 10 ) 1793 - 1798 .
Gribben JC ( 1997 ) . Biologie response modifiers in acute lymphoblastic leukemia . Leukemia vol. 11 , ( SUPPL. 4 )
Gribben JG ( 1997 ) . Bone marrow transplantation for low-grade B-cell malignancies . Current Opinion in Oncology vol. 9 , ( 2 ) 117 - 121 .
Gribben JG, Schultze JL ( 1997 ) . The detection of minimal residual disease: implications for bone marrow transplantation . Cancer treatment and research vol. 77 , 99 - 120 .
Gribben JG, Freedman A, Nadler LM ( 1996 ) . Bone marrow transplantation in low grade lymphomas . Onkologe . vol. 2 ,
Gimmi CD, Morrison BW, Mainprice BA, Gribben JG, Boussiotis VA, Freeman GJ, Park SY, Watanabe M et al. ( 1996 ) . Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells . Nat Med vol. 2 , ( 12 ) 1367 - 1370 .
Boussiotis VA, Freeman GJ, Gribben JG, Nadler LM ( 1996 ) . The Role of B7-1/B7-2:CD28/CLTA-4 Pathways in the Prevention of Anergy, Induction of Productive Immunity and Down-Regulation of the Immune Response . Immunological Reviews ( 153 )
Zwicky CS, Maddocks AB, Andersen N, Gribben JG ( 1996 ) . Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation . Blood vol. 88 , ( 9 ) 3314 - 3322 .
Freedman AS, Gribben JG, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Pandite L, Robertson MJ et al. ( 1996 ) . High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission . Blood vol. 88 , ( 7 ) 2780 - 2786 .
Provan D, Bartlett-Pandite L, Zwicky C, Neuberg D, Maddocks A, Corradini P, Soiffer R, Ritz J et al. ( 1996 ) . Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation . Blood vol. 88 , ( 6 ) 2228 - 2235 .
Boussiotis VA, Barber DL, Lee BJ, Gribben JG, Freeman GJ, Nadler LM ( 1996 ) . Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation . Journal of Experimental Medicine vol. 184 , ( 2 ) 365 - 376 .
Cardoso AA, Schultze JL, Boussiotis VA, Freeman GJ, Seamon MJ, Laszlo S, Billet A, Sallan SE et al. ( 1996 ) . Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen . Blood vol. 88 , ( 1 ) 41 - 48 .
Gribben JG, Guinan EC, Boussiotis VA, Ke XY, Linsley L, Sieff C, Gray GS, Freeman GJ et al. ( 1996 ) . Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: A method to ameliorate graft-versus-host disease and extend the donor pool . Blood vol. 87 , ( 11 ) 4887 - 4893 .
Schultze J, Nadler LM, Gribben JG ( 1996 ) . B7-mediated costimulation and the immune response . Blood Reviews vol. 10 , ( 2 ) 111 - 127 .
Gribben JG ( 1996 ) . Characterization of molecular signals that prevent the induction of anergy . Journal of Investigative Medicine vol. 44 , ( 3 )
Boussiotis VA, Barber DL, Freeman GJ, Lee BJ, Gribben JG, Nadler LM ( 1996 ) . Differential association of t cell receptor (tcr) with protein tyrosine kinases is critical for selective signaling resulting in anergy or productive immunity . Journal of Investigative Medicine vol. 44 , ( 3 )
Keating M, Cheson B, Gribben JG, Robertson B, Nadler L ( 1996 ) . Innovative strategies for the treatment of CLL . Leukemia and Lymphoma . vol. 22 , 53 - 64 .
Schultze JL, Gribben JG ( 1996 ) . Minimal residual disease in non-Hodgkin's lymphoma . Biomedicine and Pharmacotherapy vol. 50 , ( 9 ) 451 - 458 .
Gribben JG ( 1996 ) . PCR monitoring of response in patients treated with high-dose chemotherapy for low-grade lymphoma . Cancer treatment and research vol. 85 , 141 - 160 .
Boussiotis VA, Barber DL, Freeman GJ, Lee BJ, Gribben JG, Nadler LM ( 1996 ) . Prevention of t cell clonal anergy is directly linked to jak3 kinase activation . Journal of Investigative Medicine vol. 44 , ( 3 )
Gribben JG ( 1995 ) . Minimal residual disease in non-Hodgkin's lymphoma . FORUM - Trends in Experimental and Clinical Medicine vol. 5 , ( 6 ) 650 - 667 .
Schultze JL, Cardosa AA, Freeman GJ, Seamon MJ, Daley J, Pinkus GS, Gribben JG, Nadler LM ( 1995 ) . Erratum: Follicular lymphomas can be induced to present alloantigen efficiently: A conceptual model to improve their tumor immunogenicity (Proceedings of the National Academy of Sciences of the United States of America (August 29, 1995) 92:18 (8200-8204)) . Proceedings of the National Academy of Sciences of the United States of America vol. 92 , ( 23 )
Schultze JL, Cardoso AA, Freeman GJ, Seamon MJ, Daley J, Pinkus GS, Gribben JG, Nadler LM ( 1995 ) . Follicular lymphomas can be induced to present alloantigen efficiently: A conceptual model to improve their tumor immunogenicity . Proceedings of the National Academy of Sciences of the United States of America vol. 92 , ( 18 ) 8200 - 8204 .
Gribben JG, Freeman GJ, Boussiotis VA, Rennert P, Jellis CL, Greenfield E, Barber M, Restivo VA et al. ( 1995 ) . CTLA4 mediates antigen-specific apoptosis of human T cells . Proceedings of the National Academy of Sciences of the United States of America vol. 92 , ( 3 ) 811 - 815 .
Cardoso AA, Schultze JL, Provan D, Freeman GJ, Seamon M, Gribben JG, Nadler LM ( 1995 ) . Antigen-presenting function of B-cell precursor malignant cells can be modulated by crosslinking of CD40 . Journal of Cancer Research and Clinical Oncology vol. 121 , ( Suppl 1 ) a7 - a7 .
Gribben J, Nadler L ( 1995 ) . Detection of minimal residual disease . Cancer treatment and research vol. 76 , 249 - 270 .
Schultze JL, Cardoso AA, Seamon M, Freeman GJ, Gribben JG, Nadler LM ( 1995 ) . Follicular lymphoma cells stimulated through CD40 can prime alloantigen-specific T cell responses against primary malignant cells . Journal of Cancer Research and Clinical Oncology vol. 121 , ( Suppl 1 ) a8 - a8 .
Boussiotis VA, Freeman GJ, Gribben JG, Nadler LM ( 1995 ) . Induction of Alloantigen Specific T Cell Anergy by Inhibition of the B7: CD28 Pathway . Normal and Malignant Hematopoiesis ,
Boussiotis VA, Freeman GJ, Gribben JG, Nadler LM ( 1995 ) . The critical role of CD28 signalling in the prevention of human T-cell anergy . Research in Immunology . vol. 146 , 140 - 149 .
Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM ( 1994 ) . Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity . Blood vol. 84 , ( 10 ) 3261 - 3282 .
Boussiotis VA, Freeman GJ, Griffin JD, Gray GS, Gribben JG, Nadler LM ( 1994 ) . CD2 Is Involved in Maintenance and Reversal of Human Alloantigen-specific Clonal Anergy . Journal of Experimental Medicine vol. 180 , ( 5 ) 1665 - 1673 .
Engel P, Gribben JG, Freeman GJ, Zhou LJ, Nozawa Y, Abe M, Nadler LM, Wakasa H et al. ( 1994 ) . The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen . Blood vol. 84 , ( 5 ) 1402 - 1407 .
Gribben JG, Neuberg D, Barber M, Moore J, Pesek KW, Freedman AS, Nadler LM ( 1994 ) . Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow . Blood vol. 83 , ( 12 ) 3800 - 3807 .
Gribben JG ( 1994 ) . Attainment of molecular remission: A worthwhile goal? . Journal of Clinical Oncology vol. 12 , ( 8 ) 1532 - 1534 .
Boussiotis VA, Gribben JG, Freeman GJ, Nadler LM ( 1994 ) . Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance . Current Opinion in Immunology vol. 6 , ( 5 ) 797 - 807 .
Gribben JG, Nadler LM ( 1994 ) . Detection of minimal residual disease in patients with lymphomas using the polymerase chain reaction . Important advances in oncology117 - 129 .
Munro JM, Freedman AS, Aster JC, Gribben JG, Lee NC, Rhynhart KK, Banchereau J, Nadler LM ( 1994 ) . In vivo expression of the B7 costimulatory molecule by subsets of antigen- presenting cells and the malignant cells of Hodgkin's disease . Blood vol. 83 , ( 3 ) 793 - 798 .
Boussiotis VA, Barber DL, Nakarai T, Freeman GJ, Gribben JG, Bernstein GM, D'Andrea AD, Ritz J et al. ( 1994 ) . Prevention of T cell anergy by signaling through the γ<inf>c</inf> chain of the IL-2 receptor . Science vol. 266 , ( 5187 ) 1039 - 1042 .
Boussiotis VA, Freeman GJ, Gribben JG, Daley J, Gray G, Nadler LM ( 1993 ) . Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation . Proceedings of the National Academy of Sciences of the United States of America vol. 90 , ( 23 ) 11059 - 11063 .
Freeman GJ, Borriello F, Hodes RJ, Reiser H, Gribben JG, Ng JW, Kim J, Goldberg JM et al. ( 1993 ) . Murine b7-2, an alternative ctla4 counter-receptor that costimulates t cell proliferation and interleukin 2 production . Journal of Experimental Medicine vol. 178 , ( 6 ) 2185 - 2192 .
Boussiotis VA, Freeman GJ, Gray G, Gribben J, Nadler LM ( 1993 ) . B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specitlc tolerance . Journal of Experimental Medicine vol. 178 , ( 5 ) 1753 - 1763 .
Gribben J, Neuberg D, Freedman A, Gimmi C, Pesek K, Barber M, Saporito L, Woo S et al. ( 1993 ) . Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma . Blood vol. 81 , ( 12 ) 3449 - 3457 .
Grossbard M, Gribben J, Freedman A, Lambert J, Kinsella J, Rabinowe S, Eliseo L, Taylor J et al. ( 1993 ) . Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non- Hodgkin's lymphoma . Blood vol. 81 , ( 9 ) 2263 - 2271 .
Grossbard ML, Gribben JG, Freedman AS, Lambert JM, Kinsella J, Rabinowe SN, Eliseo L, Taylor JA et al. ( 1993 ) . Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma . Blood vol. 81 , ( 9 ) 2263 - 2271 .
Rabinowe SN, Soiffer RJ, Gribben JG, Daley H, Freedman AS, Daley J, Pesek K, Neuberg D et al. ( 1993 ) . Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia . Blood vol. 82 , ( 4 ) 1366 - 1376 .
Gribben JG, Nadler LM ( 1993 ) . Bone marrow purging for autologous bone marrow transplantation . Leukemia and Lymphoma vol. 11 , ( S2 ) 141 - 148 .
Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA, Lombard LA, Gray GS, Nadler LM ( 1993 ) . Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation . Science vol. 262 , ( 5135 ) 909 - 911 .
Gribben JG, Neuberg D, Freedman AS, Gimmi CD, Pesek KW, Barber M, Saporito L, Woo SD et al. ( 1993 ) . Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma . Blood vol. 81 , ( 12 ) 3449 - 3457 .
Gribben JG ( 1993 ) . High-dose chemotherapy and autologous transplant with peripheral-blood stem cells: Commentary I . ONCOLOGY vol. 7 , ( 8 ) 29 - 30 .
Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM ( 1993 ) . Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation . Proceedings of the National Academy of Sciences of the United States of America vol. 90 , ( 14 ) 6586 - 6590 .
Gimmi CD, Gribben JG, Freeman GJ, Nadler LM ( 1993 ) . Lack of B7-costimulation causes a peripheral clonal T-cell anergy in a human antigen-specific model . Schweizerische Medizinische Wochenschrift . vol. 123 , 2255 - 2256 .
Gribben JG, Nadler LM ( 1993 ) . Monitoring minimal residual disease . Seminars in Oncology vol. 20 , ( SUPPL. 5 ) 143 - 155 .
Gribben JG, Nadler LM ( 1993 ) . Purging of autologous bone marrow in the treatment of non-Hodgkin's lymphoma . Important advances in oncology139 - 156 .
Gribben JG, Nadler LM ( 1993 ) . The immunological treatment of human marrow in vitro in transplantation biology . Cancer treatment and research vol. 64 , 189 - 211 .
Gribben J, Saporito L, Barber M, Blake K, Edwards R, Griffin J, Freedman A, Nadler L ( 1992 ) . Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion . Blood vol. 80 , ( 4 ) 1083 - 1089 .
Murgo AJ, Weinberger BB, Johnson JR, Gribben JG, Nadler LM ( 1992 ) . Immunologic purging of marrow assessed by polymerase chain reaction . New England Journal of Medicine vol. 326 , ( 17 ) 1163 - 1164 .
Freeman G, Disteche C, Gribben J, Adler D, Freedman A, Dougery J, Nadler L ( 1992 ) . The gene for B7, a costimulatory signal for T-cell activation, maps to chromosomal region 3q13.3-3q21 . Blood vol. 79 , ( 2 ) 489 - 494 .
Gribben JG, Saporito L, Barber M, Blake KW, Edwards RM, Griffin JD, Freedman AS, Nadler LM ( 1992 ) . Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion . Blood vol. 80 , ( 4 ) 1083 - 1089 .
Spector NL, Samson W, Ryan C, Gribben J, Urba W, Welch WJ, Nadler LM ( 1992 ) . Growth arrest of human B lymphocytes is accompanied by induction of the low molecular weight mammalian heat shock protein (hsp28) . Journal of Immunology vol. 148 , ( 6 ) 1668 - 1673 .
Freeman GJ, Disteche CM, Gribben JG, Adler DA, Freedman AS, Dougery J, Nadler LM ( 1992 ) . The gene for B7, a costimulatory signal for T-cell activation, maps to chromosomal region 3q13.3-3q21 . Blood vol. 79 , ( 2 ) 489 - 494 .
Gribben J, Freedman A, Woo S, Blake K, Shu R, Freeman G, Longtine J, Pinkus G et al. ( 1991 ) . All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment . Blood vol. 78 , ( 12 ) 3275 - 3280 .
Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard ML, Rabinowe SN et al. ( 1991 ) . Immunologic purging of marrow assessed by pcr before autologous bone marrow transplantation for B-cell lymphoma . New England Journal of Medicine vol. 325 , ( 22 ) 1525 - 1533 .
Freeman GJ, Gray GS, Gimmi CD, Lombard DB, Zhou LJ, White M, Fingeroth JD, Gribben JG et al. ( 1991 ) . Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7 . Journal of Experimental Medicine vol. 174 , ( 3 ) 625 - 631 .
Gimmi CD, Freeman GJ, Gribben JG, Sugita K, Freedman AS, Morimoto C, Nadler LM ( 1991 ) . B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2 . Proceedings of the National Academy of Sciences of the United States of America vol. 88 , ( 15 ) 6575 - 6579 .
Rabinowe S, Soiffer R, Tarbell N, Neuberg D, Freedman A, Seifter J, Blake K, Gribben J et al. ( 1991 ) . Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies . Blood vol. 77 , ( 8 ) 1837 - 1844 .
Lim SH, Mcmillan AK, Gribben J, Galvin MC, Goldstone AH ( 1991 ) . A unique case of three autografts for acute myelogenous leukaemia with subsequent long term survival in second remission . Leukemia and Lymphoma vol. 5 , ( 2-3 ) 207 - 209 .
Gribben JG, Freedman AS, Woo SD, Blake K, Shu RS, Freeman G, Longtine JA, Pinkus GS et al. ( 1991 ) . All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment . Blood vol. 78 , ( 12 ) 3275 - 3280 .
Rabinowe SN, Soiffer RJ, Tarbell NJ, Neuberg D, Freedman AS, Seifter J, Blake KW, Gribben JG et al. ( 1991 ) . Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies . Blood vol. 77 , ( 8 ) 1837 - 1844 .
McMillan A, Goldstone A, Linch D, Gribben J, Patterson K, Richards J, Franklin I, Boughton B et al. ( 1990 ) . High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia . Blood vol. 76 , ( 3 ) 480 - 488 .
Gribben JG, Devereux S, Thomas NSB, Keim M, Jones HM, Goldstone AH, Linch DC ( 1990 ) . Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF . The Lancet vol. 335 , ( 8687 ) 434 - 437 .
Mcmillan AK, Gribben JG, Linch DC, Anderson C, Richards JDM, Goldstone AH ( 1990 ) . Autologous bone-marrow transplantation in acute lymphoblastic leukaemia: 1980-89 . Leukemia and Lymphoma vol. 1 , ( 3-4 ) 157 - 162 .
McMillan AK, Goldstone AH, Linch DC, Gribben JG, Patterson KG, Richards JDM, Franklin I, Boughton BJ et al. ( 1990 ) . High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia . Blood vol. 76 , ( 3 ) 480 - 488 .
Golidstone A, Gribben J, Mcmillan A ( 1990 ) . The role of growth factors in bone-marrow transplantation . Leukemia and Lymphoma vol. 1 , ( 2 ) 87 - 93 .
Devereaux S, Linch DC, Gribben JG, McMillan A, Patterson K, Goldstone AH ( 1989 ) . GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease . Bone Marrow Transplantation vol. 4 , ( 1 ) 49 - 54 .
Armitage JO, Barnett MJ, Carella AM, Dicke KA, Diehl V, Gribben JG, Pfreundschuh M ( 1989 ) . Bone marrow transplantation in the treatment of Hodgkin's lymphoma: problems, remaining challenges, and future prospects . Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer vol. 117 , 246 - 253 .
Goldstone AH, Gribben JG, Linch DC ( 1989 ) . Double autografting in first remission acute myeloid leukaemia . Folia Haematologica vol. 116 , ( 3-4 ) 501 - 504 .
Gribben JG, Goldstone AH, Linch DC, MacMillan AK, Richards JDM ( 1989 ) . Double autologous bone marrow transplantation in acute myeloid leukaemia . Bone Marrow Transplantation vol. 4 , ( SUPPL. 1 ) 209 - 211 .
Goldstone AH, Gribben JG ( 1989 ) . EBMT experience of autologous bone marrow transplantation in lymphoma . Folia haematologica (Leipzig, Germany : 1928) vol. 116 , ( 3-4 ) 505 - 508 .
Gribben JG, Goldstone AH, Linch DC, Taghipour G, McMillan AK, Souhami RL, Earl H, Richards JDM ( 1989 ) . Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy . Journal of Clinical Oncology vol. 7 , ( 11 ) 1621 - 1629 .
Roberts PJ, Cummins D, Bainton AL, Walshe KJ, Fisher‐Hoch SP, McCormick JB, Gribben JG, Machin SJ et al. ( 1989 ) . Plasma from patients with severe Lassa fever profoundly modulates f‐met‐leu‐phe induced superoxide generation in neutrophils . British Journal of Haematology vol. 73 , ( 2 ) 152 - 157 .
Gribben JG, Goldstone AH, Linch DC ( 1989 ) . Preliminary results of autologous bone marrow transplantation in the management of resistant Hodgkin's disease: experience of the Bloomsbury Transplant Group at University College, London . Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer vol. 117 , 242 - 245 .
Gribben JG, Linch DC, Singer CRJ, McMillan AK, Jarrett M, Goldstone AH ( 1989 ) . Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation . Blood vol. 73 , ( 1 ) 340 - 344 .
Goldstone AH, Linch DC, Gribben JG, McMillan A ( 1988 ) . Experience of autologous bone marrow transplantation in the first 100 lymphomas . Bone Marrow Transplantation vol. 3 , ( SUPPL. 1 ) 65 - 66 .
Goldstone AH, Singer CRJ, Gribben JG, Jarrett M ( 1988 ) . Fifth report of EBMTG experience of ABMT in malignant lymphoma . Bone Marrow Transplantation vol. 3 , ( SUPPL. 1 ) 33 - 36 .
Gribben JG, Hudson BV, Linch DC ( 1987 ) . The potential value of very intensive therapy with autologous bone marrow rescue in the treatment of malignant lymphomas . Hematological Oncology vol. 5 , ( 4 ) 281 - 293 .
Goldstone AH, Gribben JG ( 1987 ) . The role of autologous bone marrow transplantation in the treatment of malignant disease . Blood Reviews vol. 1 , ( 3 ) 193 - 200 .
Patterson J, Prentice HG, Brenner MK, Gilmore M, Janossy G, Ivory K, Skeggs D, Morgan H et al. ( 1986 ) . Graft rejection following HLA matched T‐lymphocyte depleted bone marrow transplantation . British Journal of Haematology vol. 63 , ( 2 ) 221 - 230 .
Atrah HI, Sheehan T, Gribben J, Crawford RJ, O'Donnel JR, Sandilands GP ( 1986 ) . Improvement of post platelet transfusion increments following intravenous immunoglobulin therapy for leukaemic HLA‐immunized patients . Scandinavian Journal of Haematology vol. 36 , ( 2 ) 160 - 164 .
Mackinnon AS, Garden OJ, Gribben JG, Burns HJG, Hutchieson SJ, Burnett AK ( 1986 ) . Reduction of Catheter Sepsis in Marrow Transplant Recipients by Prophtlactic . Clinical Science vol. 71 , ( s15 ) 22p - 23p .
Simpson IA, Rae AP, Simpson K, Gribben J, Boulton Jones JM, Allison ME, Hutton I ( 1986 ) . Ultrafiltration in the management of refractory congestive heart failure . British Heart Journal vol. 55 , ( 4 ) 344 - 347 .
Patterson J, Prentice HG, Gilmore M, Blacklock H, Brenner MK, Janossy G, Skeggs D, Ivory K et al. ( 1985 ) . Analysis of Rejection in HLA Matched T-Depleted Bone Marrow Transplants . 11th Annual meeting of the EBMT ,
Platt DJ, Sommerville JS, Gribben J ( 1984 ) . Sequential acquisition of r-plasmids in vivo by salmonella typhimurium . Journal of Antimicrobial Chemotherapy vol. 13 , ( 1 ) 65 - 69 .
Leung AC, Simpson K, Gribben J, Wallace J, Mactier R, Allison ME, Telfer AB ( 1983 ) . Arteriovenous haemofiltration . British medical journal (Clinical research ed.) vol. 287 , ( 6406 )
Leung ACT, Gribben J, Sleigh JD, Boulton Jones JM ( 1983 ) . Successful treatment of multiresistant pseudomonas peritonitis with combination of azlocillin and amikacin . Scottish Medical Journal vol. 28 , ( 1 ) 69 - 70 .